Document:

Patent License Agreement with University of Pennsylvania

 Exhibit 10.6 

EXECUTION VERSION 

[CONFIDENTIAL TREATMENT REQUESTED] /*/ INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED
MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

UNIVERSITY of PENNSYLVANIA 

PATENT LICENSE AGREEMENT 

This Patent License Agreement (this “Agreement”) is between The Trustees of the University of Pennsylvania, a
Pennsylvania nonprofit corporation (“Penn”), and Aegerion Pharmaceuticals, Inc, a Delaware corporation (“Company”). This Agreement is effective on May 19, 2006 (the “Effective Date”).

 BACKGROUND 

In 2003, Penn and Bristol-Myers Squibb Company (“BMS”) entered into that certain Technology Donation Agreement
(the “Original TDA”) concerning a compound designated “BMS-201,038”, whereby among other things BMS donated to Penn one patent claim that covered BMS-201,038, granted to Penn certain rights in and to related BMS
know-how, and transferred to Penn quantities of BMS-201,038 in the form of bulk drug substance (that substance as supplied to Penn by BMS, the “Penn Materials”). 

Simultaneously with the execution of this Agreement, Penn and BMS are amending and restating the Original TDA, a complete copy of which
as amended and restated is attached hereto as Exhibit A (the “TDA”). Under the TDA, among other things and in addition to the rights granted to Penn under the Original TDA, BMS is assigning certain additional patent
rights to Penn related to BMS-201,038, and Penn is granting back to BMS rights in and to those patent rights pursuant to the “Grant-back Licenses” as defined in the TDA. 

Prior to the execution of this Agreement, Penn and Company have entered into one Clinical Trial Research Agreement, and soon after the
execution of this Agreement, Penn and Company intend to enter into a second Clinical Trial Research Agreement (such two agreements, collectively, the “Clinical Research Agreements”). 

Company desires to obtain an exclusive license under those patent rights and other Penn patent rights and to use the Penn Materials. Penn
has determined that the exploitation of those rights and the use of the Penn Materials is in the best interest of Penn and is consistent with its educational and research missions and goals. 

 PATENT LICENSE AGREEMENT 

 

 In consideration of the mutual obligations contained in this Agreement, and intending to
be legally bound, the parties agree as follows: 
 1. LICENSE 

1.1 License Grant. Penn hereby grants to Company an exclusive (even as to Penn but subject to Sections 1.3 and 1.4),
world-wide license (the “License”) to research, develop, commercialize, make, have made, use, import, offer for sale and sell (a) under the Penn Existing Patents and Penn New Patents, Licensed Products and Penn Materials
in all fields during the Term, and (b) under the Assigned BMS Patents and Assigned BMS Technical Information, the Designated Compounds and Penn Materials in the Field of Use during the Term (as such terms may be defined in Sections 1.2
and 6.1). The License includes the right to sublicense as permitted by this Agreement. Except as expressly provided herein, no other rights or licenses are granted hereunder by Penn. Any intellectual property created or conceived during the
performance of the Clinical Research Agreements or any Sponsored Research Agreement between Penn and Company (collectively, the “Other Agreements”) will be governed by the terms of the applicable Other Agreement. For clarity,
to the extent that any Penn Patent Rights is jointly owned with Company (optionally along with one or more third parties), the License shall apply to all of Penn’s right, title and interest in and to the same notwithstanding Company’s
joint ownership interest therein. 
 1.2 Related Definitions. 

(i) “Affiliate” means a legal entity that is controlling, controlled by or under common control with
Company and that has executed either a counterpart to this Agreement or a written joinder agreement agreeing to be bound by all of the terms and conditions of this Agreement. For purposes of this Section 1.2(i), the word
“control” means (x) the direct or indirect ownership of more than fifty percent (50%) of the outstanding voting securities of a legal entity, (y) the right to receive fifty percent (50%) or more of the profits or
earnings of a legal entity, or (z) the right to determine the policy decisions of a legal entity. 
 (ii)
“Assigned BMS Patents” means both (1) (a) the patents and patent applications listed on Exhibit B-1, (b) all direct and indirect divisionals and continuations of any such patent applications, and
(c) all patents issuing on any such patent applications, together with all reissues, re examinations, renewals, supplemental protection certificates and extensions of any of the foregoing in this clause (a) (collectively,
the “Composition Patents”), and (2) the patent listed on Exhibit B-2, together with all reissues, re examinations, renewals, supplemental protection certificates and extensions of any of the foregoing in
this clause (b) (collectively, the “Combination Patents”). 
 (iii) “Assigned
BMS Technical Information” means all technology, know-how, information, results, data and regulatory filings and other correspondences donated to Penn by BMS pursuant to the TDA, but not including the Assigned BMS Patents. 

(iv) “Designated Compound” means: (a) BMS-201,038; (b) prodrugs or metabolites of BMS-201,038,
to the extent any such prodrug or metabolite is covered by a composition claim in a Composition Patent; and (c) stereoisomers, hydrates, anhydrides, 

 

 2 

 PATENT LICENSE AGREEMENT 

 

 
solvates, salt forms, or polymorphs of BMS-201,038 or any compounds covered by the foregoing clause (b) or this clause (c); furthermore, in the case of a prodrug or metabolite as
referred to under clause (b) above, the compound in question will constitute a “Designated Compound” hereunder only if the making, use or sale of such compound is necessary for or results from the making, use and sale of
BMS-210,038 within the Field of Use. 
 (v) “Field of Use” means: (a) monotherapy or in
combination with other dyslipidemic therapies for treatment of patients with homozygous familial hypercholesterolemia; (b) monotherapy or in combination with other dyslipidemic therapies for treatment of patients with severe
hypercholesterolemia of any etiology unable to come within 15% of NCEP LDL cholesterol goal on maximal tolerated oral therapy, as determined by the patient’s prescribing physician; (c) monotherapy or in combination with other dyslipidemic
therapies for treatment of patients with severe combined hyperlipidemia of any etiology unable to come within 15% of NCEP non-HDL cholesterol goal on maximal tolerated oral therapy, as determined by the patient’s prescribing physician; and
(d) monotherapy or in combination with other dyslipidemic therapies for treatment of patients with severe hypertriglyceridemia unable to reduce TG<1000 on maximal tolerated therapy. 

(vi) “Licensed Products” means: (a) Designated Compounds, and (b) products that are made, made
for, used or sold by Company or its Affiliates or sublicensees and that (i) would infringe at least one Valid Claim of Penn Existing Patents or Penn New Patents in the absence of the License, or (ii) use a method covered by at least one
Valid Claim of Penn Existing Patents or Penn New Patents (provided that the proviso contained in clause (b) of the definition of Valid Claim shall not apply to the two foregoing uses of such term). For the avoidance of doubt, “Licensed
Products” include the combination of any of the Licensed Products identified in clauses (a) and (b) with other component(s) which is active alone or in a combination. 

(vii) “Penn Existing Patents” means: all patent rights contained in Penn Dockets Q3474 and/or otherwise
related to BMS-201,038 and represented by: (a) the patents and patent applications listed on Exhibit B-3; (b) all divisionals, continuations, continuations-in-part (but excluding new matter) thereof or any other patent application
claiming priority directly or indirectly to any of the patents or patent applications from clause (a); and (c) all patents issuing on any of the foregoing, and any foreign counterparts thereof, together with all reissues, re-examinations,
renewals, supplemental protection certificates and extensions of any of the foregoing, and any foreign counterparts thereof. 

(viii) “Penn New Patents” means: (a) the patents and patent applications (if any) added to this
Agreement in accordance with the terms of any Other Agreements; (b) all patents and patent applications disclosing or claiming any Improvements that become subject to this Agreement pursuant to Section 1.8; (c) all divisionals,
continuations, continuations-in-part (but excluding new matter) thereof or any other patent application claiming priority directly or indirectly to any of the patents or patent applications from clause (a) or (b); and (d) all patents
issuing on any of the foregoing, and any foreign counterparts thereof, together with all reissues, re-examinations, renewals, supplemental protection certificates and extensions of any of the foregoing, and any foreign counterparts thereof.

  

 3 

 PATENT LICENSE AGREEMENT 

 

 (ix) “Penn Patent Rights” means the Assigned BMS
Patents, Penn Existing Patents and Penn New Patents. 
 (x) “Valid Claim” means a claim of
(a) an issued and unexpired patent, which claim has not been revoked or held invalid or unenforceable by a court or other government agency of competent jurisdiction from which no appeal can be or has been taken and has not been held or
admitted to be invalid or unenforceable through re-examination or disclaimer, reissue, opposition procedure, nullity suit or otherwise, or (b) a pending patent application that has not been cancelled, withdrawn or abandoned, provided that if a
claim of a pending patent application shall not have issued within five (5) years (or in Japan, seven (7) years) after the earliest filing date from which such claim takes priority, such claim shall not constitute a Valid Claim for the
purposes of this Agreement unless and until a patent issues with such claim. 
 1.3 Reservation of Rights by Penn. Penn
reserves the right to use, and to permit other non-commercial entities to use, the Penn Patent Rights and Assigned BMS Technical Information for non-exclusive, non-commercial educational and research purposes (but not when sponsored by any
commercial entity other than Company). 
 1.4 U.S. Government Rights. The parties acknowledge that the United States
government retains rights in intellectual property funded under any grant or similar contract with a Federal agency. The License is expressly subject to all applicable United States government rights, including any applicable requirement that
products, which result from such intellectual property and are sold in the United States, must be substantially manufactured in the United States. The parties acknowledge and agree that none of the Assigned BMS Patents or the Assigned BMS Technical
Information is subject to this Section 1.4. 
 1.5 Affiliates and Sublicensing. Affiliates of Company may obtain
rights under this Agreement as if they were Company (including as a licensee under the License) by agreeing in writing to be bound by the terms of this Agreement by executing a counterpart to this Agreement or a written joinder agreement.
Company’s right (and its sublicensee(s)’s right) to sublicense granted by Penn under the License is subject to each of the following conditions: 

(i) In each sublicense agreement, Company (and each Company sublicensee) will require the sublicensee to comply with the
terms and conditions of this Agreement. 
 (ii) Within thirty (30) days after Company or its sublicensee
enters into a sublicense agreement, Company will deliver to Penn a complete and accurate copy of the entire sublicense agreement written in the English language. Penn’s receipt of the sublicense agreement, however, will constitute neither an
approval of the sublicense nor a waiver of any right of Penn or obligation of Company under this Agreement. All such sublicense agreements will be treated as Confidential Information of Company and will be subject to Section 5.2. 

(iii) Upon a Trigger Event (as defined in Section 6.5) but subject to Section 6.8, all payments due to Company
from its sublicensees under the applicable sublicense agreement, but only to the extent such payment would be owed to Penn under the terms hereof, will, upon notice from Penn to such sublicensee, become payable directly to Penn for the account of
Company. 
  

 4 

 PATENT LICENSE AGREEMENT 

 

 (iv) Company’s execution of a sublicense agreement will not relieve
Company of any of its obligations under this Agreement. Company is primarily liable to Penn for any act or omission of an Affiliate or sublicensee of Company that would be a breach of this Agreement if performed or omitted by Company, and Company
will be deemed to be in breach of this Agreement as a result of such act or omission. 
 1.6 Updating Penn Patent Rights.
At Company’s reasonable request during the Term, Penn will provide Company with an updated Exhibit B, which update shall include without limitation any patents or patent applications that have become Penn New Patents. Once both
parties are satisfied that the updated Exhibit B is accurate and complete, the parties will execute an amendment to this Agreement, which will replace the then current Exhibit B with the updated Exhibit B. 

1.7 Penn Materials. All right, title and interest Penn has in and to the Penn Materials is hereby transferred to Company. Penn
will use the Penn Materials only in collaboration with Company pursuant to any Other Agreements and will not use any of the Penn Materials for any other purpose. Penn will not provide the Penn Materials to any person at Penn, other than any
individual working in collaboration with Company pursuant to such Other Agreements, or to any other person or entity. Penn will hold or will at Company’s expense transfer the Penn Materials as Company may reasonably direct. Penn acknowledges
that, for purposes of this Agreement, all Designated Compound in Penn’s possession as of the Effective Date will be treated as “Penn Materials” hereunder. 

1.8 Improvements and New Developments. 

(i) Improvements. Penn hereby grants to Company the first option to license exclusively each Improvement (as
defined below) and related patent rights for [CONFIDENTIAL TREATMENT REQUESTED] /*/ ([CONFIDENTIAL TREATMENT REQUESTED] /*/) months after Company has been notified of the existence of each such Improvement. Within sixty (60) days after
Penn’s Center for Technology Transfer receives written disclosure of any Improvement, Penn will notify Company in writing of such Improvement, furnishing Company a copy of any invention disclosure and any related patent applications on a
confidential basis. At Company’s request, Penn will provide such additional information regarding such Improvement as Company may reasonably request. Penn will take reasonable steps, consistent with its customary and usual practices, to ensure
that any such notification to Company is made reasonably before the occurrence of any disclosure or other activity that might impair any patentability of such Improvement. By written notice to Penn, within [CONFIDENTIAL TREATMENT REQUESTED]
/*/ ([CONFIDENTIAL TREATMENT REQUESTED] /*/) months after receipt of such notice from Penn, Company may exercise the option to license such Improvement and related patent rights, whereupon the parties will promptly amend this Agreement to add
such Improvements to the License as Penn New Patents, without the payment of any incremental consideration to Penn, other than reimbursement of patent prosecution and maintenance costs under Article 7 and possible extension or expansion of any
royalties or sublicense fees under Article 3 as a result of any Penn New Patents. Penn shall not grant any license or other rights in or to any Improvement or any related patent rights until Penn has complied with this Section 1.8(i). For
purposes of this Agreement, “Improvement” means (1) any invention or further improvement to the Penn Patent 

 

 5 

 PATENT LICENSE AGREEMENT 

 

 
Rights that (i) is developed, discovered or reduced to practice by, or under the direction of Dr. Rader in the Field of Use during the three (3) year period after the Effective
Date, (ii) is dominated by the Penn Patent Rights, (iii) is in Penn’s full control (e.g., not arising from research funded by third party commercial entities), and (iv) is not covered by an Other Agreement, and
(2) any invention arising from or otherwise attributable to the use of any Penn Materials that is not solely owned by Company under any Other Agreement. 

(ii) New Developments. Penn hereby grants to Company the first option to negotiate an exclusive license to each New
Development (as defined below) and related patent rights. Within sixty (60) days after Penn’s Center for Technology Transfer receives written disclosure of any New Development, Penn will notify Company in writing of such New Development,
furnishing Company a copy of the invention disclosure and any related patent applications on a confidential basis. At Company’s request, Penn will provide such additional information regarding such New Development as Company may reasonably
request. Penn will take reasonable steps, consistent with its customary and usual practices, to ensure that any such notification to Company is made reasonably before the occurrence of any disclosure or other activity that might impair the
patentability of such New Development. By written notice to Penn, Company may exercise the option to negotiate a license to such New Development within [CONFIDENTIAL TREATMENT REQUESTED] /*/ ([CONFIDENTIAL TREATMENT REQUESTED] /*/) days after
receipt of such notice from Penn, whereupon the parties shall negotiate in good faith for up to [CONFIDENTIAL TREATMENT REQUESTED /*/ ([CONFIDENTIAL TREATMENT REQUESTED] /*/) months to agree on commercially reasonable terms for such license. Any
amounts payable to Penn pursuant to any such license shall be subject to Sections 3.7(ii), 3.7(iii) and 3.7(iv). Penn shall not grant any license or other rights in or to any New Development or any related patent rights until Penn has
complied with this Section 1.8(ii). For purposes of this Agreement, “New Development” means any invention or further improvement to the Penn Patent Rights that (i) is developed, discovered or reduced to practice by,
or under the direction of Dr. Rader in the Field of Use during the [CONFIDENTIAL TREATMENT REQUESTED] /*/ ([CONFIDENTIAL TREATMENT REQUESTED] /*/) year period after the Effective Date, (ii) is not dominated by the Penn Patent Rights,
(iii) is in Penn’s full control, (iv) is not covered by an Other Agreement and (v) is not an Improvement. 

(iii) For each Improvement or New Development, If Penn does not receive written notice from Company of its desire to
exercise an option under Sections 1.8(i) or (ii) during the applicable option period, or if no amendment or license is thereafter executed as provided in such Sections (provided that Penn has complied in full with all its obligations under
those Sections), then the option will expire automatically and Penn will be free to negotiate and enter into a license agreement with a third party and will have no further obligations, financial or otherwise, to Company with respect to the
applicable Improvement or New Development, as the case may be. 
 (iv) Relationship to Other Agreements.
This Section 1.8 shall apply to any invention, technology, know-how, information, results, data and regulatory filings and other correspondences (whether or not ultimately patentable) in which Penn has an ownership interest and which do not
arise from the performance of or otherwise in connection with any Other Agreement. 
  

 6 

 PATENT LICENSE AGREEMENT 

 

 (v) Joint Ownership. To the extent that any Improvements or New
Developments or any related patent rights are jointly owned by Penn and Company (optionally along with one or more third parties), this Section 1.8 shall apply to all of Penn’s right, title and interest in and to the same notwithstanding
Company’s joint ownership interest therein. 
 1.9 Penn and the TDA. During the Term: 

(i) Penn will take all reasonable steps necessary to maintain in full force and effect the TDA. Penn will provide Company
with prompt notice (and in any event substantially before the end of any applicable cure period under the TDA) of any claim of a material breach of the TDA. Penn will provide Company with copies of all notices and other documents Penn receives
pursuant to the TDA (including all sublicense agreements received by Penn pursuant to Article 3.3(d) of the TDA). Absent Company’s prior written consent, Penn will not remove Company as a noticed party pursuant to Article 15.7 of the
TDA. 
 (ii) Penn will not amend, restate, alter, waive or otherwise change any of the terms and conditions of
the TDA in effect as of the Effective Date, nor will Penn enter into any other agreement or understanding with BMS or any of its Affiliates (as defined in the TDA) or any of BMS’s sublicensees under the Grant-back licenses relating to the
Designated Compounds or the Assigned BMS Patents or the BMS Know-how, that in either case, would have a material impact on Company’s rights under this Agreement without the prior written consent of Company, which consent will not be
unreasonably withheld or delayed, provided that Penn will in all instances notify Company in writing reasonably in advance of taking any such action whether material or not. 

(iii) Penn will not terminate the TDA without the prior written consent of Company, and Penn will provide Company with
prompt notice of termination of the TDA. 
 (iv) Penn will not enforce any rights under the TDA without the prior
written consent of Company, which consent will not be unreasonably withheld or delayed. At Company’s written request, Penn will timely enforce (a) Article 4 of the TDA as it applies to Company and its Affiliates and sublicensees and
their assigns, suppliers, vendors and customers, and Penn will provide Company with prompt notice of any breach of such Article 4, (b) Article 5.1 of the TDA against BMS and the other parties subject thereto, and Penn will provide
Company with prompt notice of any breach of such Article 5.1, and (c) Penn’s rights under Article 7 of the TDA, provided that in each such case at Penn’s request, Company will indemnify Penn from and against any award, fees
or expenses incurred by Penn by reason of Penn enforcing those rights under the TDA, subject to off-set for any amounts recovered by Penn under the TDA as part of such enforcement activities. Each party will cooperate with the other in any such
enforcement activities by the other party, including Penn agreeing to be a named party in any action or other litigation reasonably recommended by Company under the TDA concerning such rights following Company’s written re-commitment to
indemnify Penn in accordance with this Agreement. 
 (v) Upon written notice from Company, Penn will work with
Company in approaching BMS in order to seek a limitation on the field of use in the Grant-back Licenses 
  

 7 

 PATENT LICENSE AGREEMENT 

 

 
with respect to the Assigned BMS Patents and Assigned BMS Technical Information as part of Company negotiating an expansion of the Field of Use under this Agreement. 

(vi) In addition and without limitation to any other provisions of this Agreement, Penn will cooperate with Company
(including enforcing the terms of the TDA) to allow Company to enjoy the benefits of the other rights of Penn under the TDA not expressly addressed in this Section 1.9 to the extent both (a) such action is permitted by the TDA and
(b) such rights relate to the subject matter of this Agreement (including the License, the Designated Compounds and the Assigned BMS Patents). 

2. DILIGENCE 
 2.1
Development Plan. Company will deliver to Penn, within one hundred-eighty (180) days after the Effective Date, a copy of an initial development plan for the Penn Patent Rights (the “Development Plan”). Thereafter,
Company will deliver to Penn an annual updated Development Plan no later than December 1 of each year during the Term. The Development Plan will include, at a minimum, the information listed in Exhibit C. The Development Plan will
be treated as Confidential Information of Company and will be subject to Section 5.2. 
 2.2 Company’s Efforts.
During the Term, Company will use commercially reasonable efforts to develop, commercialize, market and sell one or more Licensed Products in a manner consistent with the Development Plan. 

3. FEES AND ROYALTIES 

3.1 License Initiation Fee. In partial consideration of the License, Company will pay to Penn within thirty (30) days of the
Effective Date a non-refundable, non-creditable license initiation fee of $75,000, provided that twenty-five percent (25%) of all cash payments made by Company to DSS Partners as such payment will be creditable against such $75,000, except that
in no event will the payment due to Penn under this Section 3.1 be less than $56,250. 
 3.2 Milestone Payments. In
partial consideration of the License, Company will pay to Penn the applicable milestone payment listed in the table below after achievement of each milestone event. Company will provide Penn with written notice within forty-five (45) days after
achieving each milestone. For the first Designated Compound covered by a Valid Claim of the Assigned BMS Patents that is licensed to Company under the License: 

(i) Where the indication is limited to “homozygous familial hypercholesterolemia” or “severe refractory
hypercholesterolemia”: 
  

			
	 [CONFIDENTIAL TREATMENT REQUESTED] /*/
	  	$ [CONFIDENTIAL TREATMENT REQUESTED] /*/
	 [CONFIDENTIAL TREATMENT REQUESTED] /*/
	  	$ [CONFIDENTIAL TREATMENT REQUESTED] /*/

  

 8 

 PATENT LICENSE AGREEMENT 

 

 (ii) Where the indication is not so limited but falls within the Field
of Use: 
  

			
	 [CONFIDENTIAL TREATMENT REQUESTED] /*/
	  	$ [CONFIDENTIAL TREATMENT REQUESTED] /*/
	 [CONFIDENTIAL TREATMENT REQUESTED] /*/
	  	$ [CONFIDENTIAL TREATMENT REQUESTED] /*/
	 [CONFIDENTIAL TREATMENT REQUESTED] /*/
	  	$ [CONFIDENTIAL TREATMENT REQUESTED] /*/

Each such milestone payment shall be payable by Company only once. In the event that any milestone payments are made by the Company under
the foregoing clause (ii), then no milestone payments shall thereafter be due under the foregoing clause (i). Any milestone payments already made by Company under such clause (i) shall be fully creditable against milestone payments
owed under such clause (ii). 
 3.3 Earned Royalties. In partial consideration of the License and subject to
Sections 3.7 and 3.8, Company will pay to Penn: 
 (i) a graduated royalty as set forth in the table
below based upon worldwide annual Net Sales made by Company and its Affiliates (but not sublicensees) of any Designated Compound Sold for use in the Field of Use while covered in the country of Sale of expected use by a Valid Claim of the Assigned
BMS Patents that is licensed to Company under the License (but no other Licensed Product): 
  

			
	 Annual Net Sales by Company and its Affiliates
	  	 Royalty Rate

	 <$500 million
	  	[CONFIDENTIAL TREATMENT REQUESTED] /*/%
	 >$500 million but <$750 million
	  	[CONFIDENTIAL TREATMENT REQUESTED] /*/%
	 >$750 million but <$1 billion
	  	[CONFIDENTIAL TREATMENT REQUESTED] /*/%
	 >$1 billion
	  	[CONFIDENTIAL TREATMENT REQUESTED] /*/%

 [CONFIDENTIAL
TREATMENT REQUESTED] /*/ 
  

 9 

 PATENT LICENSE AGREEMENT 

 

 (ii) a royalty of [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent
([CONFIDENTIAL TREATMENT REQUESTED] /*/%) of Net Sales made by Company and its Affiliates (but not sublicensees) for all Licensed Products that qualify as “Licensed Products” hereunder based on clause (b) of that definition and Sold
while covered in the country of Sale of expected use by a Valid Claim of the Penn Existing Patents or Penn New Patents; provided that, notwithstanding any credits provided for in Section 3.7 but subject in all events to Section 3.8,
royalties payable by Company for such Net Sales for such Licensed Products shall not be less than [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%). 

Only one royalty shall be due hereunder on the Sale of the same unit of Licensed Product. If a royalty accrues to a Sale of a Licensed Product under both
clause (i) and (ii) above, then the higher rate of clause (i) shall apply. Only one royalty shall be due hereunder on the Sale of a Licensed Product even if the manufacture, use, sale, offer for sale or importation of such Licensed
Product infringes more than one Valid Claim of the Penn Patent Rights. 
 3.4 Related Definitions. The term
“Sale” means any bona fide transaction for which amounts are received by Company or its Affiliate or sublicensee for the sale, use, transfer or other disposition of a Licensed Product to an unrelated third party. A Sale is deemed
completed at the time that Company or its Affiliate receives payment or other consideration for a Licensed Product. The term “Quarter” means each three-month period beginning on January 1, April 1, July 1
and October 1. Subject to Section 3.8(iii) for certain Licensed Products, the term “Net Sales” means the amounts or the fair market value attributable to each Sale actually received by Company or its Affiliates, less
Qualifying Costs that are directly attributable to a Sale, specifically identified on an invoice or other documentation and actually borne by Company or its Affiliates. For purposes of determining Net Sales, the words “fair market
value” mean the cash consideration that Company or its Affiliates would realize from an unrelated buyer in an arms length sale of an identical item sold in the same quantity and at the time and place of the transaction. No Net Sales or
royalties shall accrue on the Sale of Licensed Product in reasonable quantities by Company or its Affiliates for promotional or marketing purposes, as part of an expanded access program, as part of clinical trials or as donations to non-profit
institutions or government agencies for non-commercial purposes. Net Sales shall not include any payments between any of Company, its Affiliates and sublicensees. The term “Qualifying Costs” means: (a) customary discounts and
rebates in the trade for quantity purchased, for prompt payment or to purchasers, wholesalers and distributors; (b) credits or refunds for price adjustments, recalls, claims or returns that do not exceed the original received amount; (c) outbound
transportation, handling and shipping expenses and transportation insurance premiums; (d) sales and use taxes and other fees imposed by a governmental agency; and (e) charge back payments and/or rebates provided to managed health care organizations,
international organizations, or governmental agencies (including in the United States, Medicare and Medicaid). 
  

 10 

 PATENT LICENSE AGREEMENT 

 

 3.5 Sublicense Fees. In partial consideration of the License and subject to
Sections 3.7 and 3.8, Company will pay to Penn: 
 (i) [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent
([CONFIDENTIAL TREATMENT REQUESTED] /*/%) of sublicensing royalties actually received by Company and its Affiliates in consideration of sublicenses of the License for Licensed Products Sold by sublicensees for use in the Field of Use while covered
in the country of Sale of expected use by a Valid Claim of the Penn Patent Rights that is licensed to Company under the License, provided that, such amounts payable to Penn with respect to such sublicensing royalties for such Sales of such Licensed
Products shall not be less than [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%) of Net Sales of such Licensed Products made by sublicensees (as such Net Sales definition is applied to sublicensees, and
applying Section 3.8 to such sublicensees’ Net Sales); and 
 (ii) [CONFIDENTIAL TREATMENT REQUESTED]
/*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%) of all other sublicensing fees and payments and other consideration actually received by Company in consideration of sublicenses under the License granted by Company or its Affiliates, excluding
for this clause (ii) (1) sublicensing royalties addressed by clause (i) above, (2) equity investments to the extent not in excess of fair market value made by sublicensees in Company or its Affiliates, (3) payments by
sublicensees to Company or Affiliates for payment or reimbursement of patent prosecution, defense, enforcement and maintenance and/or other related expenses, and (4) payments by sublicensees to Company or its Affiliates for future research,
development or commercialization activities (including pre-clinical or clinical studies) undertaken by or for Company or its Affiliates (including payments for FTEs), and further provided that if Company pays to Penn a milestone payment under
Section 3.2 for achieving a milestone for which Company receives from a sublicensee a payment for achieving the same milestone subject to this Section 3.5(ii), then the amount of the Company’s payment to Penn under Section 3.2
shall be deducted from such sublicensee’s payment for purposes of this Section 3.5(ii) and shall not be subject to such [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%) share. 

3.6 Transaction Fee. In partial consideration of the License, Company will reimburse Penn, within [CONFIDENTIAL TREATMENT
REQUESTED] /*/ ([CONFIDENTIAL TREATMENT REQUESTED] /*/) days after the Effective Date, for Penn’s reasonable out-of-pocket legal fees, a one-time, non-refundable, non-creditable transaction fee up to $[CONFIDENTIAL TREATMENT REQUESTED] /*/
with respect to Penn’s negotiation and execution of this Agreement and the Term Sheet between the parties dated November, 2005 (the “Term Sheet”) and the TDA. 

 

 11 

 PATENT LICENSE AGREEMENT 

 

 3.7 Payment Reductions and Credits. The following credits will apply to amounts
payable to Penn under Sections 3.2, 3.3 and 3.5 (except as otherwise provided in Section 3.7(i)). In no event will the aggregate credits under this Section 3.7 reduce, due to the application of the credits, any individual payment
otherwise due under Sections 3.2, 3.3 or 3.5 for a given Quarter to less than [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%) of the amount that would have otherwise been due in the absence of such
credit(s) (taking into account for all purposes Section 3.8). Any unused credits will be carried forward to future Quarters, provided that in no event will any unused credits or prior payments by Company be refundable. 

(i) [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%) of milestone payments paid by
Company under Section 3.2 will be creditable against future amounts owed to Penn under Sections 3.3 and 3.5. 

(ii) Royalties and milestones payable by Company and its Affiliates to BMS for the actual cost to Company and its
Affiliates of licenses or assignments by Company, its Affiliates or sublicensees to intellectual property relating to the Field of Use will be creditable. As of the Effective Date, there are no such costs payable to BMS. 

(iii) Third party royalties and milestones (other than as credited under Section 3.7(ii)) for actual costs to Company
and its Affiliates of licenses and acquisitions by Company, its Affiliates or sublicensees of intellectual property rights dominating or dominated by the Penn Patent Rights and therefore necessary to practice the Penn Patent Rights in a particular
country will be creditable. 
 (iv) Third party royalties and milestones (other than as credited under
Section 3.7(ii) or 3.7(iii)) for the actual costs to Company and its Affiliates of licenses and acquisitions by Company, its Affiliates or sublicensees of intellectual property rights reasonably necessary for the manufacture, use, sale,
offer for sale or importation of any Licensed Product in a particular country will be creditable, provided that, in the case of royalties, only where the aggregate royalty burden for such Licensed Product in a particular country exceeds
(a) [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%) of the Blended Rate (as defined below) or (b) [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%), as
applicable, and in such a royalty case, Company will be entitled to a credit in the amount of [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%) of such excess. For purposes of this Agreement, “Blended
Rate” means (1) the total amount of royalties that would be payable in the applicable Quarter and prior three (3) Quarters with respect to the applicable Designated Compound under Section 3.3(i), divided by (2) the total
Net Sales of such Designated Compound for that same period, expressed as a percentage (assuming for this definition only that all worldwide Sales of such Designated Compound made by sublicensees produce corresponding Net Sales that are attributed to
Company for determining such royalties under Section 3.3 (and applying Section 3.8 to such sublicensees’ Net Sales)). 
  

 12 

 PATENT LICENSE AGREEMENT 

 

 3.8 Other Royalty Provisions. 

(i) Notwithstanding anything herein to the contrary, if a Licensed Product is not covered at the time of Sale in the
country of Sale of expected use by a Valid Claim of the Penn Patent Rights that is licensed to Company under the License, such Sale of Licensed Product will not be treated as a “Sale” hereunder, will not give rise to any Net Sales,
and no royalty or other amount will be payable under Section 3.3 or 3.5 with respect to such Sale. 

(ii) Notwithstanding anything herein to the contrary, if a Licensed Product on which royalties are owed Penn under
Section 3.3 or 3.5(i) is covered at the time of Sale in the country of Sale of expected use only by Valid Claim(s) of the Penn Patent Rights jointly owned by Company and Penn and no other Valid Claims of the Penn Patent Rights solely owned
by Penn, then the royalty rate set forth in Section 3.3(ii) shall be reduced by [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%) for such Sales in such country. 

(iii) In the event that a Licensed Product includes a component(s) or its use covered at the time of Sale in the country
of Sale by a Valid Claim of the Penn Patent Rights that is licensed to Company under the License (each, a “Patented Component”) and a component(s) which is active alone or in a combination and is not so covered, then Net Sales
of such Licensed Product shall be calculated as follows: Net Sales for such Licensed Product for Section 3.3 and the proviso in Section 3.5(i) shall be calculated by multiplying actual Net Sales of such Licensed Product by the fraction
A/B, where A is the [CONFIDENTIAL TREATMENT REQUESTED] /*/ price of the [CONFIDENTIAL TREATMENT REQUESTED] /*/ in such [CONFIDENTIAL TREATMENT REQUESTED] /*/ if [CONFIDENTIAL TREATMENT REQUESTED] /*/ in [CONFIDENTIAL TREATMENT REQUESTED] /*/, and B
is [CONFIDENTIAL TREATMENT REQUESTED] /*/ of such [CONFIDENTIAL TREATMENT REQUESTED] /*/. If such Licensed Product is not sold separately in finished form in a given country, the parties shall determine Net Sales for such Licensed Product by mutual
agreement based on the relative contribution of such Patented Component(s) and each such other active component(s) in such Licensed Product (including whether there are any reasonable substitutes available for such Patented Component(s) or such
other active ingredient(s)), and shall take into account in good faith any applicable allocations and calculations that may have been made for the same period in other countries. 

4. REPORTS AND PAYMENTS 

4.1 Royalty Reports. Within forty-five (45) days after the end of each Quarter following the first Sale and during the
remainder of the Term, Company will deliver to Penn a report, certified by the chief financial officer of Company, detailing the calculation of all royalties, fees and other payments due to Penn for such Quarter. The report will include, at a
minimum, the following information for the Quarter, each listed by product, by country of Sale and by category of royalty or sublicense fee rate, as applicable: (a) the number of units of Licensed Products constituting Sales made by Company and
Affiliates on which royalties are owed Penn hereunder; (b) the gross amount invoiced, billed or received for such Sales made by Company and Affiliates; (c) Qualifying Costs corresponding to Net Sales arising from such Sales, listed by
category of cost; (d) such Net Sales; (e) the gross amount of any payments 
  

 13 

 PATENT LICENSE AGREEMENT 

 

 
received by Company from sublicensees subject to sharing with Penn under Section 3.5; (f) the amounts of any credits or reductions permitted by Section 3.7 with respect to Sales
made by Company and Affiliates; (g) the royalties, fees and other payments owed to Penn, listed by category; and (h) the computations for any applicable currency conversions by Company and Affiliates. Company will use commercially
reasonable efforts to obtain permission from each sublicensee to share with Penn the information listed in the foregoing clauses (other than clause (e)) as it relates to Sales made by such sublicensee, and to the extent successful, will include
such sublicensee information in such royalty report. Each royalty report will be substantially in the form of the sample report attached as Exhibit D. All such royalty reports will be treated as Confidential Information of Company and
will be subject to Section 5.2. 
 4.2 Payments. Company will pay all royalties, fees and other payments due to Penn
under Sections 3.2, 3.3 and 3.5 within [CONFIDENTIAL TREATMENT REQUESTED] /*/ ([CONFIDENTIAL TREATMENT REQUESTED] /*/) days after the end of the Quarter in which the royalties, fees or other payments accrued. 

4.3 Records. Company will maintain, and will cause its Affiliates and sublicensees to maintain, complete and accurate books and
records to verify Sales, Net Sales, and all of the royalties, fees, and other payments due or paid under this Agreement, as well as the various computations reported under Section 4.1. The records for each Quarter will be maintained for at
least three (3) years after submission of the applicable report required under Section 4.1. 
 4.4 Audit
Rights. Upon reasonable prior written notice to Company, Company and its Affiliates and sublicensees will provide an independent, nationally recognized auditor selected by Penn and reasonably acceptable to Company with access to all of the
books, records and related background information required by Section 4.3 to conduct an audit of Sales, Net Sales, and all of the royalties, fees, and other payments payable under this Agreement. Access will be made available: (a) during
normal business hours; (b) in a manner reasonably designed to facilitate such auditor’s audit without unreasonable disruption to Company’s or Affiliate’s or sublicensee’s business; and (c) no more than once each
calendar year during the Term and for a period of three (3) years thereafter. The auditor shall execute and deliver to Company or its Affiliate or sublicensee a confidentiality agreement reasonably acceptable to Company and shall disclose to
Penn only the results and the basis for such results of such audit, all of which will be treated as Confidential Information of Company and will be subject to Section 5.2. Company will promptly pay to Penn the amount of any underpayment
determined by such audit, plus accrued interest. If such audit determines that Company has underpaid any payment by [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%) or more, then Company will also promptly
reimburse Penn for its reasonable out-of-pocket costs of the audit; otherwise, Penn shall bear all such costs. Any overpayments will be fully creditable against amounts payable by Company to Penn in subsequent Quarters. 

4.5 Currency. All dollar amounts referred to in this Agreement are expressed in United States dollars. All payments will be made
in United States dollars. If Company receives payment from a third party in a currency other than United States dollars for which a royalty or fee is owed under this Agreement, then (a) the payment will be converted into United States dollars
at the conversion rate for the foreign currency as published in the eastern edition of the 
  

 14 

 PATENT LICENSE AGREEMENT 

 

 
Wall Street Journal as of the last business day of the Quarter in which the payment was received by Company, and (b) the conversion computation will be documented by Company in the
applicable report delivered to Penn under Section 4.1. 
 4.6 Place of Payment. All payments by Company are payable
to “The Trustees of the University of Pennsylvania” and will be made to the following addresses: 
  

			
	 By Electronic Transfer:
	  	 By Check:

	 [CONFIDENTIAL TREATMENT REQUESTED] /*/

[*] /*/ #[*] /*/
	  	 The Trustees of the University of Pennsylvania

c/o Center for Technology Transfer
 P.O. Box
7777-W3850
 Philadelphia, PA 19175-3850

	Account Number: [CONFIDENTIAL TREATMENT REQUESTED] /*/	  
	c/o: [CONFIDENTIAL TREATMENT REQUESTED] /*/	  

 4.7 Interest. All amounts that are not paid by Company
when due will accrue interest from the date due until paid at a rate equal to [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%) per month (or the maximum allowed by law, if less). 

5. CONFIDENTIALITY AND USE OF PENN’S NAME 

5.1 Confidentiality Agreement. If Company and Penn entered into one or more Confidential Disclosure Agreements prior to the
Effective Date, then such agreements will continue to govern the protection of confidential information under this Agreement, and each Affiliate and sublicensee of Company will be bound to Company’s obligations under such agreements. If,
however, no Confidential Disclosure Agreement has been entered into between Company and Penn prior to the Effective Date, then in connection with the execution of this Agreement, the parties will enter into a Confidential Disclosure Agreement
substantially similar to Penn’s standard form. The term “Confidentiality Agreement” means all Confidential Disclosure Agreements between the parties that remain in effect after the Effective Date, and the term
“Confidential Information” refers to confidential or proprietary information thereunder. 
 5.2 Other
Confidential Matters. Penn is not obligated to accept any Confidential Information from Company, except for the reports and other disclosures required by Sections 1.5(ii), 2.1, 4.1, 4.4 and 6.7. Penn, acting through its Center for
Technology Transfer and Finance Offices, will not during the Term or thereafter disclose to any third party outside of such Center or Office (including any other internal office or department of Penn) without Company’ prior written consent the
terms of this Agreement or any Confidential Information of Company contained in those reports or other disclosures, for so long as such information or terms remains confidential. Penn bears no institutional responsibility for maintaining the
confidentiality of any other information of Company, except as provided in this Section 5.2 or in the Confidentiality Agreement. Company may elect to enter into confidentiality agreements with individual investigators at Penn that comply with
Penn’s internal policies. 
  

 15 

 PATENT LICENSE AGREEMENT 

 

 5.3 Use of Penn’s Name. Company and its Affiliates, sublicensees, employees,
and agents may not use the name, logo, seal, trademark, or service mark (including any adaptation of them) of Penn or any Penn school, organization, employee, student or representative, without the prior written consent of Penn, provided that any of
them may state that Company, its Affiliates and sublicensees are licensed by Penn under the Penn Patent Rights, may make statements of fact (including of past or present consulting relationships), and may make disclosures or statements required by
law or regulation. 
 6. TERM AND TERMINATION 

6.1 Term. This Agreement will commence on the Effective Date and will expire, on a country-by-country basis, upon there no longer
being any Valid Claim of the Penn Patent Rights that is licensed to Company under the License, unless terminated earlier as provided in Section 6.2, 6.3 or 6.4 (the “Term”). On a country-by-country basis, upon
expiration (but not termination) of this Agreement, the License will become irrevocable and fully paid up. 
 6.2 Early
Termination by Company. Company may terminate this Agreement at any time effective upon completion of each of the following conditions: (a) providing at least sixty (60) days prior written notice to Penn of such intention to terminate;
(b) ceasing to make, have made, use, import, offer for sale and sell all Licensed Products on which royalties would be due Penn hereunder; (c) terminating all sublicenses and causing all Affiliates and sublicensees to cease making, having
made, using, importing, offering for sale and selling all such Licensed Products, subject to Section 6.8; and (d) paying all amounts owed to Penn under this Agreement and the Other Agreements through the effective date of termination.

 6.3 Early Termination by Penn. After completion of the informal dispute resolution procedure outlined in the first
sentence of Section 13.11, Penn may terminate this Agreement if: (a) Company is more than thirty (30) days late in paying to Penn any undisputed amounts owed under this Agreement and does not immediately pay Penn such amounts in full,
including accrued interest, upon demand; (b) Company or its Affiliate or sublicensee materially breaches this Agreement and does not cure such material breach within one hundred twenty (120) days after written notice from Penn specifying the
alleged material breach in reasonable detail; or (c) Company experiences a Trigger Event. 
 6.4 Early Termination by
Company. After completion of the informal dispute resolution procedure outlined in the first sentence of Section 13.11, Company may terminate this Agreement if Penn materially breaches this Agreement and does not cure such material breach
within one hundred twenty (120) days after written notice from Company specifying the alleged material breach in reasonable detail. 

6.5 Trigger Event. The term “Trigger Event” means any of the following: (a) if Company (i) becomes
bankrupt or generally fails to pay its debts as such debts become due, (ii) is adjudicated insolvent or bankrupt, (iii) admits in writing its inability to pay its debts, (iv) suffers the appointment of a custodian, receiver or trustee
for it or its property and, if 
  

 16 

 PATENT LICENSE AGREEMENT 

 

 
appointed without its consent, not discharged within ninety (90) days, (v) makes an assignment for the benefit of creditors, or (vi) suffers proceedings being instituted against it
under any law related to bankruptcy, insolvency, liquidation or the reorganization, readjustment or release of debtors and, if contested by it, not dismissed or stayed within ninety (90) days; (b) the institution or commencement by Company of
any proceeding under any law related to bankruptcy, insolvency, liquidation or the reorganization, readjustment or release of debtors; (c) the entering of any order for material relief relating to any of the proceedings described in
clause (a) or (b) above; or (d) the act or failure to act by Company indicating its consent to, approval of or acquiescence in any of the proceedings described in clauses (a) to (c) above. 

6.6 Effect of Termination. Upon the termination of this Agreement for any reason: (a) the License terminates (unless already
expired in a country as provided for and with the consequences specified in Section 6.1); (b) Company and all its Affiliates and sublicensees will cease all making, having made, using, importing, offering for sale and selling all Licensed
Products on which royalties would be due Penn hereunder, except to the extent permitted by Sections 6.7 or 6.8; (c) Company will pay to Penn all amounts, including accrued interest, owed to Penn under this Agreement and the Other
Agreements through the date of termination; (d) Company will, at Penn’s request, return to Penn all Confidential Information of Penn; (e) Penn will, at Company’s request, return to Penn all Confidential Information of Company
subject to Section 5.2; and (f) in the case of termination under Section 6.3, all duties of Penn and all rights (but not duties except as otherwise provided by Section 6.9) of Company under this Agreement immediately terminate
without further action required by either Penn or Company, provided that with respect to the foregoing clauses (d) and (e), each of Company and Penn will have the right to retain the other’s Confidential Information to the extent it
relates to a proprietary or licensed interest hereunder that survives such termination, and further in all events shall be entitled to retain one archival copy of the other’s Confidential Information strictly for legal purposes. 

6.7 Inventory & Sell Off. Upon the termination of this Agreement for any reason (and subject to Section 6.8),
Company will cause physical inventories to be taken immediately of: (a) all completed Licensed Products on which royalties would be due Penn hereunder on hand under the control of Company or its Affiliates or sublicensees; and (b) such
Licensed Products as are in the process of manufacture on the date of termination of this Agreement. Company will deliver promptly to Penn a copy of the written inventory, certified by an officer of Company, which will be treated as Confidential
Information of Company and will be subject to Section 5.2. Upon termination of this Agreement for any reason (and subject to Section 6.8), Company will use commercially reasonable efforts to promptly remove, efface or destroy all
references to Penn from any advertising, labels, web sites or other materials used in the promotion of the business of Company or its Affiliates or sublicensees, and Company and its Affiliates and sublicensees will not represent in any manner that
it has rights in or to the Penn Patent Rights, provided that Company, Affiliates and sublicensees may make statements of fact (including of past or present consulting relationships) and may make disclosures or statements required by law or
regulation. Upon the termination of this Agreement for any reason(and subject to Section 6.8), Company, Affiliates and sublicensees may sell off their inventory of Licensed Products existing on the date of termination for a period of

  

 17 

 PATENT LICENSE AGREEMENT 

 

 
six (6) months and may complete the manufacture of Licensed Products then in the process of manufacture and sell them, provided that Company pay Penn royalties on Sales of such inventory as
provided in Article 3 within thirty (30) days following the expiration of such six (6) month period. 
 6.8 Surviving
Sublicenses. In the event that the License is terminated hereunder for any reason, any sublicense under the License granted by Company prior to termination of the License in conformance with Section 1.5 (and any sublicenses granted under
such sublicense) will remain in full force and effect, provided that: 
 (i) such Company sublicensee is not then
in breach of its sublicense agreement; 
 (ii) such Company sublicensee agrees in writing within ninety (90)
days of such termination to be bound to Penn as the licensor under the terms and conditions of its sublicense agreement, as modified by the provisions of this Section 6.8; 

(iii) such Company sublicensee, at Penn’s written request, assumes in a signed writing the same obligations to Penn
as those of Company under Articles 11 and 12 (provided that the insurance requirements may be satisfied by self-insurance if such sublicensee elects to self-insure generally); 

(iv) Penn will have the right to receive any payments payable to Company under such sublicense agreement to the extent
they are reasonably and equitably attributable to such Company sublicensee’s right under such sublicense to use and exploit Penn Patent Rights; 

(v) such Company sublicensee agrees to be bound by the due diligence obligations of Company pursuant to Section 2.2
in the field and territory of the sublicense; and 
 (vi) Penn will not assume, and will not be responsible to
such Company sublicensee for, any representations, warranties or obligations of Company to such sublicensee, other than to permit such sublicensee to exercise any rights in or to Penn Patent Rights, Penn Materials and Assigned BMS Technical
Information that are granted under such sublicense agreement in a manner consistent with the terms of this Agreement; 
 whereupon the
consequences set forth in Sections 1.5(iii), 6.2, 6.6 and 6.7 or elsewhere hereunder regarding any terminated sublicense under the License shall not apply to any such sublicenses. 

6.9 Survival. Company’s obligation to pay all amounts, including accrued interest, owed to Penn under this Agreement will
survive the termination or expiration of this Agreement for any reason. Further, neither party shall be relieved of any other liability or obligation or right that accrued prior to the effective date of any termination or expiration of this
Agreement. Sections 1.2, 1.8 (but only to the extent that an Improvement or New Development is subject to such Section as of such expiration or termination) and 9.3 and Articles 4, 5, 6, 8 (but only with

  

 18 

 PATENT LICENSE AGREEMENT 

 

 
respect to infringement occurring before, or any litigation, action or proceeding already initiated as of, such expiration or termination), 10, 11, 12 and 13 will survive the termination or
expiration of this Agreement for any reason in accordance with their respective terms, and all other provisions hereunder shall terminate. 

7. PATENT MAINTENANCE AND REIMBURSEMENT 

7.1 Patent Maintenance. As provided in the TDA, as between BMS and Penn, Penn will have exclusive control (subject to reasonable
communication on a periodic basis with BMS regarding the status of the prosecution of pending patent applications within the Assigned BMS Patents, including amendments to claim scope) of the prosecution and maintenance of the Assigned BMS Patents,
including regarding any extensions, interferences, oppositions, reissue proceedings and re-examinations with respect thereto. As between Penn and Company, Company will manage the preparation, prosecution and maintenance of the Penn Patent Rights and
will make all decisions with regards thereto (including regarding any interferences, oppositions, reissue proceedings and re-examinations with respect thereto), and with respect to the Assigned BMS Patents, Penn hereby delegates its prosecution and
maintenance control under Section 6.1(a) of the TDA to Company, provided that Company and Penn have entered into with patent counsel a Client and Billing Agreement in substantially the form attached as Exhibit E. Company will select
patent counsel reasonably acceptable to Penn to prepare, prosecute and maintain the Penn Patent Rights, Penn and Company will be the client of that counsel, Penn will receive copies of all invoices, payments and material correspondence relating to
the prosecution of the Penn Patent Rights, and Penn retains the right to advise Company regarding such activities. Penn will promptly provide to Company all papers concerning the ownership, prosecution and maintenance of the Assigned BMS Patents
Penn receives from BMS (including all assignment documents required by Article 3.1 of the TDA). 
 7.2 Patent
Reimbursement. Within [CONFIDENTIAL TREATMENT REQUESTED] /*/ ([CONFIDENTIAL TREATMENT REQUESTED] /*/) days after the Effective Date, Company will reimburse Penn for all historically accrued attorneys fees, expenses, official fees and all other
charges accumulated prior to the Effective Date incident to the preparation, filing, prosecution and maintenance of the Penn Patent Rights (including any interference negotiations, claims or proceedings), including those amounts paid by Penn to BMS
before the Effective Date pursuant to the TDA, Penn’s good faith estimate is that such fees, expenses and other charges in the aggregate are $[CONFIDENTIAL TREATMENT REQUESTED] /*/. Thereafter during the Term, Company will either pay directly
under the Client and Billing Agreement then in effect or reimburse Penn for all its out-of-pocket and documented attorneys fees, expenses, official fees and all other charges accumulated on or after the Effective Date incident to the preparation,
filing, prosecution and maintenance of the Penn Patent Rights, including any interference negotiations, claims or proceedings, within [CONFIDENTIAL TREATMENT REQUESTED] /*/ ([CONFIDENTIAL TREATMENT REQUESTED] /*/) days after Company’s receipt
of invoices from Penn for such fees, expenses and other charges. Penn will invoice Company for any such fees, expenses and other charges on a monthly basis. 

7.3 Patent Abandonment. Under Section 6.1(a)(ii) of the TDA, Penn has the right to discontinue paying the Patent Costs (as
defined in the TDA), or to discontinue prosecution and 
  

 19 

 PATENT LICENSE AGREEMENT 

 

 
maintenance of any of the Assigned BMS Patent(s). Before exercising any such rights with respect to BMS, Penn will first provide Company with sufficient notice so that Company may cure any
failure hereunder to pay any such Patent Costs or otherwise before any patent rights are forfeited or offered for assignment to BMS under that Section of the TDA. If after such notice Company then fails to pay the Patent Costs, as contemplated in
Section 7.2, or otherwise elects not to continue to prosecute or maintain any Assigned BMS Patent(s), as contemplated by Section 7.1, then Penn will have the right to offer such Assigned BMS Patent(s) to BMS for assignment or absence such
an assignment abandon them as provided in that Section of the TDA. Company may elect not to prosecute or maintain any Penn Patent Rights effective upon written notice to Penn, whereupon such Penn Patent Right will no longer be subject to the License
or be treated as a “Penn Patent Right” hereunder, provided that Company will remain responsible for all expenses incurred with respect to such Penn Patent Right as provided in Section 7.2 until Penn’s receipt of such notice.

 7.4 Patent Extensions and Orange Book Listings. If elections with respect to obtaining patent term extensions
(including any available pediatric extensions) or supplemental protection certificates or their equivalents in any country with respect to Penn Patent Rights are available, Company will have the exclusive right to make any such elections based on
Licensed Products. With respect to data exclusivity periods (such as those periods listed in the FDA’s Orange Book (including any available pediatric extensions) or periods under national implementations of Article 10.1(a)(iii) of
Directive 2001/EC/83 or orphan exclusivity periods, and all equivalents in any country), Company will have the sole right to seek and maintain all such data exclusivity periods available for the Licensed Products. With respect to all of the
rights and activities identified in this Section 7.4, Penn hereby appoints Company as its agent for such purposes with the authority to act on Penn’s behalf with respect to the Penn Patent Rights, provided that such actions are consistent
with this Agreement and provided further that Company’s actions, in Company’s reasonable judgment, are not likely to harm Penn’s reputation or good standing. 

8. INFRINGEMENT 
 8.1
Notice. Company and Penn will notify each other promptly of any infringement of the Penn Patent Rights (but with respect to the Assigned BMS Patents, only to the extent that Penn has enforcement rights thereunder as provided in
Section 6.1 of the TDA), or any declaratory judgment action or any other action or proceeding alleging invalidity, unenforceability or non-infringement of the Penn Patent Rights (other than interferences, oppositions, reissue proceedings and
re-examinations with respect thereto, which are addressed in Section 7.1), that may come to their attention. Company and Penn will consult each other in a timely manner concerning any appropriate response to such infringement or action or
proceeding. 
 8.2 Prosecution. Company may (but is not obligated to) prosecute under its sole control any infringement
of the Penn Patent Rights at Company’s expense (but with respect to the Assigned BMS Patents, only to the extent that Penn has enforcement rights thereunder as provided in the TDA). For clarity, Company has the first right to enforce the
Assigned BMS Patent Rights in the “Exclusive Area,” as such term is defined in the TDA and as applied to the “University” thereunder, notwithstanding the fact that the License under the Assigned BMS

  

 20 

 PATENT LICENSE AGREEMENT 

 

 
Patents only extends to the Field of Use. In the event that any such declaratory judgment action or such other action or proceeding is brought, Company shall have the first right to defend any
such action at Company’s expense, including defending against any counterclaims or crossclaims brought by any party against Company or Penn regarding the Penn Patent Rights and defending against any claim that the Penn Patent Rights are
invalid in the course of any infringement action or in a declaratory judgment action. With respect to the Assigned BMS Patents, Company shall have all the rights and obligations afforded “University” or “Licensee Entities”
under Section 6.1(b) of the TDA (including the right to participate at Company’s own cost in any BMS-controlled litigation activities concerning the Assigned BMS Patents). Company must not settle or compromise any such litigation, action
or proceeding in a manner that imposes any obligations or restrictions on Penn or grants any rights to the Penn Patent Rights without Penn’s prior written permission (unless any such grant by Company amounts to a permitted sublicense
hereunder). If Penn chooses not to intervene voluntarily, but Penn is a necessary party to the action, then Company may join Penn in the litigation. If Company prosecutes any infringement claims with Penn involuntarily joined as a party, then
Company will reimburse Penn for Penn’s reasonable litigation expenditures as a result of such involuntary joinder (but not for any active participation by Penn, which resulting expenditures shall be addressed as if Penn had intervened
voluntarily as contemplated by Section 8.3), including any attorney’s fees, expenses, official fees and other charges incurred by Penn, even if there are no financial recoveries from the infringement action. Company will reimburse Penn for
such reasonable expenditures within thirty (30) days after receiving each invoice from Penn. After reimbursing Penn for such reasonable expenditures, recoveries from any such litigation, action or proceeding will be: (a) first, applied to
reimburse Company for its related expenditures; and (b) second, as to any remainder, retained by Company but treated (as appropriate by reference to the commercializing entity in the affected country(ies)) as either (i) Net Sales for the
purpose of determining the royalties due to Penn under Section 3.3 or (ii) sublicense consideration for the purpose of determining the sublicense fees due to Penn under Section 3.5(i), provided that Company shall retain all damage
recoveries for willful infringement. 
 8.3 Intervention. Penn reserves the right to intervene at Penn’s expense and
join Company in any litigation, action or proceeding under Section 8.2, provided that Company retains sole control of the same subject to reasonable consultation with Penn. If Penn elects to participate in any such litigation, action or
proceeding, then, clause (a) of Section 8.2 shall be replaced with the following “first, applied to reimburse Company and Penn for their respective related expenditures (and if such recoveries are inadequate to reimburse the parties
in full, then on a pro rata basis in proportion with their respective shares of the aggregate related expenditures),”. 

8.4 Penn Prosecution. If Company does not prosecute any infringement of the Penn Patent Rights by any unrelated third parties,
then Penn may elect (but is not obligated) to prosecute such infringement under Penn’s sole control at Penn’s expense. Alternatively, if Company does not defend any such declaratory judgment action or such other action or proceeding, then
Penn may elect (but is not obligated) to defend the same at Penn’s expense. If Penn elects to prosecute such infringement or so defend, then any financial recoveries therefrom will retained by Penn in their entirety, provided that Company may
elect to intervene as provided in Section 8.3, with the parties’ roles reversed thereunder and the financial recoveries as provided in Section 8.2 as a result of such Company intervention. 

 

 21 

 PATENT LICENSE AGREEMENT 

 

 8.5 Patent Certifications. Penn shall notify and provide Company with copies of
any allegations of alleged patent invalidity, unenforceability or non-infringement of a Penn Patent Right pursuant to a Paragraph IV Patent Certification by a third party filing an Abbreviated New Drug Application, an application under
§505(b)(2) or any other similar patent certification by a third party, and any foreign equivalent thereof. Such notification and copies shall be provided to Company within five (5) business days after Penn receives such certification, and
shall be sent to the addresses specified in Section 13.6. 
 8.6 Cooperation. In any litigation, action, proceeding
or other activities under this Article 8, or any prosecution, maintenance or other activities under Article 7, either party, at the request and expense of the other party, will cooperate to the fullest extent reasonably possible, including
Penn agreeing to be a named party in any Company-controlled or -managed litigation, action or proceeding under Section 8.2. This Section 8.6 will not be construed to require either party to undertake any activities, including legal
discovery, at the request of any third party, except as may be required by lawful process of a court of competent jurisdiction. 
 9.
REPRESENTATIONS AND WARRANTIES 
 9.1 Penn Representations. Penn hereby represents to Company on the Effective Date
that: (a) it is a nonprofit corporation existing under the laws of the Commonwealth of Pennsylvania and has the power and authority to enter into this Agreement; (b) it has taken all necessary action to authorize its execution and delivery
of this Agreement and to authorize the performance of its obligations hereunder; (c) execution and delivery of this Agreement and its performance by Penn will not result in any breach or violation of, or constitute a default under, any
agreement, instrument, judgment or order to which Penn is a party or by which it is bound; (d) it is has the right to grant all of the licenses and privileges granted herein; (e) to the knowledge of Penn’s Center for Technology
Transfer (without inquiry), there are no pending declaratory judgment actions, interferences, oppositions, reissue proceedings or re-examinations involving the Penn Patent Rights; (f) to the knowledge of Penn’s Center for Technology
Transfer (without inquiry), the manufacture, use, sale, offer for sale or importation of any Licensed Product, or the practice of an Penn Patent Rights, does not and will not infringe or misappropriate any third party patent or other intellectual
property rights; and (g) to the knowledge of Penn’s Center for Technology Transfer (without inquiry), there are no patent applications or issued patents in which Penn has an ownership interest and for which Dr. Rader is a named
inventor claiming any Improvements, other than the Penn Existing Patents. 
 9.2 Company Representations. Company hereby
represents to Penn on the Effective Date that: (a) it is a corporation existing under the laws of the State of Delaware and has the power and authority to enter into this Agreement; (b) it has taken all necessary action to authorize its
execution and delivery of this Agreement and to authorize its performance of its obligations hereunder; and (c) execution and delivery of this Agreement and its performance by Company will not result in any breach or violation of, or constitute
a default under, any agreement, instrument, judgment or order to which Company is a party or by which it is bound. 
 9.3
Disclaimer. EXCEPT AS PROVIDED IN SECTIONS 9.1 AND 9.2, (a) THE PENN PATENT RIGHTS, LICENSED PRODUCTS, PENN MATERIALS AND ANY OTHER TECHNOLOGY LICENSED UNDER THIS AGREEMENT BY PENN ARE PROVIDED ON

  

 22 

 PATENT LICENSE AGREEMENT 

 

 
AN “AS IS” BASIS, AND (b) NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF ACCURACY, COMPLETENESS, PERFORMANCE, MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE, COMMERCIAL UTILITY, NON-INFRINGEMENT OR TITLE. 
 10. LIMITATION OF LIABILITY 

10.1 Mutual Limitation of Liability. NEITHER PENN NOR COMPANY WILL BE LIABLE TO THE OTHER PARTY, ITS AFFILIATES, SUBLICENSEES,
EMPLOYEES, TRUSTEES, SUCCESSORS OR ASSIGNS, OR ANY THIRD PARTY WITH RESPECT TO ANY CLAIM: ARISING FROM THE OTHER PARTY’S USE OF THE PENN PATENT RIGHTS, LICENSED PRODUCTS, OR ANY OTHER TECHNOLOGY LICENSED UNDER THIS AGREEMENT; OR FOR LOST
PROFITS, BUSINESS INTERRUPTION, OR INDIRECT, PUNITIVE, SPECIAL OR CONSEQUENTIAL DAMAGES OF ANY KIND. 
 10.2 Limitation on
Penn’s Liability. Penn assumes no responsibilities whatsoever with respect to the practice by Company or its Affiliates or sublicensees of the Penn Patent Rights, Licensed Products or any other technology licensed under this Agreement. Penn
relies on Company to practice such intellectual property in accordance with accepted research, development, governmental and medical requirements. Company shall, as of the Effective Date, assume all risk, liability and lawsuits arising out of or in
the course of such practice as between Penn and Company. 
 11. INDEMNIFICATION 

11.1 Indemnification. Company will defend, indemnify, and hold harmless each Indemnified Party from and against any and all
Liabilities with respect to an Indemnification Event. The term “Indemnified Party” means each of Penn and its trustees, officers, faculty, agents, contractors, employees and students. The term “Liabilities” means
all damages, awards, deficiencies, settlement amounts, defaults, assessments, fines, dues, penalties, costs, fees, liabilities, obligations, taxes, liens, losses, lost profits and expenses (including court costs, interest and reasonable fees of
attorneys, accountants and other experts) that are incurred by an Indemnified Party or awarded or otherwise required to be paid to third parties by an Indemnified Party. The term “Indemnification Event” means any Claim against one
or more Indemnified Parties arising out of or resulting from: (a) the development, testing, use, manufacture, promotion, sale, practice or other disposition of any Penn Patent Rights (to the extent subject to the License), BMS Assigned
Technical Information or Penn Materials by Company, its Affiliates, sublicensees, assignees or vendors, or of any Licensed Products manufactured, sold or provided by Company, its Affiliates, sublicensees, assignees or vendors, including (x) any
product liability or other Claim of any kind related to use by a third party of such Penn Materials or Licensed Product, (y) any Claim by a third party (other than any Indemnified Party) that the practice of any of the Penn Patent Rights or BMS
Assigned Technical Information by Company, its Affiliates, sublicensees, assignees or vendors, or the design, composition, manufacture, use, sale or other disposition of any such Penn Materials or Licensed Product, infringes or violates any patent,
copyright, trade secret, trademark or other intellectual property right of such third party, and (z) any Claim by a third party relating to clinical trials or studies for such Licensed Products; (b) any Claim by a third party arising from
any material breach of this Agreement by 
  

 23 

 PATENT LICENSE AGREEMENT 

 

 
Company or its Affiliates or sublicensees; and (c) the enforcement of this Article 11 by any Indemnified Party, except for (1) any Claims arising out of the willful misconduct or
gross negligence of, or material breach of this Agreement by, Penn or any other Indemnified Party, or (2) any Claims arising out of the development, testing, use, manufacture, promotion, sale, practice or other disposition of any Penn Patent
Rights, BMS Assigned Technical Information or Licensed Products pursuant to the retained rights under Section 1.3 (and not as part of any Other Agreement). The term “Claim” means any charges, complaints, actions, suits,
proceedings, hearings, investigations, claims or demands. 
 11.2 Other Provisions. Penn shall give prompt and timely
notice to Company after Penn becomes aware of any Indemnification Event as to which indemnity may be sought (and in any event no less than fifteen (15) days notice), and shall permit Company to assume the sole defense and settlement of the
applicable Claim, provided that failure of Penn to give prompt and timely notice shall not relieve Company of its obligations under this Article 11, except and only to the extent that Company is actually prejudiced as a result of such failure
to give prompt notice. Each Indemnified Party shall furnish such information regarding itself or the Claim in question, and shall otherwise cooperate in the defense of any such Claim, as Company may reasonably request. Company will not settle or
compromise any Indemnification Event giving rise to Liabilities in any manner that imposes any restrictions or obligations on Penn or grants any rights to the Penn Patent Rights or the Licensed Products without Penn’s prior written consent
(unless any such grant by Company amounts to a permitted sublicense hereunder). If Company fails or declines to assume the defense of any Indemnification Event within thirty (30) days after notice of the applicable Claim, then Penn may assume
the defense of such Claim for the account and at the risk of Company, and any Liabilities related to such Claim will be conclusively deemed a liability of Company. 

12. INSURANCE 
 12.1
Coverages. Company will procure and maintain insurance policies for the following coverages with respect to personal injury, bodily injury and property damage arising out of Company’s performance under this Agreement: (a) during the
Term, comprehensive general liability, including broad form and contractual liability, in a minimum amount of $2,000,000 combined single limit per occurrence and in the aggregate; (b) prior to the commencement of clinical trials involving
Licensed Products, clinical trials coverage in a minimum amount of $3,000,000 combined single limit per occurrence and in the aggregate; and (c) prior to the Sale of the first Licensed Product, product liability coverage, in a minimum amount of
$2,000,000 combined single limit per occurrence and in the aggregate, with the coverage provided for in clauses (b) and (c) to remain in force during the Term and for at least five (5) years thereafter. Penn may review periodically
the adequacy of the minimum amounts of insurance for each coverage required by this Section 12.1, and Penn reserves the right to require Company to adjust the limits accordingly (but in all events in no more than customary industry norms for a
company of Company’s size and at its stage of development). The required minimum amounts of insurance do not constitute a limitation on Company’s liability or indemnification obligations to Penn under this Agreement. 

12.2 Other Requirements. The policies of insurance required by Section 12.1 will be issued by an insurance carrier with an
A.M. Best rating of “A” or better and will name Penn as 
  

 24 

 PATENT LICENSE AGREEMENT 

 

 
an additional insured with respect to Company’s performance under this Agreement. Company will provide Penn with insurance certificates evidencing the required coverage within thirty
(30) days after the Effective Date and the commencement of each policy period and any renewal periods. Each certificate will provide that the insurance carrier will notify Penn in writing at least thirty (30) days prior to the cancellation
or material change in coverage. 
 13. ADDITIONAL PROVISIONS 

13.1 Independent Contractors. The parties are independent contractors. Nothing contained in this Agreement is intended to create an
agency, partnership or joint venture between the parties. At no time will either party make commitments or incur any charges or expenses for or on behalf of the other party. Notwithstanding the foregoing, Company may exercise its rights hereunder at
the direction of and on behalf of one or more sublicensees, provided that there shall be no express or implied third-party beneficiaries of this Agreement. 

13.2 No Discrimination. Neither Penn nor Company will discriminate against any employee or applicant for employment because of
race, color, sex, sexual or affectional preference, age, religion, national or ethnic origin, handicap, or veteran status. 

13.3 Compliance with Laws. Company must comply with all prevailing laws, rules and regulations that apply to its activities or
obligations under this Agreement. For example, Company will comply with applicable United States export laws and regulations. The transfer of certain technical data and commodities may require a license from the applicable agency of the United
States government and/or written assurances by Company that Company will not export data or commodities to certain foreign countries without prior approval of the agency. Penn does not represent that no license is required, or that, if required, the
license will issue. 
 13.4 Modification, Waiver & Remedies. This Agreement may only be modified by a written
amendment that is executed by an authorized representative of each party. Any waiver must be express and in writing. No waiver by either party of a breach by the other party will constitute a waiver of any different or succeeding breach. Unless
otherwise specified, all remedies are cumulative. 
 13.5 Assignment. Company may not assign this Agreement or any part
of it, either directly or by merger or operation of law, without the prior written consent of Penn, provided, however, that Company may assign this Agreement as a whole (either directly or by merger or operation of law) without such consent
(1) to an Affiliate or (2) in connection with an acquisition (whether by merger, consolidation, sale or otherwise) by a third party of Company, provided that such Affiliate or third party (a) agrees in writing to be legally bound by
this Agreement and to deliver to Penn an updated Development Plan within ninety (90) days after the closing of the proposed transaction, and (b) Company provides Penn with a copy of such Affiliate’s or third party’s undertaking
and provided further that such assignment to such third party is not likely, in Company’s reasonable judgment at the time of the transaction, to harm Penn’s reputation or good standing. Any permitted assignment will not relieve Company of
responsibility for performance of any obligation of Company that has accrued at the time of the assignment. Any prohibited assignment will be null and void. Subject to the foregoing, this Agreement will inure to the benefit of and be binding on each
party’s legal representatives, successors and assigns. 
  

 25 

 PATENT LICENSE AGREEMENT 

 

 13.6 Notices. Any notice or other required communication (each, a
“Notice”) must be in writing, addressed to the party’s respective Notice Address listed on the signature page, and delivered: (a) personally; (b) by certified mail, postage prepaid, return receipt requested;
(c) by recognized overnight courier service, charges prepaid; or (d) by facsimile. A Notice will be deemed received: if delivered personally, on the date of delivery; if mailed, five (5) days after deposit in the United States mail;
if sent via courier, one (1) business day after deposit with the courier service; or if sent via facsimile, upon receipt of confirmation of transmission provided that a confirming copy of such Notice is sent by certified mail, postage prepaid,
return receipt requested or recognized overnight courier, charges prepaid. 
 13.7 Severability & Reformation.
If any provision of this Agreement is held to be invalid or unenforceable by a court of competent jurisdiction, then the remaining provisions of this Agreement will remain in full force and effect. Such invalid or unenforceable provision will be
automatically revised to be a valid or enforceable provision that comes as close as permitted by law to the parties’ original intent. 

13.8 Headings, Counterparts & Defined Terms. The headings of the Articles and Sections included in this Agreement are
inserted for convenience only and are not intended to affect the meaning or interpretation of this Agreement. This Agreement may be executed in several counterparts, all of which taken together will constitute the same instrument. Facsimile
execution and delivery of this Agreement by either party will constitute a legal, valid and binding execution and delivery of this Agreement by such party. Headings and captions are for convenience only and are not be used in the interpretation of
this Agreement. The words “include”, “includes” and “including” will be deemed to be followed by the phrase “without limitation”. The words “herein”, “hereof” and “hereunder”, and
words of similar import, will be construed to refer to this Agreement in its entirety and not to any particular provision hereof. All references herein to Articles, Sections or Exhibits, unless otherwise specifically provided, will be construed to
refer to Articles, Sections and Exhibits of this Agreement. 
 13.9 Governing Law. This Agreement will be governed in
accordance with the laws of the Commonwealth of Pennsylvania, without giving effect to the conflict of law provisions of any jurisdiction. 

13.10 Sophisticated Parties. Each of the parties acknowledges and agrees that this Agreement has been diligently reviewed by and
negotiated by and between them, that in such negotiations each of them has been represented by competent counsel and that the final agreement contained herein, including the language whereby it has been expressed, represents the joint efforts of the
parties hereto and their counsel. Accordingly, in interpreting this Agreement or any provision hereof, no presumption shall apply against either party hereto as being responsible for the wording or drafting of this Agreement or any such provision,
and ambiguities, if any, in this Agreement shall not be construed against any party , irrespective of which party may be deemed to have authored the ambiguous provision. 

13.11 Dispute Resolution. If a dispute arises between the parties concerning any right or duty under this Agreement, then the
parties will meet in person and confer, as soon as practicable after written notice from one party to the other party identifying the reasons for such dispute, in an attempt to resolve the dispute. If the parties are unable to resolve the dispute

  

 26 

 PATENT LICENSE AGREEMENT 

 

 
amicably within thirty (30) days after such notice, then the parties will submit to the exclusive jurisdiction of, and venue in, the state and Federal courts located in the Eastern District
of Pennsylvania with respect to all disputes arising under this Agreement. 
 13.12 Force Majeure. Neither party shall be
held liable or responsible to the other party nor be deemed to have defaulted under or breached this Agreement for failure or delay in fulfilling or performing any term of this Agreement if, but only to the extent that, such failure or delay results
from causes beyond the reasonable control of the affected party, potentially including fire, floods, embargoes, terrorism, war, acts of war (whether war be declared or not), insurrections, riots, civil commotions, strikes, lockouts or other labor
disturbances, acts of God or acts, omissions or delays in acting by any governmental authority or any other party; provided that the party affected shall promptly notify the other of the force majeure condition and shall exert reasonable efforts to
eliminate, cure or overcome any such causes and to resume performance of its obligations as soon as possible. 
 13.13
Integration. This Agreement with its Exhibits, and the Other Agreements and the Confidentiality Agreement in effect on the Effective Date, contain the entire agreement between the parties with respect to the Penn Patent Rights and the License
and supersede all other oral or written representations, statements, or agreements with respect to such subject matter, including the Term Sheet. 

[remainder of this page intentionally left blank] 
  

 27 

 PATENT LICENSE AGREEMENT 

 

 Each party has caused this Agreement to be executed by its duly authorized representative. 

 

									
	THE TRUSTEES OF THE
UNIVERSITY OF PENNSYLVANIA	 		 	AEGERION PHARMACEUTICALS, INC.
					
	By:	 	/s/ John S. Zawad	 		 	By:	 	/s/ Gerald Wisler
	Name:	 	John S. Zawad	 		 	Name: 	 	Gerald Wisler
	Title:	 	Managing Director,
Center for Technology Transfer	 		 	Title:	 	President & CEO

  

			
	 Notice address:
	  	
		
	 University of Pennsylvania
	  	Aegerion Pharmaceuticals
	 Center for Technology Transfer
	  	c/o Scheer & Company, Inc.
	 3160 Chestnut Street, Suite 200
	  	250 West Main Street
	 Philadelphia, PA 19104-6283
	  	Branford, CT 06405
	 Attention: Managing Director
	  	Attention: President & CEO
	 Facsimile: 215-898-9519
	  	Facsimile: 203-481-4164
		
	 With a required copy to:
	  	
		
	 University of Pennsylvania
	  	Goodwin Procter LLP
	 Office of General Counsel
	  	Exchange Place
	 133 South 36th Street, Suite 300
	  	Boston, MA 02109
	 Philadelphia, PA 19104-3246
	  	Attention: Kingsley L. Taft, Esq.
	 Attention: General Counsel
	  	Facsimile: (617) 523-1231
	 Facsimile: 215-746-5222
	  	

 PATENT LICENSE AGREEMENT 

 

 EXHIBIT INDEX 

 

			
	Exhibit A	  	TDA
		
	Exhibit B	  	Penn Patent Rights
		
	Exhibit C	  	Minimum Contents of Development Plan
		
	Exhibit D	  	Format of Royalty Report
		
	Exhibit E	  	Form of Client and Billing Agreement

 EXECUTION VERSION 

 

 AMENDED AND RESTATED TECHNOLOGY DONATION AGREEMENT 

This Agreement, which shall be effective as of the last date of execution hereof by the parties (“Effective Date”), is made
between Bristol-Myers Squibb Company (“BMS”) with a headquarters at 345 Park Avenue, New York, NY 10154 and The Trustees of the University of Pennsylvania, a non-profit corporation organized and existing under the laws of the Commonwealth
of Pennsylvania, with a principal office at 3160 Chestnut Street, Suite 200, Philadelphia, PA 19104-8283 (“University”). 

BACKGROUND 

A. BMS is the owner of certain patent rights (in the United States and certain other countries) and related technical
and/or proprietary information and trade secrets that University believes can be used in the treatment of hypercholesterolemia with Compound BMS-201,038, and University was actively engaged in the research and development in that field. In 2003,
University indicated its interest in receiving a donation of certain BMS patent rights and in receiving BMS Know-How in that field, and BMS was willing to donate certain rights in certain of those BMS patent rights and BMS Know-How to University.

 B. The parties acknowledge that BMS-201,038, in clinical trials run by BMS prior to 2003, was shown to have
significant and serious hepatotoxicities at the dosages used and therefore, while apparently efficacious for the treatment of certain lipid metabolism disorders, could not be developed as a pharmaceutical product of general or wide utility. However,
based on certain available clinical data, the parties believed that BMS-201,038 might be useful as a treatment for certain rare and life-threatening disorders or conditions, for which there was no effective medical treatment. While it was not
commercially feasible for BMS to develop the compound for such use, University was willing to pursue such development, and BMS was willing to facilitate University’s development, with a view to benefiting the public. 

C. Based on the premises described in the foregoing paragraphs A and B, the parties entered into that certain Technology
Donation Agreement, effective as May 5, 2003 (the “Prior Agreement”, and such date, the “Prior Effective Date”). Since entering into the Prior Agreement, further medical research has been conducted with BMS-201,038
by University that has further demonstrated the efficacy of BMS-201,038 and potential ways to mitigate adverse events observed in earlier trials. Additionally, clinical trials have demonstrated the benefits to patients of more aggressive cholesterol
management, leading the National Cholesterol Education Program (“NCEP”) to recommend a low-density-lipoprotein (“LDL”) serum cholesterol level of less than 70 mg/dL for certain patients in 2004. As a result, University, in
collaboration with a potential sublicensee, now desires to have additional clinical trials conducted to further explore and define a potential role of the Designated Compounds (as defined below) in achieving lower LDL-levels in patients in an effort
to address a significant unmet clinical need in the Designated Field (as defined below). 
  

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

 TECHNOLOGY DONATION AGREEMENT 

 

 D. To that end, BMS is willing to donate and grant to University certain
additional rights. 
 E. The parties to the Prior Agreement desire to amend and restate the Prior Agreement in
its entirety as set forth herein. 
 NOW, THEREFORE, in consideration of the mutual promises and covenants contained in this
Agreement and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows: 

ARTICLE 1 RESTATEMENT OF PRIOR AGREEMENT 

The Prior Agreement is hereby amended and restated in its entirety and, as of the Effective Date, is in its entirety superseded by this
Agreement. For the avoidance doubt, the amendment of the Prior Agreement by this Agreement shall be of no prejudice to the rights, obligations and liabilities of either party accrued under the Prior Agreement prior to the Effective Date. 

ARTICLE 2 DEFINITIONS 

The terms designated in initial capital letters (except for the heading of Articles) shall have the meanings set forth below or set forth
in other Articles of this Agreement. 
 2.1 “Affiliate” of an entity means any other entity controlling, controlled by
or under common control with such entity. The term “control” for purposes of this definition means possession, direct or indirect, of the powers to direct or cause the direction of the management and policies of an entity, whether through
the ownership of voting securities, by contract or otherwise. 
 2.2 “Assigned Patents” means the Composition Patents
and the Combination Patents, together. 
 2.3 “BMS Know-How” means BMS technical information described in
Appendix A. 
 2.4 “Composition Patents” means (a) the patents and patent applications listed on
Appendix B-1, (b) all direct and indirect divisionals and continuations of such patent applications (namely, direct and indirect Canadian divisionals or continuations of Canadian patent application 2,213,446 and direct and indirect
Japanese divisionals or continuations of Japanese patent application 525,679/1996), and (c) all patents issuing on any such patent applications, together with all reissues, re examinations, renewals, supplemental protection certificates and
extensions of any of the foregoing. 
 2.5 “Combination Patents” means the patent listed on Appendix B-2,
together with all reissues, re examinations, renewals, supplemental protection certificates and extensions of any of the foregoing. 

2.6 “Designated Compound(s)” means (a) BMS-201,038, (b) prodrugs or metabolites of BMS-201,038, to the extent any
such prodrug or metabolite is covered by a compound claim 
  

 2 

FOIA CONFIDENTIAL TREATMENT REQUESTED 

 TECHNOLOGY DONATION AGREEMENT 

 

 
in a Composition Patent, and (c) stereoisomers, hydrates, anhydrides, solvates, salt forms, or polymorphs of BMS-201,038 or any compounds covered by the foregoing clause (b) or this
clause (c). Furthermore, in the case of a prodrug or metabolite as referred to under clause (b) above, the compound in question shall constitute a “Designated Compound” hereunder only if the making, use or sale of such
compound is necessary for or results from the making, use and sale of BMS-201,038 within the Designated Field. 
 2.7
“Designated Field” means the use of the compound in question in: (a) monotherapy or in combination with other dyslipidemic therapies for the treatment of patients with homozygous familial hypercholesterolemia; (b) monotherapy or
in combination with other dyslipidemic therapies for the treatment of patients with severe hypercholesterolemia of any etiology unable to come within 15% of NCEP LDL cholesterol goal on maximal tolerated oral therapy, as determined by the
patient’s prescribing physician; (c) monotherapy or in combination with other dyslipidemic therapies for the treatment of patients with severe combined hyperlipidemia of any etiology unable to come within 15% of NCEP non-HDL cholesterol
goal on maximal tolerated oral therapy, as determined by the patient’s prescribing physician; and (d) monotherapy or in combination with other dyslipidemic therapies for the treatment of patients with severe hypertriglyceridemia unable to
reduce TG<1000 on maximal tolerated therapy. 
 2.8 “Exclusive Area” means: (a) with respect to BMS,
infringement or potential infringement of any Assigned Patent arising from the exploitation outside the Designated Field of a compound that is not a Designated Compound; and (b) with respect to University, infringement or potential infringement
of any Assigned Patent arising from the exploitation either (i) within the Designated Field of any compound or (ii) of a Designated Compound within or without the Designated Field. 

2.9 “Grant-back Licenses” means the licenses granted by University to BMS in Articles 1.1(i)(a) and 1.1(i)(b). 

2.10 “Licensee Entities” means each licensee of University or its transferee under any of the Assigned Patents, along with such
licensee’s Affiliates and its (direct and indirect) sublicensees granted sublicenses under any such Assigned Patents and their customers, and “Licensee Entity” shall refer to any one of them. 

ARTICLE 3 ASSIGNMENT AND LICENSING OF RIGHTS 

3.1 Subject to Article 12.1 and the Grant-back Licenses, BMS hereby donates and assigns to University, free of charge, all right,
title and interest in and to the Assigned Patents; such assignment to University includes BMS’s right to enforce the Assigned Patents and to recover damages for any infringement retroactively, as the law allows, of the Assigned Patents. BMS
agrees to promptly record, at University’s expense, the Assignment attached hereto as Appendix C (or other suitable form) in favor of University with the U.S. Patent and Trademark Office and other foreign patent offices for the Assigned
Patents. In addition, BMS agrees to execute such further documentation as may be reasonably requested by University, and to permit University to record its title at University’s expense. For clarity, the parties confirm that, to the

  

 3 

FOIA CONFIDENTIAL TREATMENT REQUESTED 

 TECHNOLOGY DONATION AGREEMENT 

 

 
extent that BMS has not already assigned to University the “Donated Claim” (as defined in the Prior Agreement), BMS hereby assigns to University the Donated Claim as well as the
remainder of the Assigned Patents as provided above. 
 3.2 BMS hereby grants to University a paid-up, non-royalty bearing,
exclusive worldwide license to use and otherwise exploit BMS-Know How, including the making, use and sale of Designated Compound, but solely for purposes of developing and commercializing (or otherwise making available to the public) Designated
Compound within the Designated Field. University is under no requirement to keep the BMS Know-How confidential. 
 3.3
Grant-back Licenses: 
 (a) University hereby grants back to BMS an irrevocable, paid-up, non-royalty bearing, exclusive
worldwide license (with the right to sublicense subject to Article 1.1(i)(d)) under the Composition Patents to make, have made, import, offer for sale, sell and use any compound other than Designated Compound, subject to University’s
reservation of rights under the Composition Patents for its internal, non-exclusive, non-commercial research and educational purposes. 

(b) University hereby grants back to BMS an irrevocable, paid-up, non-royalty bearing, exclusive worldwide license (with the right to
sublicense subject to Article 1.1(i)(d)) under the Combination Patents to make, have made, import, offer for sale, sell and use any pharmaceutical composition other than that containing one or more Designated Compounds, subject to
University’s reservation of rights under the Combination Patents for its internal, non-exclusive, non-commercial research and educational purposes. 

(c) Except as expressly provided hereunder, no other rights to the Assigned Patents are granted to BMS by this Agreement, either express
or implied. 
 (d) BMS’s right (and its sublicensee(s)’s right) to sublicense the Grant-back Licenses is subject to
each of the following conditions: 
 (i) In each sublicense agreement, BMS shall require the sublicensee and its
Affiliates to comply with the applicable restrictions, requirements and limitations as set forth in this Agreement; 

(ii) Within thirty (30) days after BMS enters into a sublicense agreement, BMS shall deliver to University, solely
for purposes of determining BMS’s compliance with this Agreement (but without implying that such sublicense agreement shall be subject to University’s consent, approval or comment) and subject to redaction as to financial and other
confidential commercial information, a complete and accurate copy of the entire sublicense agreement written in the English language, the delivery by BMS and receipt by University of which shall be without prejudice to any rights or obligations of
either party under this Agreement; and 
 (iii) BMS’s execution of a sublicense agreement shall not relieve
BMS of any of its obligations under this Agreement, and BMS remains liable to University for any act or omission of a sublicensee of BMS that would be a breach of this Agreement if performed or omitted by BMS. 

 

 4 

FOIA CONFIDENTIAL TREATMENT REQUESTED 

 TECHNOLOGY DONATION AGREEMENT 

 

 ARTICLE 4 NON-ASSERTION OF CERTAIN PATENT RIGHTS 

BMS shall not assert, and shall not permit any of its Affiliates, licensees or (direct or indirect) sublicensees to assert against
University or any of its Licensee Entities or transferees (i) any rights under the Assigned Patents obtained by BMS pursuant to the Grant-back Licenses or (ii) any other patent rights held or controlled now or hereafter by BMS or any of
its Affiliates necessary for the manufacture, use, license, importation, offer for sale, sale, development or commercialization of Designated Compound within the Designated Field (such other patent rights, collectively “Other Patent
Rights”). For the avoidance of doubt, the foregoing shall not be construed as precluding BMS from asserting any Assigned Patents or Other Patent Rights against University or any other party with respect to the manufacture, use, license,
importation, offer for sale, sale, development or commercialization of any Designated Compound outside of the Designated Field, except that University shall continue to have its reservation of rights under the Assigned Patent for its internal,
non-exclusive, non-commercial research and educational purposes. BMS shall impose the foregoing non assertion covenant (with respect to the Assigned Patents or Other Patent Rights) on any third party to which BMS or any of its Affiliates may assign,
license, sublicense or otherwise transfer any rights in or to any Assigned Patents or Other Patent Rights. Except as expressly provided hereunder, no other rights to the Assigned Patents or Other Patent Rights are granted to University by this
Agreement, either express or implied. 
 ARTICLE 5 CERTAIN LIMITATIONS 

5.1 Without prejudice to University’s rights as owner of the Assigned Patents, BMS shall not, nor shall it permit any of its
Affiliates, licensees, (direct or indirect) sublicensees or transferees (other than University transferees and Licensee Entities) to, make, have made, use, sell, offer for sale, import, develop or commercialize any compound (including Designated
Compound) covered by any issued and unexpired Composition Patents within the Designated Field. In addition, BMS shall ensure for itself and its Affiliates and transferees that each sublicense agreement with a sublicensee (unless such sublicensee is
a University transferee or Licensee Entity) under the Grant-back Licenses requires that such sublicensee not, and not permit any of such sublicensee’s Affiliates or (direct or indirect) sublicensees to, make, have made, import, sell, offer to
sell, use, develop or commercialize any such compound (including Designated Compound) within the Designated Field. 
 5.2
Without prejudice to BMS’s rights under the Grant-back Licenses, University shall not, and shall not permit any of its Affiliates or Licensee Entities to, make, have made, import, sell, offer to sell or use, develop or commercialize any
Designated Compound outside the Designated Field. In addition, University shall ensure for itself and its Affiliates and transferees (including all Licensee Entities) that each license agreement with a licensee under any Assigned Patents requires
that such licensee not, and not permit any of such licensee’s Licensee Entities to make, have made, import, sell, offer to sell, use, develop or commercialize any Designated 

 

 5 

FOIA CONFIDENTIAL TREATMENT REQUESTED 

 TECHNOLOGY DONATION AGREEMENT 

 

 
Compound outside the Designated Field. This Article 5.2 shall not be construed as precluding University’s exercise of rights under the Assigned Patents for University’s internal,
non-exclusive, non-commercial research and educational purposes as contemplated by Articles 1.1(i)(a) and 1.1(i)(b). 

5.3 For the avoidance of doubt, nothing in this Agreement shall preclude the combination of Designated Compounds with other active
ingredient(s), provided, however, that such clarification shall not be construed as conferring on University any right to make, have made, import, offer to sell, sell, use, develop or commercialize any compound (other than Designated Compounds)
covered by one or more valid and enforceable claims of issued and unexpired patent(s) held or controlled by BMS or its Affiliates. 

ARTICLE 6 PATENT MATTERS 

6.1 Prosecution and Enforcement of the Assigned Patents. 

(a) Prosecution and Maintenance. 

(i) Upon the assignment of the Assigned Patents by BMS pursuant to Article 3.1, University shall have exclusive
control of (subject to reasonable communication on a periodic basis with BMS regarding the status of the prosecution of pending patent applications within the Assigned Patents, including amendments to claim scope) and pay (or have Licensee Entities
pay on behalf of University) for the prosecution and maintenance of the Assigned Patents (“Patent Costs”), including regarding any extensions, interferences, oppositions, reissue proceedings and reexaminations with respect thereto. To the
extent that BMS has possession of any file wrapper materials concerning the prosecution of the Assigned Patents, BMS shall transfer to University copies of the same promptly after the Effective Date. BMS shall reasonably cooperate with University
with respect to such prosecution and maintenance. 
 (ii) Notwithstanding Article 6.1(a)(i), University
shall have the right to discontinue paying the Patent Costs, or to discontinue prosecution and maintenance of any of the Assigned Patent(s) as follows (and only as follows). In the event that University (and any Licensee Entities) no longer desires
to pay the Patent Costs, or otherwise to prosecute or maintain one or more of the Assigned Patent(s), University shall offer to assign such Assigned Patent(s) back to BMS at least sixty (60) days prior to the date upon which any failure to pay
such cost or take such action, as the case may be, would result in the abandonment of such Assigned Patent. BMS may accept such offer of assignment only by giving written notice to University within thirty (30) days after its receipt of written
notice offering to assign any such Assigned Patent(s). Should BMS decline such offer of assignment, University shall thereafter have the right to abandon such Assigned Patent(s) or otherwise to assign such Assigned Patent(s) to any third party and
in any event to terminate the Grant-back Licenses with respect to such abandoned Assigned Patent(s) (but no other Assigned Patent(s)), including all sublicenses thereunder, without liability to BMS or any sublicensee of BMS, the licensee under the
license referred to in Article 12.1 or any sublicensee of such licensee. Furthermore, BMS 
  

 6 

FOIA CONFIDENTIAL TREATMENT REQUESTED 

 TECHNOLOGY DONATION AGREEMENT 

 

 
shall not decline such offer of assignment to the extent that any abandonment of such Assigned Patent(s) would be a breach of the license referred to in Article 12.1. Alternatively, should BMS
accept such offer of assignment, University shall assign to BMS all right, title and interest in and to such Assigned Patent(s), any and all licenses theretofore granted by University to any Licensee Entities under such Assigned Patent(s) (but no
other Assigned Patent(s)) shall be terminated, and BMS shall be free thereafter to abandon such Assigned Patent(s), without liability to University or any Licensee Entities. 

(b) Enforcement and Defense. 

(i) Each party shall have the exclusive right, but not the obligation, to enforce at its sole expense the Assigned
Patents in its respective Exclusive Area, and the other party shall have no right to enforce any of the Assigned Patents in the other party’s Exclusive Area. Each party shall retain all recoveries resulting from its enforcement activities.

 (ii) In the event that a third party challenges the validity or enforceability of any Assigned Patent(s)
(other than by way of interference, opposition, reissue proceeding or reexamination, which is addressed in Article 6.1(a), or as a counterclaim or otherwise in connection with a proceeding related to the enforcement by BMS within the scope of
the Grant-back Licenses, which shall be addressed by reversal of the roles of University and BMS in the remainder of this Article 1.1(ii)), then University shall have the first right, but not the obligation, to take such action, under its
control and at its sole expense, as University deems reasonably necessary to defend the validity or enforceability of such Assigned Patent(s). If University elects not to take such action, University shall provide at least fifteen (15) days
notice to BMS prior to any material litigation deadline, and BMS may then, at BMS’s option, assume control and defense of such action at BMS’s sole expense. 

(iii) With respect to the foregoing activities under this Article 6.1(b): 

(1) Neither party shall settle any action or admit as to invalidity or unenforceability or otherwise disclaim a patent right that could
materially impair the other party’s rights in the Assigned Patents without the other party’s prior written consent (not to be unreasonably withheld or delayed). For the avoidance of doubt, either party granting rights to a third party
within the scope of such party’s rights under this Agreement (such as a Licensee Entity granting a sublicense within the scope of the license under the applicable Assigned Patents granted to it by University in conformance with this Agreement,
or BMS granting a sublicense under the Grant-back License in conformance with this Agreement) shall not be deemed to impair in a material fashion such other party’s rights in the Assigned Patents hereunder and thus shall not require such other
party’s consent. 
 (2) Each party shall cooperate with the other party in any such activities by the other party,
including University agreeing, at the request of BMS, to be a named party or being joined involuntarily as a party in any BMS-controlled litigation, subject to 

 

 7 

FOIA CONFIDENTIAL TREATMENT REQUESTED 

 TECHNOLOGY DONATION AGREEMENT 

 

 
indemnification of University by BMS from and against any award, fees or expenses (including reasonable fees and expenses of counsel) of University by reason of University being named in any such
litigation, provided that BMS shall not be a named party in any University-controlled litigation, unless otherwise required by applicable patent law to enforce University- or Licensee Entity-rights in the Assigned Patent(s) or any licenses or
sublicenses granted thereunder, in which case BMS shall, subject to indemnification of BMS by University or such Licensee Entity from and against any award or fees or expenses (including reasonable fees and expenses of counsel) of BMS by reason of
BMS being named in any such litigation, join as a named party to such litigation. University, and any Licensee Entity having rights in the affected Assigned Patent(s), shall have the right (but not the obligation) to participate voluntarily in the
absence of any request by BMS, at its own cost, in any BMS-controlled litigation activities concerning the Assigned Patents. 

ARTICLE 7 CERTAIN OTHER RELATED MATTERS 

7.1 In order that the public be given access to the safety information pertaining to BMS-201,038, BMS will publish on the internet,
thereby putting into the public domain (a) substantially all of the documents included in BMS’s Investigational New Drug Application (“IND”) for BMS-201,038 filed with the Food and Drug Administration (the “FDA”)
and (b) all other, if any, relevant safety information not reflected in such documents. 
 7.2 The parties intend that the
published IND documents referred to in Article 7.1 are also to enable University and its Licensee Entities to file its own IND with the FDA. BMS agrees otherwise to provide University with any additional data or information in BMS’s
possession as of the Prior Effective Date for the purpose of facilitating University’s or a Licensee Entity’s filing of its own IND. For the avoidance of doubt, BMS has already fulfilled its obligations under this Article 7.2.

 7.3 Under the Prior Agreement, BMS provided University, free of charge, with certain quantities of BMS-201,038 in the form of
bulk drug substance solely for purposes of (a) nonclinical studies, (b) formulation of drug substance in a form suitable for clinical study in the Designated Field as permitted (and only as permitted) by Article 7.4, and (c) subject
to the strict limitation of scope of use for developing and commercializing (or otherwise making available to the public) BMS-201,038 within the Designated Field, provided that as of the Effective Date, BMS shall have no further obligation to
provide BMS-201,038. University hereby agrees not to, nor shall it permit any third party to, use directly or indirectly any quantity of Designated Compound so received from BMS beyond such specified purposes and scope of use. 

7.4 It is contemplated that University will use some of the BMS-201,038 provided by BMS for clinical studies in the Designated Field to
be conducted by University or its Licensee Entities strictly within the healthy volunteer/patient criteria and dosage limitations set forth in that certain email communication from a Licensee Entity to BMS, dated April 5th, 2006. University
hereby agrees not to, nor shall it permit any third party to, use in humans any BMS-201,038 received from BMS other than for the purpose of such clinical studies. University acknowledges that, as so supplied, the Designated Compound will require
revalidation before they can be used. 
  

 8 

FOIA CONFIDENTIAL TREATMENT REQUESTED 

 TECHNOLOGY DONATION AGREEMENT 

 

 7.5 In reference to Articles 7.3 and 7.4, upon any breach thereof BMS reserves
the right to require University to return any and all unused quantities of Designated Compound provided to University by BMS. 

7.6 Upon reasonable request of University, BMS agrees to transfer to University’s designee (which may be a Licensee Entity) the
manufacturing/formulation processes and know-how for BMS-201,038, as heretofore practiced by BMS, to the extent that such processes and know-how are reasonably necessary for such designee to assume the manufacturing of BMS-201,038 and reasonably
available within BMS for such transfer, provided that such designee shall be an established drug manufacturer with expertise, experience and equipment in the manufacturing of active pharmaceutical ingredients in accordance with good manufacturing
practices under FDA regulations. BMS’s obligations under this Article 7.6 shall expire as of the second anniversary of the Effective Date. 

7.7 Notwithstanding anything contained herein, University and Licensee Entities, with respect to the donation and license grants
contained in Articles 3.1 and 3.2 or other rights granted to University hereunder, shall have no diligence obligations to develop or commercialize any Designated Compound or to report to BMS on, or to pay BMS for, any such development or
commercialization. 
 ARTICLE 8 DISCLAIMER OF WARRANTIES; INDEMNITY 

8.1 BMS is not aware of any claim or written threat of claim by any third party that the practice of the Assigned Patents in the
Designated Field with Designated Compound will infringe third party patents. Other than as set forth above, BMS makes no warranties as to the validity of the Assigned Patents, or with respect to freedom from infringement of third party patents, or
freedom from third party infringers, and BMS shall not be under any obligation to hold University or Licensee Entities or transferees of University harmless against such alleged infringement of third party patents or third party infringers.

 8.2 BMS makes no warranties with respect to the potential earning capacity, potential revenue generation or other future
financial performance of the development or commercialization of any Designated Compound for any period after the Prior Effective Date. 

8.3 BMS assumes no responsibilities whatsoever with respect to the practice by University or its Licensee Entities, assignees or
transferees of BMS Know-How and/or the Assigned Patents. BMS relies upon University to practice, if at all, the Assigned Patents in accordance with all accepted research, development, governmental and medical requirements. University shall as of the
Effective Date assume all risk, liability and lawsuits arising out of or in the course of such practice by University, its Licensee Entities, assignees or transferees as between BMS and University, and, accordingly, University agrees to indemnify
BMS, including its officers, directors, and employees, from any claims, costs or damages (including reasonable fees and expenses of counsel), including special, indirect or consequential damages, under any theory of liability, arising after the
Effective Date out of, in connection with, or in the course of the practice of the Assigned Patents and/or BMS Know-How by University, its Licensee Entities, assignees or transferees. The parties agree that University shall assume no responsibility
for any 
  

 9 

FOIA CONFIDENTIAL TREATMENT REQUESTED 

 TECHNOLOGY DONATION AGREEMENT 

 

 
claims, costs or damages (including reasonable fees and expenses of counsel) arising from BMS’s use of Assigned Patents and/or BMS Know-How, or from negligent or fraudulent interpretation or
use of preclinical or clinical data, prior to the Effective Date and that, notwithstanding anything herein to the contrary, BMS shall indemnify University, its trustees, officers and employees, from any claims, costs or damages (including reasonable
fees and expenses of counsel), including special, indirect or consequential damages, under any theory of liability, arising on or before the Effective Date out of, in connection with the Assigned Patents and/or BMS Know-How. Further, the parties
agree that University shall assume no responsibility for any claims, costs or damages (including reasonable fees and expenses of counsel) arising from the exercise or sublicensing of the Grant-back Licenses or arising from the license referred to in
Article 12.1 and that, notwithstanding anything herein to the contrary, BMS shall indemnify University, its trustees, officers and employees, from any claims, costs or damages (including reasonable fees and expenses of counsel), including
special, indirect or consequential damages, under any theory of liability, arising out of or in connection with (i) on or after the Effective Date the Grant-back Licenses or (ii) the license referred to in Article 12.1. 

For the avoidance of doubt, this Article 8.3 shall not be construed as superseding or otherwise replacing, with respect to the period
from and after the Prior Effective Date through (but not including) the Effective Date, Article 8.3 of the Prior Agreement, which shall remain in full force and effect with respect to such period. 

8.4 BMS represents and warrants that it has all right, title and interest in and to the Assigned Patents (subject, however, to the
license referred to in Article 12.1) and BMS Know-How and has the authority to enter this Agreement. BMS further represents and warrants that it is not aware of any claims it has (whether asserted or unasserted) against third parties arising
out of any contract negotiations, or any claims other parties may have against BMS based upon the Assigned Patents or BMS Know-How. As used in this paragraph, “claims” shall mean a litigation claim, or a written threat of a claim. In all
other respects, BMS provides the Assigned Patents “as is.” EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, BMS MAKES NO WARRANTY, EXPRESS OR IMPLIED, OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE NOR ANY OTHER
EXPRESS OR IMPLIED WARRANTY WHATSOEVER. 
 ARTICLE 9 EXPORT OF INFORMATION OR TECHNOLOGY 

9.1 Each party will not at any time after the Effective Date knowingly export or re-export any information or software received from the
other party or the direct products of such information or software to any country, person or entity or for any use prohibited by the U.S. Export Administration Regulations, unless properly authorized by the U.S. Government. 

ARTICLE 10 GOVERNING LAW 

10.1 This Agreement shall be governed by the laws of the Commonwealth of Pennsylvania excluding those laws pertaining to conflicts of
law. 
  

 10 

FOIA CONFIDENTIAL TREATMENT REQUESTED 

 TECHNOLOGY DONATION AGREEMENT 

 

 ARTICLE 11 EXECUTION 

11.1 The parties have caused this Agreement to be signed in duplicate by their duly authorized representatives on the dates set forth
below. Each party represents and warrants to the other party that (a) it has all requisite corporate power and authority to enter into this Agreement and to perform its obligations under this Agreement, (b) execution of this Agreement and
the performance by such party of its obligations hereunder have been duly authorized, (c) this Agreement is legally binding and enforceable on each party in accordance with its terms, and (d) the performance of this Agreement by it does
not create a breach or default under any other agreement to which it is a party. 
 ARTICLE 12 OTHER 

12.1 University acknowledges and agrees that BMS has heretofore granted a license to a certain third party, certain terms and conditions
of which are set forth (as excerpted from the related license agreement) on Appendix D, which terms and conditions BMS represents are true and correct in all respects and represent all the materials terms concerning (i) the nature and
scope of the license grant under any of the Assigned Patents and (ii) BMS’s and such third party’s respective rights and obligations with respect to the prosecution, enforcement, defense and maintenance of the Assigned Patents. In
addition, BMS represents and warrants that such license provides no option or right on the part of such third party to change the nature or scope of such license, nor to include any additional patent rights under such license. By this Agreement, BMS
does not assign any part of such third party license to University, and University does not assume any rights or obligations thereunder, except that University takes the Assigned Patents as encumbered by such third party license. BMS represents that
no term or condition of such license is in conflict with the terms and conditions of this Agreement, that the entry and performance of this Agreement by BMS will not breach or otherwise be in conflict with such license, and that there are no current
disputes between BMS and the other party to such license. BMS shall not amend, waive or otherwise modify the terms or conditions of such license agreement in a manner that impairs University’s rights in or to the Assigned Patents under this
Agreement. 
 12.2 Other than as set forth herein, BMS has placed no conditions or restrictions on the gift to University of the
Assigned Patents. 
 ARTICLE 13 PUBLICITY 

13.1 In the event of any public announcement regarding the subject matter or terms of this Agreement, except where required by applicable
law, the party making such announcement shall provide at least five business days in advance the other party with a copy of the proposed text, and such other party shall be entitled to require the incorporation of its reasonable comments, prior to
such announcement. For purposes of this Article 13, any public announcement by a Licensee Entity shall be deemed to be a public announcement by University, in which event University shall cause such Licensee Entity to comply with the foregoing
provisions. 
  

 11 

FOIA CONFIDENTIAL TREATMENT REQUESTED 

 TECHNOLOGY DONATION AGREEMENT 

 

 ARTICLE 14 INTEGRATION 

14.1 This Agreement with its Appendices contains the entire agreement between the parties for the donation of certain BMS patent rights
related to BMS-201,038 and supersedes all other oral or written representations, statements, or agreements with respect to such subject matter (including the Prior Agreement). 

ARTICLE 15 MISCELLANEOUS 

15.1 Each of the parties acknowledges and agrees that this Agreement has been diligently reviewed by and negotiated by and between them,
that in such negotiations each of them has been represented by competent counsel and that the final agreement contained herein, including the language whereby it has been expressed, represents the joint efforts of the parties hereto and their
counsel. Accordingly, in interpreting this Agreement or any provision hereof, no presumption shall apply against any party hereto as being responsible for the wording or drafting of this Agreement or any such provision, and ambiguities, if any, in
this Agreement shall not be construed against any party, irrespective of which party may be deemed to have authored the ambiguous provision. 

15.2 Each party is an independent contractor under this Agreement. Nothing contained herein is intended or is to be construed so as to
constitute BMS and University as partners, agents or joint venturers. Neither party shall have any express or implied right or authority to assume or create any obligations on behalf of or in the name of the other party or to bind the other party to
any contract, agreement or undertaking with any third party. 
 15.3 This Agreement shall inure to the benefit of and be binding
on the parties’ successors and assigns. University may exercise its rights hereunder at the direction of and on behalf of one or more Licensee Entities, provided that there shall be no express or implied third-party beneficiaries of this
Agreement in favor of any Licensee Entity or any other third party. 
 15.4 Each party agrees to do and perform all such further
acts and things and shall execute and deliver such other agreements, certificates, instruments and documents necessary or that the other party may reasonably deem advisable in order to carry out the intent and accomplish the purposes of this
Agreement and to evidence, perfect or otherwise confirm its rights hereunder. 
 15.5 The failure of any party to insist on the
performance of any obligation hereunder shall not be deemed to be a waiver of such obligation. Waiver of any breach of any provision hereof shall not be deemed to be a waiver of any other breach of such provision or any other provision on such
occasion or any succeeding occasion. No waiver, modification, release or amendment of any obligation under or provision of this Agreement shall be valid or effective unless in writing and signed by all parties hereto. 

15.6 If any one or more of the provisions of this Agreement is held to be invalid or unenforceable, the provision shall be considered
severed from this Agreement and shall not serve to invalidate any remaining provisions hereof. The parties shall make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable one such that the objectives
contemplated by the parties when entering this Agreement may be realized. 
  

 12 

FOIA CONFIDENTIAL TREATMENT REQUESTED 

 TECHNOLOGY DONATION AGREEMENT 

 

 15.7 Any notice required or permitted to be given by this Agreement shall be in writing
and shall be delivered by hand or overnight courier with tracking capabilities or mailed postage prepaid by first class, registered or certified mail addressed as set forth below unless changed by notice so given: 

If to BMS: 
 Bristol-Myers Squibb Company

 Route 206 & Province Line Road 

Princeton, New Jersey 08540 
 Attention: Vice
President, Licensing 
 If to University: 

University of Pennsylvania 
 Center for
Technology Transfer 
 3160 Chestnut Street, Suite 200 

Philadelphia, PA 19104-6283 
 Attention: Managing
Director 
 With a required copy to: 

University of Pennsylvania 
 Office of General
Counsel 
 133 South 36th Street, Suite 300 

Philadelphia, PA 19104-3246 
 Attention: General
Counsel 
 And with a second required copy to: 

Aegerion Pharmaceuticals 
 c/o Scheer &
Company, Inc. 
 250 West Main Street 

Branford, CT 06405 
 Attention:
President & CEO 
 Any such notice shall be deemed given on the date received. A party may add, delete or change the person or address
to whom notices should be sent at any time upon written notice delivered to the party’s notices in accordance with this Article 0. 

15.8 Headings and captions are for convenience only and are not be used in the interpretation of this Agreement. The words
“include”, “includes” and “including” shall be deemed to be followed by the phrase “without limitation”. The words “herein”, “hereof” and “hereunder”, and words of similar import,
shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof. All references herein to Articles or Appendices, unless otherwise specifically provided, shall be construed to refer to Articles and Appendices
of this Agreement. 
  

 13 

FOIA CONFIDENTIAL TREATMENT REQUESTED 

 TECHNOLOGY DONATION AGREEMENT 

 

 15.9 This Agreement may be executed in counter-parts with the same effect as if both
parties had signed the same document. All such counterparts shall be deemed an original, shall be construed together and shall constitute one and the same instrument. Facsimile execution and delivery of this Agreement by either party shall
constitute a legal, valid and binding execution and delivery of this Agreement by such party. 
 [remainder of this page
intentionally left blank] 
  

 14 

FOIA CONFIDENTIAL TREATMENT REQUESTED 

 TECHNOLOGY DONATION AGREEMENT 

 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their
respective duly authorized officers. 
  

			
	 THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
	  	 BRISTOL-MYERS SQUIBB COMPANY

		
	 By: /s/ John S. Zawad
	  	 By: /s/ [Illegible]

		
	Title: Managing Director	  	Title: SVP, Discovery and Exploratory Clinical Research
		
	Date: May 17, 2006	  	Date: May 17, 2006
		
	Witness: /s/ [Illegible]	  	
		
	Title: /s/ Director Finance	  	
		
	Date: May 17, 2006	  	

  

 15 

FOIA CONFIDENTIAL TREATMENT REQUESTED 

 TECHNOLOGY DONATION AGREEMENT 

 

 APPENDIX A 

BMS Know-How 
 All
limited to BMS-201,038: 
 All information contained in the IND 

Complete version (including all amendments) of the Investigational Drug Brochure (IDB) 

All chronic and acute animal studies performed after the most recent IDB. 

All clinical trial results (in and outside US) 

All manufacturing information 

FDA correspondences regarding BMS-201,038 
  

 16 

FOIA CONFIDENTIAL TREATMENT REQUESTED 

 TECHNOLOGY DONATION AGREEMENT 

 

 APPENDIX B-1 

Composition Patents 

U.S. Patent Nos. 5,712,279, 5,739,135, 6,492,365 and 6,066,650 

European Patent 0,886,637 
 Israeli Patent
116,917 
 Canadian Patent Application 2,213,466 

Japanese Patent Application 525,679 / 1996 

APPENDIX B-2 

Combination Patents 

U.S. Patent No. 5,883,109 
  

 17 

FOIA CONFIDENTIAL TREATMENT REQUESTED 

 APPENDIX C 

Form Assignments for the Assigned Patents 

Assignment 

Bristol-Myers Squibb Company, a Delaware corporation, having a place of business at Lawrenceville-Princeton Road, Princeton, New Jersey
08543-4000, owner of the entire right, title, and interest in and to the inventions claimed in the Patents listed below: 
 1.
U.S. Patent No. 5,712,279 
 2. U.S. Patent No. 5,739,135 

3. U.S. Patent No. 5,883,109 

4. U.S. Patent No. 6,066,650 

5. U.S. Patent No. 6,492,365 

6. European Patent No. 0,866,637 validated in the following countries as: 

A. British Patent 0,866,637 

B. French Patent 0,866,637 

C. German Patent 69,633,983.8 

D. Italian Patent 0,866,637 

E. Spanish Patent 0,866,637 

7. Israeli Patent No. 116,917 

together with all right, title, and interest in and to the above-listed Patents and any reissues, reexaminations, renewals, supplemental protection
certificates, and extensions thereof, does hereby assign all right, title, and interest in and to the inventions claimed in the above-listed Patents together with all right, title, and interest in and to the above-listed Patents, and any reissues,
reexaminations, renewals, supplemental protection certificates, and extensions thereof, to The Trustees of The University of Pennsylvania, having a place of business at Center for 

 

 18 

FOIA CONFIDENTIAL TREATMENT REQUESTED 

 
Technology Transfer, 3160 Chestnut Street, Suite 200, Philadelphia, PA 19104-6283. We hereby convey all of our rights arising under or pursuant to any and all United States laws and international
agreements, treaties or laws relating to the protection of industrial property in the above-listed Patents, and we hereby authorize and request the European, British, French, German, Italian, Spanish, Israeli and United States Patent Offices to
issue any such European, British, French, German, Italian, Spanish, Israeli and United States reissues, reexaminations, renewals, supplemental protection certificates, and extensions to The Trustees of The University of Pennsylvania. 

 

			
	BRISTOL-MYERS SQUIBB COMPANY
		
	By:	 	  

	
	 Louis J. Wille

Vice President and Chief Patent Counsel

	Date:	 	  

		
	Witness:	 	  

		
	Name:	 	  

	Title:	 	  

	Date:	 	  

	
	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
		
	By:	 	  

		
	Name:	 	  

	Title:	 	  

	Date:	 	  

		
	Witness:	 	  

		
	Name:	 	  

	Title:	 	  

	Date:	 	  

  

 19 

FOIA CONFIDENTIAL TREATMENT REQUESTED 

 Assignment 

Bristol-Myers Squibb Company, a Delaware corporation, having a place of business at Lawrenceville-Princeton Road, Princeton, New Jersey
08543-4000, owner of the entire right, title, and interest in and to the inventions described in the Patent Applications listed below: 

1. Canadian Patent Application No. 2,213,466 

2. Japanese Patent Application No. 525,679/1996 

and any patent to be granted thereon, and all divisions, continuations, reissues, reexaminations, renewals, supplementary protection certificates, and
extensions thereof, does hereby assign all right, title, and interest in and to the inventions claimed in the above-listed Patent Applications together with all right, title and interest in and to said applications and any patents to be granted
thereon, and all divisions, continuations, reissues, reexaminations, renewals, supplemental protection certificates, and extensions thereof filed or issued in or by the Canadian and Japanese Patent Offices, to The Trustees of The University of
Pennsylvania, having a place of business at Center for Technology Transfer, 3160 Chestnut Street, Suite 200 Philadelphia, PA 19104-6283. We hereby convey all of our rights arising under or pursuant to any and all United States laws and international
agreements, treaties or laws relating to the protection of industrial property by filing any such applications, and we hereby authorize and request the Canadian and Japanese Patent Offices to issue any such Canadian and Japanese patent to The
Trustees of The University of Pennsylvania. 
  

 20 

FOIA CONFIDENTIAL TREATMENT REQUESTED 

			
	BRISTOL-MYERS SQUIBB COMPANY
		
	By:	 	  

	
	 Louis J. Wille

Vice President and Chief Patent Counsel

	Date:	 	  

		
	Witness:	 	  

		
	Name:	 	  

	Title:	 	  

	Date:	 	  

	
	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
		
	By:	 	  

		
	Name:	 	  

	Title:	 	  

	Date:	 	  

		
	Witness:	 	  

		
	Name:	 	  

	Title:	 	  

	Date:	 	  

  

 21 

FOIA CONFIDENTIAL TREATMENT REQUESTED 

 APPENDIX D 

Certain Terms and Conditions 

from the Related License Agreement from Article 12.1 

License Grant “Subject to the terms and conditions of this Agreement, BMS hereby grants to [Licensee] a non-transferable (except in
accordance with Section 7.2), non-exclusive, worldwide license under the Licensed Patents, with the right to grant sublicenses solely as permitted by Section 2.2, to research and develop Compounds and Products in the Field in the Territory
and to make, use, sell, have sold, import, and export Compounds and Products in the Field in the Territory and for no other purposes.” 

Patent Prosecution and Enforcement 

There are no provisions in such related license agreement concerning the prosecution, maintenance, enforcement or defense with respect
to the Licensed Patents. 
 Term 

The related license agreement expires by its terms when there are no more Valid Claims of the Licensed Patents. 

Related Definitions 

“‘Compound’ means any compound (including without limitation, any small molecule or any biomolecule) other than a
polynucleotide compound that decreases the amount of activity of microsomal triglyceride transfer protein.” 

“‘Field’ means the prevention, treatment or control of any animal disease, disorder or condition. For the avoidance of
doubt, the Field does not include the prevention, treatment or control of any human disease, disorder of condition.” 

“‘Licensed Patents’ means those patents and patent applications listed in Exhibit A*, and any foreign counterparts
thereof, excluding claims directed solely to compositions of matter per se or methods of treating mammals using specifically claimed compositions of matter, together with (a) all divisionals, continuations, continuations-in-part (but only to
the extent that such application includes new data/information in support of claims previously submitted in a prior originally filed application) of any of the foregoing, and any foreign counterparts thereof, but excluding all claims directed solely
to compositions of matter per se or methods of treating mammals using specifically claimed compositions of matter, and (b) all patents issuing on any of the foregoing, and any foreign counterparts thereof, together with all registrations,
reissues, re-examinations, supplemental protection certificates, or extensions thereof, and any foreign counterparts thereof, but excluding all claims directed solely to compositions of matter per se or methods of treating mammals using specifically
claimed compositions of matter.” 
 * Appendix A lists only US patent application serial 08/486,929 and US patent No.
6,492,365. 
  

 22 

FOIA CONFIDENTIAL TREATMENT REQUESTED 

 “‘Product’ means any veterinary product containing a Compound, in all forms,
presentations, formulations and dosage forms in which the manufacture, use or sale is covered by a Valid Claim of a Licensed Patent.” 

“‘Territory’ means the entire world.” 

“‘Valid Claim’ means a claim of an issued and unexpired patent or a supplementary protection certificate, which claim has
not been held invalid or unenforceable by a court or other government agency of competent jurisdiction from which no appeal can be or has been taken and has not been held or admitted to be invalid or unenforceable through re-examination or
disclaimer, opposition procedure, nulity suit or otherwise.” 
  

 23 

FOIA CONFIDENTIAL TREATMENT REQUESTED 

 PATENT LICENSE AGREEMENT 

 

 EXHIBIT B 

Penn Patent Rights 

EXHIBIT B-1 

Composition Patents 

Penn Docket No. P3233: 

U.S. Patent Nos. 5,712,279 and 5,739,135 

European Patent 0,886,637 (UK, IRE, ITL, SPA, GER, FRA, DEN, SWE and SWIT) 

Israeli Patent 116,917 

Canadian Patent Application 2,213,466 

Japanese Patent Application 525,679 / 1996 

Australian Patent 699865 

U.S. Patent Nos. 6,492,365 and 6,066,650 

EXHIBIT B-2 

Combination Patents 

U.S. Patent No. 5,883,109 

EXHIBIT B-3 

Penn Existing Patents 

Penn Docket No. Q3474: 

U.S. Provisional Patent Application No. 60/550,915, filed 3/5/04 

PCT Application No. US05/007435, filed 3/5/05 

EXHIBIT B-4 

Penn New Patents 
 To be
updated by the parties as provided in Section 1.6. 

 PATENT LICENSE AGREEMENT 

 

 EXHIBIT C 

Minimum Contents of Development Plan 

The Development Plan will contain non-binding estimates for significant development milestones. It is anticipated that the Development Plan will include
the achievement of each of the following diligence events by the applicable non-binding estimated date listed in the table below: 

[CONFIDENTIAL TREATMENT REQUESTED] /*/ 

 PATENT LICENSE AGREEMENT 

 

 EXHIBIT D 

Format of Royalty Report 
  

			
	

	  	 Center for Technology Transfer

University of Pennsylvania
 Royalty
Report

  

									
	Licensee:	 	 	  	 	  	Agreement:	  	 
					
	Inventor:	 	 	  	 	  	Patent #:	  	 
				
	Period Covered: From:	  	______/_____/____________	  	Through:	  	______/_____/___________________________________
					
	Prepared By:	 	 	  	 	  	 Date:
	  	 
					
	Approved By:	 	 	  	 	  	 Date:
	  	 

 If License covers several
major product lines, please prepare a separate report for each line. Then combine all product lines into a summary report. 
  

			
	Report Type:	  	  ̈ Single Product Line Report:

 
  ̈ Multi-product Summary Report: Page
1 of ____ Pages
  
  ̈ Product
Line Detail: Line: ____________ Trade name: ___________ Page: _______

		
	 Report Currency:
	  	 ̈ U.S.
Dollars                 ̈ Other_____________________________________________

 

													
	 Country
	  	 Gross

Sales
	  	*Less:
Allowances	  	Net
Sales	  	Royalty
Rate	  	Period Royalty Amount
	  	  	  	  	  	This Year	  	Last Year
	 U.S.A
	  		  		  		  		  		  	
	 Canada
	  		  		  		  		  		  	
	 Europe
	  		  		  		  		  		  	
		  		  		  		  		  		  	
		  		  		  		  		  		  	
		  		  		  		  		  		  	
		  		  		  		  		  		  	
	 Japan
	  		  		  		  		  		  	
	 Other
	  		  		  		  		  		  	
		  		  		  		  		  		  	
		  		  		  		  		  		  	
		  		  		  		  		  		  	
		  		  		  		  		  		  	
	 Total:
	  		  		  		  		  		  	

 Total Royalty: _________________ Conversion Rate: ________________ Royalty in U.S. Dollars $ _____________________

 The following royalty forecast is non-binding and for CTT internal planning purposes only: 

Royalty Forecast Under this agreement: Next Quarter: ___________ Q2: _____________ Q3: ___________ Q4: ____________ 

On a separate page, please indicate the reasons for returns or other adjustments if significant. 

Also note any unusual occurrences that affected royalty amounts during this period. 

To assist CTT’s forecasting, please comment on any significant expected trends in sales volume 

 PATENT LICENSE AGREEMENT 

 

 EXHIBIT E 

Form of Client and Billing Agreements 

The Trustees of the University of Pennsylvania (“Penn”), a Pennsylvania non-profit corporation doing business at 3160 Chestnut Street, Suite
200, Philadelphia, PA 19104-6283; and Aegerion Pharmaceuticals, Inc. (“Company”), a Delaware corporation doing business at _______________________________ have entered into a License Agreement with respect to certain inventions which are
the subject of the Penn Patent Rights; 
 Penn and Company have retained the services of _______________ (“Law Firm”), with offices at
______________, to prepare, file and prosecute the pending patent applications constituting the Penn Patent Rights and to maintain the patents that issue thereon; 

Penn, Company and Law Firm, intending to formalize their business relationships, agree as follows: 

 

	1.	Penn is the owner of the Penn Patent Rights 

  

	2.	Company is the licensee of Penn’s interest in the Penn Patent Rights. 

 

	3.	Penn and Company shall maintain an attorney-client relationship with Law Firm in furtherance of efforts to secure and maintain the Penn Patent Rights.

  

	4.	Law Firm will interact directly with Company on all patent prosecution and patent maintenance matters related to the Penn Patent Rights and will copy Penn on all
correspondence related thereto. Company and Law Firm agree to use all reasonable efforts to notify Penn in writing at least thirty (30) days prior to the due date or deadline for any action which could adversely affect the pending status
of any patent application within the Penn Patent Rights, the maintenance of any granted patent within the Penn Patent Rights, Penn’s right to file any continuing application or foreign counterpart application based on the Penn Patent Rights, or
any material change to the breadth of any claim within the Penn Patent Rights. In any case, Company shall give Penn written notice of any final decision regarding the action to be taken or not to be taken on such matters prior to instructing Law
Firm to implement the decision. Penn reserves the right to countermand any instruction given by Company to Law Firm. 

  

	5.	Law Firm’s legal services relating to the Penn Patent Rights will be performed on behalf of Penn and Company. Law Firm shall invoice Company directly for all
work relating to the filing, prosecution and maintenance of the Penn Patent Rights and shall provide copies of all invoices to Penn. Company is responsible for the payment of all charges and fees so invoiced by Law Firm. Company will pay invoices
directly to Law Firm and copy Penn on each payment. 

  

	6.	The parties agree that in the case of any conflict between this agreement and the License Agreement, the terms of the License Agreement shall control.

 PATENT LICENSE AGREEMENT 

 

 This agreement is in effect with respect to each Penn Patent Right only as long as the license granted
by Penn to Company is in effect with respect thereto. 
 This agreement represents the complete understanding of each of the undersigned parties
as to the client and billing arrangements defined herein. Additions or deletions of dockets identified in Appendix A will become effective only by written addendum as provided in the License Agreement. All such additions or deletions of individual
patents or applications filed in the US, or as foreign counterparts thereof are considered to be within the terms of this agreement. 

 FIRST AMENDMENT TO PATENT LICENSE AGREEMENT 

This is the First Amendment (this “Amendment”) to the Patent License Agreement effective as of May 19, 2006 between The
Trustees of the University of Pennsylvania (“Penn”) and Aegerion Pharmaceuticals, Inc. (“Company”) (the “Existing Agreement”). 

WHEREAS, interference number 105,490 MCK was instituted by the United States Patent and Trademark Office Board of Patent Appeals and
Interferences (the “Board”) on August 4, 2006, Captiones Gregg et al. vs. Chang et al., and involves U.S. Patent No. 5,883,109 (the “109 Patent”) and U.S. patent application No. 09/298,014 (the “Interference”); and

 WHEREAS, Penn, the owner and real party in interest in and to the 109 Patent, has licensed rights under the 109 Patent to
Company pursuant to the Existing Agreement; and 
 WHEREAS Company wants Penn to settle the Interference, and Penn wants to
settle the Interference, in part upon the terms set forth in that certain Settlement and Cross-License Agreement dated as of September 27, 2006 among Pfizer, Inc., the real party in interest in and to U.S. patent application No. 09/298,014
(“Pfizer”), Penn and Company (the “Settlement and Cross-License Agreement”); and 
 WHEREAS; in part to
induce Penn to settle the Interference upon such terms, Company and Penn have agreed to amend the Existing Agreement as set forth in this Amendment. 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be
legally bound hereby, Penn and Company hereby agree as follows: 
 1. All capitalized terms used in this Amendment but not defined in this
Amendment shall have the same meaning set forth in the Existing Agreement, unless expressly stated that such term shall have the same meaning as set forth in the Settlement and Cross-License Agreement. This Amendment, once executed by both
Penn and Company, and the Existing Agreement together shall be defined as, and be deemed to be, the “Agreement”: 
 2. The following
is hereby added to the Existing Agreement as new Section 14: 
 14. TERMS REGARDING PFIZER AND INTERFERENCE 105,490 MCK

 14.1: Definitions. 

As used in this Section 14 of this Agreement, the following terms shall have the following meanings: 

(i) “Pfizer” shall mean Pfizer, Inc. 
  

 (ii) “Affiliate” shall have the same meaning as set forth in the Settlement and
Cross-License Agreement. 
 (iii) “Settlement and Cross-License Agreement” shall mean that certain Settlement and
Cross-License Agreement dated as of September 27, 2006 among Pfizer, Penn and Company. 
 (iv) “Authorized Pfizer
Sublicensee” shall mean a person or entity that is authorized pursuant to Section 4.1 of the Settlement and Cross-License Agreement to receive a sublicense from Pfizer of certain patent rights under one or more claims in the Penn Existing
Patents. 
 (v) “Change in Control Transaction” shall mean any asset, equity, contractual, or other legal transaction
through which one person or entity acquires control of, becomes controlled by, or comes under common control with, the other person or entity. For the purposes of this definition, the term “control” (including, with correlative meanings,
the terms “controlled by” and “under common control with”) means (a) the possession, directly or indirectly, of the power to direct the management or policies of an entity, whether through the ownership of voting securities,
by contract relating to voting rights or corporate governance or otherwise, or (b) the ownership, directly or Indirectly, of at least fifty percent (50%) of the voting securities or other ownership interest of an entity (or, with respect
to a limited partnership or other similar entity, its general partner or controlling entity); provided, that if local law restricts foreign ownership, “control” shall be deemed established by direct or Indirect ownership of the maximum
ownership percentage that may, under such local law, be owned by foreign interests. 
 14.2 Business Interactions with
Pfizer. Notwithstanding anything to the contrary in this Agreement (including, without limitation, Section 13.5, “Assignment”), Company shall not, and shall not authorize or permit any Company Affiliate or sublicensee of a Penn
Patent Right to, directly or indirectly enter into any license, sublicense, contract or other legally-binding oral or written agreement with Pfizer or a Pfizer Affiliate or an Authorized Pfizer Sublicensee, regarding or under any of the Penn Patent
Rights, other than the Settlement and Cross-License Agreement, which would: (a) legally allow Company not to pay Penn, or to pay Penn less money, under this Agreement, as a result of Penn having entered into the Settlement and Cross-License
Agreement; or (b) legally allow Company not to comply with a term or obligation set forth in this Agreement which Company otherwise would have been obligated to comply with had Penn never entered into the Settlement and Cross-License Agreement.

 3. This Amendment shall become effective as of the same date and time as the execution of the Settlement and Cross-License Agreement by all
parties. Except as expressly amended in this Amendment, no other terms or conditions in the Existing Agreement are, or are intended to be, amended or waived as a result of the execution of this Amendment. This is the final and entire agreement
between Penn and Company on the subject matter herein, and supersedes any prior discussions, negotiations, understandings or agreements on the subject matter herein. 

 

 2 

 IN WITNESS WHEREOF, each party has caused this Amendment to be executed by its duly
authorized representative as a document under seal. 
  

			
	 THE TRUSTEES OF THE

UNIVERSITY OF PENNSYLVANIA
	 	AEGERION PHARMACEUTICALS, INC.
		
	 By: /s/ John Zawad 

Name: John S. Zawad
 Title: Managing Director

           Center for Technology Transfer
	 	 By: /s/ Gerald Wisler

Name: Gerald Wisler
 Title: President and Chief
Executive Officer

		
	Date Signed: September 27, 2006	 	Date Signed: September 27, 2006

  

 3License Agreement with Bayer Healthcare AG

 Exhibit 10.7 

EXECUTION COPY 
 [CONFIDENTIAL
TREATMENT REQUESTED] /*/ INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER
THE SECURITIES ACT OF 1933, AS AMENDED. 
 LICENSE AGREEMENT 

This License Agreement (this “Agreement”), dated as of May 31, 2006 (the “Effective Date”), is made by
and between Bayer HealthCare AG, a German corporation (“Bayer”), and Aegerion Pharmaceuticals, Inc., a Delaware corporation (“Aegerion”). Bayer and Aegerion are sometimes hereinafter referred to each as a “Party” and
collectively as the “Parties.” 
 WHEREAS, Bayer has been engaged in the development of implitapide as an inhibitor of
microsomal triglyceride transfer protein (“MTP”), and owns and otherwise controls certain patent rights and know-how with respect thereto; 

WHEREAS, Aegerion desires to acquire exclusive rights under the Bayer Patent Rights and Bayer Know-How (as defined below) in order to
continue the development thereof and products based thereupon; and 
 WHEREAS, the Parties desire to enter into an agreement
pursuant to which Bayer will grant an exclusive license to Aegerion under the Bayer Patent Rights and Bayer Know-How for Aegerion to develop and commercialize Licensed Compounds and Licensed Products (as defined below). 

NOW, THEREFORE, the Parties hereby agree as follows: 

Section 1. Definitions. 

For the purpose of this Agreement, the following words and phrases shall have the meanings set forth below: 

1.1 “Affiliate” of an entity means any other entity which (directly or indirectly) is controlled by, controls or is under
common control with such entity. For the purposes of this definition, the term “control” (including, with correlative meanings, the terms “controlled by” and “under common control with”) as used with respect
to an entity means (i) in the case of a corporate entity, direct or indirect ownership of voting securities entitled to cast at least fifty percent (50%) of the votes in the election of directors or (ii) in the case of a non-corporate
entity, direct or indirect ownership of at least fifty percent 50%) of the equity interests with the power to direct the management and policies of such entity, provided that if local law restricts foreign ownership, control shall be
established by direct or indirect ownership of the maximum ownership percentage that may, under such local law, be owned by foreign interests. 

1.2 “Bayer Know-How” means all Technology, now existing or hereafter arising during the time the license grant set forth in
Section 2.1 is in effect, owned or otherwise Controlled by Bayer or any of its Affiliates, that is related to the Bayer Patent Rights or that is reasonably necessary or useful for the manufacture, use, sale, offer for sale, importation,
research, development or commercialization or other exploitation of any Licensed Compounds or Licensed Products or Improvements. Exhibit A attached hereto lists specific Bayer Know-How. 

 LICENSE AGREEMENT 

 

 1.3 “Bayer Patent Rights” means: 

(a) the patents and patent applications listed in Exhibit B-1 attached hereto, plus (a) all divisionals,
continuations, continuations-in-part thereof or any other patent application claiming priority directly or indirectly to (i) any of the patents or patent applications identified on Exhibit B-1 or (ii) any patent or patent
application from which the patents or patent applications identified on Exhibit B-1 claim direct or indirect priority, and (b) all patents issuing on any of the foregoing; and 

(b) all other patents and patent applications owned or otherwise Controlled by Bayer or any of its Affiliates during the
time the license grant set forth in Section 2.1 is in effect that (i) claim any Improvements or their manufacture or use, or (ii) that are reasonably necessary for the manufacture, use sale, offer for sale, importation, research,
development or commercialization or other exploitation of any Licensed Compounds or Licensed Products (the patents and patent applications of this clause (b), collectively “Bayer Improvement Patents”), which Bayer Improvement
Patents the Parties shall list on Exhibit B-2 attached hereto during the term of this Agreement as provided for in Section 6.1, together with all registrations, reissues, re examinations, renewals, supplemental protection
certificates and extensions of any of the foregoing, and all foreign counterparts thereof. 
 1.4 “Combination
Product” means a Licensed Product that includes at least one additional active ingredient other than Licensed Compound. Drug delivery vehicles, adjuvants, and excipients shall not be deemed to be “active ingredients”, except in the
case where such delivery vehicle, adjuvant, or excipient is recognized as an active ingredient in accordance with 21 C.F.R. 210.3(b)(7). 

1.5 “Commercially Reasonable Efforts” means, with respect to Licensed Products, the carrying out of development and
commercialization activities in a sustained manner using good faith commercially reasonable and diligent efforts, using the efforts that a company within the pharmaceutical industry and similarly situated to Aegerion would reasonably devote to a
product of similar market potential or profit potential resulting from its own research efforts, based on conditions then prevailing and taking into account, without limitation, issues of safety and efficacy, product profile, the proprietary
position, the then current competitive environment for such product and the likely timing of such product’s entry into the market, the regulatory environment and status of such product, and other relevant scientific, technical and commercial
factors. 
 1.6 “Confidential Information” means all Technology, chemical or biological materials, marketing plans,
strategies and customer lists, and other information that are disclosed or provided by such Party or its Affiliates to the other Party or its Affiliates, regardless of whether any of the foregoing are marked “confidential”
or “proprietary” or communicated to the other by the disclosing Party or its Affiliates in oral, written, graphic, or electronic form. 

1.7 “Confidentiality Agreement” means that certain Mutual Nondisclosure Agreement, dated October 5, 2005, by and between
the Parties. 
 1.8 “Controlled” or “Controls”, when used in reference to patent or other intellectual
property rights or Technology, means the legal authority or right of a person or entity to grant a license or sublicense of intellectual property rights to another person or entity, or to otherwise disclose or provide Technology to such other person
or entity, without breaching the terms of any agreement with a different person or entity. 
 1.9 “FDA” means the
United States Food and Drug Administration or any successor agency thereto. 
 1.10 “First Commercial Sale” means,
with respect to any Licensed Product on a country-by-country basis, the first sale for use by the general public of such Licensed Product in such country after marketing approval of such Licensed Product has been granted, or marketing and sale of
such Licensed Product is otherwise permitted, by the applicable regulatory authority of such country. 
  

 2 

 LICENSE AGREEMENT 

 

 1.11 “Improvements” means all Technology that amount to improvements to any of
the inventions claimed by the Bayer Patent Rights or to the Bayer Know-How made, developed, conceived, owner or otherwise Controlled by Bayer or any of its Affiliates after the date hereof, whether or not patentable or patented. 

1.12 “Licensed Compound” means (a) the compound known as Bay 13-9952 and identified as “implitapide,” and
(b) any metabolic precursors, prodrugs, isomers (chiral and otherwise), metabolites, hydrates, anhydrides, solvates, salt forms, free acids or bases, esters, amides, ethers, complexes, conjugates or polymorphs of any compounds covered by the
foregoing clause (a) or this clause (b). 
 1.13 “Licensed Product” means any pharmaceutical product
containing a Licensed Compound (alone or with other active ingredients), in all forms, presentations, formulations and dosage forms. For clarification, Licensed Product shall include any Combination Product. 

1.14 “NDA” means a New Drug Application filed with the FDA required for marketing approval for the applicable Licensed Product
in the United States. 
 1.15 “Net Sales” means, with respect to any Licensed Product, the amount received by Aegerion
and its Affiliates and Sublicensees for bona fide sales of such Licensed Product to a Third Party (other than Sublicensees and Aegerion’s Afffiliates but including distributors for resale), less: 

(a) discounts (including cash, quantity and patient program discounts), retroactive price reductions, charge-back payments
and rebates granted to managed health care organizations or to federal, state and local governments, their agencies, and purchasers and reimbursers or to trade customers; 

(b) credits or allowances actually granted upon claims, damaged goods, rejections or returns of such Licensed Product,
including such Licensed Product returned in connection with recalls or withdrawals; 
 (c) freight out, postage,
shipping and insurance charges for delivery of such Licensed Product; and 
 (d) taxes or duties levied on,
absorbed or otherwise imposed on the sale of such Licensed Product, including value-added taxes, or other governmental charges otherwise imposed upon the billed amount, as adjusted for rebates and refunds, to the extent not paid by the Third Party.

 Net Sales shall not include any payments among Aegerion, its Affiliates and Sublicensees. Net Sales shall be determined in
accordance with generally accepted accounting principles, consistently applied. Net Sales for any Combination Product shall be calculated on a country-by-country basis by multiplying actual Net Sales of such Combination Product by the fraction A/B,
where A is the weighted average price paid for the Licensed Product contained in such Combination Product if such License Product is sold separately in finished form in such country, and B is the weighted average invoice price paid for such
Combination Product in such country. If such Licensed Product is not sold separately in finished form in such country, the parties shall determine Net Sales for such Licensed Product by mutual agreement based on the relative contribution of such
Licensed Product and each such other active ingredients in such Combination Product in accordance with the above formula, and shall take into account in good faith any applicable allocations and calculations that may have been made for the same
period in other countries. 
  

 3 

 LICENSE AGREEMENT 

 

 1.16 “Phase III Trial” means a human clinical trial of a Licensed Product
on a sufficient number of subjects that is designed to establish that a pharmaceutical product is safe and efficacious for its intended use, and to determine warnings, precautions and adverse reactions that are associated with such pharmaceutical
product in the dosage range to be prescribed, which trial is intended to support regulatory approval of a Licensed Product, all as described in 21 C.F.R. 312.21(c). For purposes of this Agreement, “Initiation of Phase III Trial”
for a Licensed Product means the first dosing of such Licensed Product in a human patient in a Phase III Trial. 
 1.17
“Technology” means know-how, trade secrets, chemical and biological materials, formulations, information, documents, studies, results, data and regulatory approvals, data, filings and correspondence (including DMFs), including biological,
chemical, pharmacological, toxicological, pre-clinical, clinical and assay data, manufacturing processes and data, specifications, sourcing information, assays, and quality control and testing procedures, whether or not patented or patentable.

 1.18 “Third Party” means any person or entity other than Aegerion or Bayer or any of their Affiliates. 

1.19 “Valid Claim” means a claim of an issued and unexpired patent contained within the Bayer Patent Rights, which claim has
not been revoked or held invalid or unenforceable by a court or other government agency of competent jurisdiction from which no appeal can be or has been taken and has not been held or admitted to be invalid or unenforceable through re-examination,
disclaimer, reissue, opposition procedure, nullity suit or otherwise, and which claim covers a Licensed Product or its use. 
 Section 2.
License Grant by Bayer. 
 2.1 Exclusive License. Bayer, for itself and on behalf of its Affiliates, hereby grants
to Aegerion and its Affiliates a non-transferable (except in accordance with Section 10.1), exclusive (even as to Bayer and its Affiliates), worldwide license, with the right to sublicense in accordance with Section 2.2 only, under the
Bayer Patent Rights and Bayer Know-How, to make, have made, use, sell, offer to sell, import, research, develop, commercialize and otherwise exploit Licensed Compounds and Licensed Products and Improvements (but with respect to Improvements, only to
the extent that any such Improvement is used in connection with the foregoing licensed activities involving Licensed Compounds and Licensed Products). The foregoing license grant includes the right to make reference to all regulatory approvals,
data, filings and correspondence (including DMFs) contained within the Bayer Know-How. 
  

 4 

 LICENSE AGREEMENT 

 

 2.2 Sublicenses. 

(a) Subject to Section 2.3, the exclusive license contained in Section 2.1 includes the right to grant
sublicenses (through multiple tiers) to Third Parties (each such Third Party sublicensee, a “Sublicensee”), provided that Aegerion shall remain responsible for the performance of its Sublicensees hereunder. Aegerion shall provide
Bayer with a copy of the sublicense agreement for its Sublicensees within ninety (90) days of execution, which copy may be redacted to exclude financial and other sensitive terms and shall be treated as Confidential Information of Aegerion
hereunder. 
 (b) Each sublicense granted by Aegerion to any rights licensed to it hereunder shall terminate
immediately upon the termination of the license from Bayer to Aegerion with respect to such rights, provided that such sublicensed rights shall not terminate if, as of the effective date of such termination by Bayer pursuant to Section 9.2, a
Sublicensee is not in material default of its obligations to Aegerion under its sublicense agreement, and within thirty (30) days of such termination the Sublicensee agrees in writing to be bound directly to Bayer under a license agreement
substantially similar to this Agreement with respect to the rights sublicensed hereunder, substituting such Sublicensee for Aegerion. 

2.3 Bayer First Right of Negotiation. In the event Aegerion desires at any time to have a Third Party sell one or more Licensed
Products after their respective First Commercial Sale in a particular country or countries (a “Commercialization Agreement”), Aegerion shall notify Bayer of its desire and provide Bayer with written notice specifying the applicable
Licensed Product(s) and country(ies). If Bayer notifies Aegerion in writing of its election to pursue a Commercialization Agreement for such Licensed Product(s) in such country(ies) within thirty (30) days of Bayer’s receipt of such
notice, Aegerion and Bayer shall enter into good faith negotiations with respect to such Commercialization Agreement for a period of ninety (90) days following Aegerion’s receipt of such election from Bayer (the “Negotiation
Period”). During the Negotiation Period, Aegerion shall provide Bayer with such information Controlled by Aegerion regarding such Licensed Product(s) as Bayer may reasonably request. If Aegerion and Bayer fail to enter into such
Commercialization Agreement (notwithstanding those good faith negotiations), or if Bayer fails to notify Aegerion in writing of Bayer’s election to initiate the Negotiation Period within such 30-day period, Aegerion shall thereafter be free to
negotiate and enter into a Commercialization Agreement with one or more Third Parties for some or all of such Licensed Product(s) and country(ies), without any further obligation or liability to Bayer. Bayer’s rights under this Section 2.3
shall not apply to any assignment by Aegerion permitted by Section 10.1, and this Section 2.3 shall terminate in full upon any such permitted assignment by Aegerion to a non-Affiliated Third Party. 

2.4 Restrictions on Bayer. 

(a) Bayer and its Affiliates shall not grant or provide to any Third Party any Technology, patent or other intellectual
property rights or Confidential Information inconsistent with the terms of this Agreement. For as long as the license grant set forth in Section 2.1 is in effect, (i) Bayer Know-How shall be treated as Confidential Information of both
Aegerion and Bayer, and Bayer and its Affiliates shall not disclose Bayer Know-How except as permitted by Sections 7.1(b) or 7.1(c), and (ii) Bayer and its Affiliates shall not provide to any person or entity (other than
Aegerion) any Licensed Compounds whose use or sale infringes a Valid Claim. 
 (b) The Parties acknowledge that
Bayer and its Affiliates do not currently have any MTP inhibitor program under development and currently do not anticipate initiating any such program. Furthermore, Bayer and its Affiliates do not currently, nor do they intend to, assist any Third
Party in developing any MTP inhibitors. Notwithstanding the foregoing, except as otherwise prohibited by the terms of this Agreement, Bayer reserves the right to do research and development in the area of MTP inhibitors after the Effective Date.

  

 5 

 LICENSE AGREEMENT 

 

 2.5 License Limitations. No licenses or other rights are granted by Bayer
hereunder to use any trademark, trade name, trade dress or service mark owned or otherwise Controlled by Bayer or any of its Affiliates. All licenses and other rights are or shall be granted only as expressly provided in this Agreement, and no other
licenses or other rights is or shall be created or granted hereunder by implication, estoppel or otherwise. 
 Section 3. Transfer of Bayer
Know-How. 
 3.1 Documentation. During the thirty (30) day period following the Effective Date, Bayer shall
provide to Aegerion one (1) electronic copy of all documents, data or other information listed on Exhibit A. 

3.2 Purchase of Licensed Compound. During the eighteen (18) month period following the Effective Date, Aegerion shall have
the right, but not the obligation, to purchase and have transferred from Bayer, in accordance with Aegerion’s directions, any portion of Bayer’s inventory of Licensed Compound from any batch that Aegerion may specify at a rate of one
thousand five hundred Euros (€1,500) per kilogram of Licensed Compound. The foregoing right shall apply with respect to any batch of Bayer’s inventory of Licensed Compound set forth in Exhibit C. During such eighteen
(18) month period, Bayer shall transfer to Aegerion, at Aegerion’s reasonable request, representative samples of Bayer’s inventory of License Compound from any such batch that Aegerion may specify for the purpose of testing such
samples for viability (at Aegerion’s cost). With respect to any remaining inventory of Licensed Compound in Bayer’s or any of its Affiliates’ possession, (i) Bayer shall not, and shall cause its Affiliates not to, use or transfer
to Third Parties any of such remaining inventory for any purpose and (ii) during such eighteen-month period, [CONFIDENTIAL TREATMENT REQUESTED] /*/. Bayer represents and warrants that (1) all of Bayer’s inventory of Licensed Compound
has been manufactured in accordance with GMP, (2) Exhibit C contains a complete and accurate list of all batches of such inventory as of the Effective Date, including accurate information related thereto, and (3) each batch of all
such inventory has a remaining shelf life as of the Effective Date equal to the period of time between the Effective Date and the “Retest date” set forth in Exhibit C for such batch. 

3.3 Technical Assistance. During the six (6) month period following the Effective Date, Bayer shall reasonably cooperate with
Aegerion to (i) provide (a) up to seventy (70) hours of technical assistance without charge to Aegerion and (b) any additional hours of technical assistance as Aegerion may reasonably request, for which Aegerion shall pay Bayer a
rate of [CONFIDENTIAL TREATMENT REQUESTED] /*/ U.S. dollars (US$ [CONFIDENTIAL TREATMENT REQUESTED] /*/) per hour of such technical assistance, and (ii) transfer to Aegerion any additional Bayer Know-How licensed under Section 2.1, in each
case to facilitate the transfer of development efforts related to Licensed Compounds and Licensed Products. Such cooperation shall include providing Aegerion with reasonable access by teleconference or in-person at Bayer’s facilities to Bayer
personnel involved in the research and development of Licensed Compounds and Licensed Products to provide Aegerion with a reasonable level of technical assistance and consultation in connection with the transfer of Bayer Know-How. 

 

 6 

 LICENSE AGREEMENT 

 

 Section 4. Development and Commercialization. 

4.1 Commercially Reasonable Efforts. Aegerion, or one of its Affiliates or Sublicensees, as applicable, shall use Commercially
Reasonable Efforts to develop and commercialize at least one Licensed Product. 
 4.2 Responsibilities and Costs.
Aegerion shall have sole responsibility for, and shall bear all its costs of conducting, all development and commercialization of Licensed Compounds and Licensed Products (including manufacturing all required materials, filing for and obtaining
all required regulatory approvals and submitting any adverse event reports to the applicable regulatory authority). Aegerion shall own the results of all such activities, and as between the Parties, all such regulatory approvals shall be obtained by
and in the name of Aegerion (or its Affiliates or Sublicensees). 
 4.3 Development Plan. Attached hereto as
Exhibit D is a summary of Aegerion’s initial “Development Plan,” which summarizes Aegerion’s plans for the development of Licensed Products. At least semi-annually until a marketing approval in a country for the first
Licensed Product, Aegerion shall provide to Bayer (i) any significant updates or revisions to the Development Plan for Bayer’s review (to the extent not prohibited by any agreement between Aegerion and a Sublicensee), and (ii) a
report presenting a meaningful summary of the development activities accomplished by Aegerion through the end of the preceding semi-annual period. Further, in the event Aegerion’s Board of Directors passes a final resolution to provide notice
of the discontinuation of the development of Licensed Compounds and Licensed Products hereunder, Aegerion shall notify Bayer in writing thereof within five (5) days of such final resolution, provided that such final resolution or
discontinuation of development shall not affect Aegerion’s rights hereunder. 
 Section 5. Aegerion Payments. 

5.1 Initial License Fee. Aegerion shall pay to Bayer seven hundred and fifty thousand U.S. dollars (US$750,000) within thirty
(30) days after the Effective Date. 
 5.2 Milestone Payments. As set forth in the following table, Aegerion shall
make Milestone Payments to Bayer upon achievement of each of the Milestones Events. Each Milestone Payment shall be payable by Aegerion to Bayer within thirty (30) days after the achievement of the corresponding Milestone Event with respect to the
first Licensed Product. Only one set of Milestone Payments are payable hereunder no matter how many times any of the Milestone Events are achieved. 
  

			
	 “Milestone Event”
	  	 “Milestone Payment”

		
	1. [CONFIDENTIAL TREATMENT REQUESTED] /*/	  	US$ [CONFIDENTIAL TREATMENT REQUESTED] /*/
		
	2. [CONFIDENTIAL TREATMENT REQUESTED] /*/	  	US$ [CONFIDENTIAL TREATMENT REQUESTED] /*/
		
	3. [CONFIDENTIAL TREATMENT REQUESTED] /*/	  	US$ [CONFIDENTIAL TREATMENT REQUESTED] /*/

5.3 Annual Payments. Aegerion shall pay to Bayer, within [CONFIDENTIAL TREATMENT REQUESTED] /*/ ([CONFIDENTIAL TREATMENT
REQUESTED] /*/) days after the start of the 
  

 7 

 LICENSE AGREEMENT 

 

 
corresponding calendar year, the following amounts, which amounts when paid shall be non-refundable: (i) for calendar year 2007, [CONFIDENTIAL TREATMENT REQUESTED] /*/ United States dollars
(US$ [CONFIDENTIAL TREATMENT REQUESTED] /*/), (ii) for calendar year 2008, [CONFIDENTIAL TREATMENT REQUESTED] /*/ United States dollars (US$ [CONFIDENTIAL TREATMENT REQUESTED] /*/), (iii) for calendar year 2009, [CONFIDENTIAL TREATMENT
REQUESTED] /*/ United States dollars (US$ [CONFIDENTIAL TREATMENT REQUESTED] /*/), (iv) for calendar year 2010, [CONFIDENTIAL TREATMENT REQUESTED] /*/ dollars (US$ [CONFIDENTIAL TREATMENT REQUESTED] /*/) and (v) for calendar year 2011,
[CONFIDENTIAL TREATMENT REQUESTED] /*/ United States dollars (US$ [CONFIDENTIAL TREATMENT REQUESTED] /*/) (each, an “Annual Payment”); provided, however, that each Annual Payment shall be creditable against the Milestone Payments as such
Milestone Payments become payable. [CONFIDENTIAL TREATMENT REQUESTED] /*/ 
 5.4 Commercialization
Milestone Payment. A one-time milestone payment of five million U.S. dollars (US$5,000,000) shall be payable by Aegerion to Bayer within thirty (30) days after the end of the calendar year in which Aegerion and its Affiliates and Sublicensees
first achieves aggregate Net Sales of all Licensed Products on which royalties are paid hereunder of two hundred fifty million U.S. dollars (US$250,000,000). 
  

 8 

 LICENSE AGREEMENT 

 

 5.5 Royalties. 

(a) Royalties. Subject to the terms and conditions of this Agreement (including the remainder of this Section
5), Aegerion shall pay to Bayer royalties, on a country-by-country and product-by-product basis for the period of time specified in Section 5.5(b), at the graduated royalty rates specified in the following table with respect to the aggregate
annual worldwide Net Sales of all Licensed Products in a calendar year: 
  

			
	 Aggregate Annual Worldwide Net Sales
of All Licensed Products in a Calendar Year
	  	 Royalty Rate

		
	On such Net Sales up to one hundred million U.S. dollars (US$100,000,000)	  	 [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent

([CONFIDENTIAL TREATMENT REQUESTED] /*/%)

		
	On such Net Sales above one hundred million U.S. dollars (US$100,000,000) and up to two hundred fifty million U.S. dollars (US$250,000,000)	  	[CONFIDENTIAL TREATMENT REQUESTED] /*/ ([CONFIDENTIAL TREATMENT REQUESTED] /*/%)
		
	On such Net Sales above two hundred fifty million U.S. dollars (US$250,000,000) and up to five hundred million U.S. dollars (US$500,000,000)	  	[CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%)
		
	On such Net Sales above five hundred million U.S. dollars (US$500,000,000)	  	[CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%)

The applicable royalty rate shall be determined by reference to all Net Sales on which royalties are paid in a given calendar year.
[CONFIDENTIAL TREATMENT REQUESTED] /*/ 
 (b) Royalty Term. The royalties due under Section 5.5(a)
shall be payable on Net Sales from the First Commercial Sale of a particular Licensed Product until the later of, on a country-by-country basis, (i) the expiration of the last to expire patent in such country within the Bayer Patent Rights
containing a Valid Claim covering such Licensed Product or its use for which regulatory approval has been obtained in such country, or (ii) ten (10) years from such First Commercial Sale, provided that such 10-year period shall apply only if
there was in such country a Valid Claim within the Bayer Patent Rights covering such Licensed Product or its use for which regulatory approval had been obtained in such country, and further provided that if royalties are owed on account of this
clause (ii) but not the preceding clause (i), the royalty rates specified in Section 5.5(a) shall be reduced by [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%). For clarity, only one 10-year
period under the foregoing clause (ii) above shall apply for all Licensed Products containing the same Licensed Compound (i.e., for a given chemical entity, not including all of the variations thereof identified in clause (b) of the
“Licensed Compound” definition). 
  

 9 

 LICENSE AGREEMENT 

 

 (c) Generic Competition. The royalty rates specified in
Sections 5.5(a) and 5.5(b) shall be reduced by [CONFIDENTIAL TREATMENT REQUESTED] /*/ ([CONFIDENTIAL TREATMENT REQUESTED] /*/) on a country-by-country basis at any such time where the sale of one or more Generic Product(s) in such country
exceeds [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%) of the unit sales volume for the applicable Licensed Product in that country, as measured by IMS Health or its successor. Such reduction shall be first
applied with respect to such country starting with sales in the calendar quarter following the first calendar quarter where the sales of the Generic Product(s) in such country exceed [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL
TREATMENT REQUESTED] /*/%) of the unit sales volume of the applicable Licensed Product. 
 (d) Only One
Royalty. Only one royalty shall be due with respect to the sale of the same unit of Licensed Product. Only one royalty shall be due hereunder on the sale of a Licensed Product even if the manufacture, use, sale, offer for sale or importation of
such Licensed Product infringes more than one claim of the Bayer Patent Rights. 
 5.6 Credits and Reductions. The
following shall apply to amounts payable to Bayer hereunder: 
 (a) Dominated IP. [CONFIDENTIAL TREATMENT
REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%) of third party royalties and milestones of actual costs paid or payable by Aegerion and its Affiliates for licenses and acquisitions by Aegerion, its Affiliates or Sublicensees of
patent or other intellectual property rights dominating or dominated by Bayer Patent Rights and therefore necessary to practice some or all of the Bayer Patent Rights in a particular country shall be creditable against payments owed Bayer under
Sections 5.2 to 5.5. 
 (b) Other IP. Third party royalties and milestones (other than as
credited under Section 5.6(a)) for the actual costs paid or payable by Aegerion and its Affiliates for licenses and acquisitions by Aegerion, its Affiliates or Sublicensees of patent or other intellectual property rights reasonably necessary
for the manufacture, use, sale, offer for sale or importation of any Licensed Product in a particular country shall be creditable against payments owed Bayer under Sections 5.2 to 5.5, provided that, in the case of royalties, only where
the aggregate royalty burden for such Licensed Product in a particular country exceeds [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%) of the Blended Rate (as defined below) and in such a royalty case,
Aegerion will be entitled to a credit in the amount of [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%) of such excess. For purposes of this Agreement, “Blended Rate” means (1) the total
amount of royalties that would be payable in the applicable calendar quarter and prior three (3) calendar quarters with respect to the applicable Licensed Product under Section 5.5 (without any reduction under this Section 5.6),
divided by (2) the total Net Sales on which royalties are paid for such Licensed Product for that same period, expressed as a percentage. 

Notwithstanding the foregoing provisions of this Section 5.6 or Sections 6.3(c) or 6.4, in no event shall Bayer receive
less than [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%) of the aggregate original payments due hereunder under Sections 5.2 to 5.5 for any given calendar quarter (with any unused credits to
accumulate and be applied against future payments due to Bayer). 
 5.7 Payment Terms. 

(a) Manner of Payment. All payments to be made by Aegerion hereunder shall be made in U.S. dollars by wire transfer
to such bank account as Bayer may designate. 
 (b) Reports and Royalty Payments. For as long as royalties
are due under Section 5.5(a), Aegerion shall furnish to Bayer a written report, within forty-five (45) days after the end of each calendar quarter, showing the amount of Net Sales of Licensed Products and royalty due for such calendar
quarter. 
  

 10 

 LICENSE AGREEMENT 

 

 
Royalty payments for each calendar quarter shall be due at the same time as such written report for the calendar quarter. The report shall include, at a minimum, the following information for the
applicable calendar quarter, each listed by product and by country of sale: (i) the number of units of Licensed Products sold by Aegerion and its Affiliates and Sublicensees on which royalties are owed Bayer hereunder; (ii) the gross
amount received for such sales; (iii) deductions taken from Net Sales as specified in the definition thereof; (iv) Net Sales; (v) the amounts of any credits or reductions permitted by Section 5.6 or elsewhere hereunder;
(vi) the royalties and Milestone Payments owed to Bayer, listed by category; and (vii) the computations for any applicable currency conversions pursuant to Section 5.7(d). Aegerion shall use commercially reasonable efforts to obtain
permission from each Sublicensee to share with Bayer the information listed in the foregoing clauses (other than clause (iv)) as it relates to Net Sales made by such Sublicensee, and to the extent successful, will include such Sublicensee
information in such report. All such reports shall be treated as Confidential Information of Aegerion. 
 (c)
Records and Audits. Aegerion shall keep, and shall cause each of its Affiliates and Sublicensees, as applicable, to keep adequate books and records of accounting for the purpose of calculating all royalties payable to Bayer hereunder. For the
two (2) years next following the end of the calendar year to which each shall pertain, such books and records of accounting (including those of Aegerion’s Affiliates and Sublicensees, as applicable) shall be kept at each of their principal
place of business and shall be open for inspection at reasonable times and upon reasonable notice by an independent certified accountant selected by Bayer, and which is reasonably acceptable to Aegerion, for the sole purpose of inspecting the
royalties due to Bayer under this Agreement. In no event shall such inspections be conducted hereunder more frequently than once every twelve (12) months. Such accountant must have executed and delivered to Aegerion and its Affiliates and
Sublicensees, as applicable, a confidentiality agreement as reasonably requested by Aegerion, which shall include provisions limiting such accountant’s disclosure to Bayer to only the results and basis for such results of such inspection. The
results of such inspection, if any, shall be binding on both Parties. Any underpayments shall be paid by Aegerion within thirty (30) days of notification of the results of such inspection. Any overpayments shall be fully creditable against
amounts payable in subsequent payment periods. Bayer shall pay for such inspections, except that in the event there is any upward adjustment in aggregate royalties payable for any calendar year shown by such inspection of more than [CONFIDENTIAL
TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%) of the amount paid, Aegerion shall reimburse Bayer for any reasonable out-of-pocket costs of such accountant. Any underpayments or overpayments under this
Section 5.7(c) shall be subject to the currency exchange provisions set forth in Section 5.7(d) as applied to the calendar quarter during which the royalty obligations giving rise to such underpayment or overpayment were incurred by
Aegerion. 
 (d) Currency Exchange. With respect to Net Sales invoiced in U.S. dollars, the Net Sales and
the amounts due to Bayer hereunder shall be expressed in U.S. dollars. With respect to Net Sales invoiced in a currency other than U.S. dollars, the Net Sales shall be expressed in the domestic currency of the entity making the sale, together with
the U.S. dollar equivalent, calculated using the official rate of exchange of such domestic currency as quoted by the Wall Street Journal, New York edition, for the last business day of the calendar quarter for which the payment is made. 

(e) Tax Withholding; Value-Added Tax. Aegerion shall have the right to withhold from payments due hereunder any tax
which Bayer is liable to under the appropriate tax laws and for the payments of which Aegerion is responsible. Bayer shall be sent tax receipts by Aegerion certifying the payments of the tax, so that Bayer may use it for claiming a credit on the tax
payable by Bayer in Germany on such payments. No deduction shall be made or a reduced amount shall be deducted if Bayer furnishes a document from all required tax authorities to Aegerion sufficiently before the due date of the payments, certifying
that the payments are exempt from tax or subject to a reduced tax rate according to the applicable convention for the avoidance of double taxation. Except for such withholding taxes and except for the personal corporate income tax of Bayer, any
other taxes, assessments, fees and charges 
  

 11 

 LICENSE AGREEMENT 

 

 
imposed against payments due to Bayer hereunder shall be borne by Aegerion. Besides the above said, both Parties will undertake commercially reasonable efforts to minimize the allover tax burden
for each of the Parties. Value-added tax shall apply as legally required. 
 (f) Interest Due. Aegerion
shall pay Bayer interest on any payments that are not paid on or before the date such payments are due under this Agreement at a rate of [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%) per month or the
maximum applicable legal rate, if less, calculated on the total number of days payment is delinquent. 
 Section 6. Patent Prosecution,
Infringement and Extensions. 
 6.1 Appointment and Cooperation. With respect to all of the rights and activities of
Aegerion set forth in this Section 6, Bayer hereby appoints Aegerion as its agent for such purposes with the authority to act on Bayer’s behalf with respect to the Bayer Patent Rights. Bayer shall cooperate with Aegerion in the exercise of
Aegerion’s authority granted herein, and shall execute such documents and take such additional action as Aegerion may request in connection therewith. The Parties shall update Exhibits B-1 and B-2 upon either
Party’s reasonable request. 
 6.2 Prosecution and Maintenance. 

(a) By Aegerion. On the Effective Date, Bayer shall provide Aegerion with copies of the complete prosecution files
for all patents and patent applications listed on Exhibit B. Aegerion shall be solely responsible for the preparation, prosecution (including any interferences, oppositions, reissue proceedings and reexaminations) and maintenance of the
Bayer Patent Rights, and all filing, prosecution, and maintenance decisions with respect to the Bayer Patent Rights shall be made by Aegerion, provided Bayer shall retain the right to give comments to Aegerion on material aspects of those
activities. Aegerion shall be responsible for all its costs incurred for such preparation, prosecution and maintenance. Each Party shall provide to the other Party copies of any papers relating to the filing, prosecution or maintenance of Bayer
Patent Rights promptly upon receipt. Bayer shall not take any action with respect to the prosecution or maintenance of any Bayer Patent Rights without the prior written consent of Aegerion, except as contemplated by Section 6.2(b). 

(b) By Bayer. Aegerion shall not knowingly permit any of the Bayer Patent Rights to be abandoned in any country
without Bayer first being given an opportunity to assume full responsibility for the continued prosecution and maintenance of same. In the event that Aegerion decides not to continue the prosecution or maintenance of a patent application or patent
within Bayer Patent Rights in any country, Aegerion shall provide Bayer with notice of this decision at least thirty (30) days prior to any pending lapse or abandonment thereof. In the event that Bayer elects to assume responsibility for such
prosecution and maintenance within thirty (30) days of Aegerion’s notice, Section 6.2(a) shall thereafter apply to such patent application(s) and patent(s) except that the role of Aegerion and Bayer shall be reversed thereunder
(including that Bayer shall be solely responsible for all costs arising from those activities). Such patent application(s) and patent(s) shall otherwise continue to be subject to all of the terms and conditions of the Agreement in the same way as
the other Bayer Patent Rights. 
 (c) Bayer Improvement Patents. For any Bayer Improvement Patents, the
roles of the Parties under this Sections 6.2 shall be reversed. 
 6.3 Enforcement and Defense. 

(a) By Aegerion. In the event that Bayer or Aegerion becomes aware of a suspected infringement of any Bayer Patent
Right, or any such Bayer Patent Right is challenged in any action or proceeding (other than any interferences, oppositions, reissue proceedings or reexaminations, which are addressed above), such Party shall notify the other Party promptly, and
following such notification, the Parties shall confer. Aegerion shall have the right, but shall not be obligated, to defend any such action or 

 

 12 

 LICENSE AGREEMENT 

 

 
proceeding or bring an infringement action with respect to such infringement at its own expense, in its own name and entirely under its own direction and control, or settle any such action or
proceeding by sublicense. Bayer shall reasonably assist Aegerion in any action or proceeding being defended or prosecuted if so requested, and shall join such action or proceeding if reasonably requested by Aegerion or required by applicable law.
Bayer shall have the right to participate in any such action or proceeding with its own counsel at its own expense and without reimbursement. 

(b) By Bayer. If Aegerion elects not to settle, defend or bring any action for infringement described in
Section 6.3(a) and so notifies Bayer, then, if and only if such infringement would give rise to royalties payable to Bayer hereunder had Aegerion conducted the alleged infringing activities, Bayer may defend or bring such action at its own
expense, in its own name and entirely under its own direction and control, subject to the following: Aegerion shall reasonably assist Bayer in any action or proceeding being defended or prosecuted if so requested, and shall join such action or
proceeding if requested by Bayer or required by applicable law. Aegerion shall have the right to participate in any such action or proceeding with its own counsel at its own expense and without reimbursement. No settlement of any such action or
proceeding which restricts the scope, or adversely affects the enforceability, of a Bayer Patent Right may be entered into by Bayer without the prior written consent of Aegerion. 

(c) Escrow in Certain Circumstances. On a country-by-country and product-by-product basis, in any action or
proceeding in which a Third Party challenges the validity or enforceability of all (and not less than all) of the Valid Claims under the Bayer Patent Rights in such country that cover such Licensed Product or its use (including by way of
interference, opposition, reissue proceeding or reexamination, or in response to enforcement pursuant to Section 6.3), then upon filing of such action or proceeding by a Third Party, fifty percent (50%) of all the royalties which would
otherwise be paid to Bayer, with respect to such Licensed Product for such country affected by such action or proceeding, shall be deposited in an interest bearing escrow account, until such time as all such Valid Claims expire. All monies in such
escrow account, together with all accrued interest, shall be retained by Aegerion if all such Valid Claims are found invalid or unenforceable by a court of proper jurisdiction in a decision unappealable or unappealed within the time allowed for
appeal, and, if at least one such Valid Claim is found not invalid and not unenforceable by a court of proper jurisdiction in such a decision, all monies in such escrow account, together with all accrued interest, shall be released to Bayer
immediately. 
 (d) Withdrawal. If either Party brings an action or proceeding under this Section 6.3
and subsequently ceases to pursue or withdraws from such action or proceeding, it shall promptly notify the other Party and the other Party may substitute itself for the withdrawing Party under the terms of this Section 6.3. 

(e) Damages. In the event that either Party exercises the rights conferred in this Section 6.3 and recovers
any damages or other sums in such action or proceeding or in settlement thereof, such damages or other sums recovered shall first be applied to all out-of-pocket costs and expenses incurred by the Parties in connection therewith (including attorneys
fees), unless not reimbursable hereunder. If such recovery is insufficient to cover all such costs and expenses of both Parties, the controlling Party’s costs shall be paid in full first before any of the other Party’s costs. If after such
reimbursement any funds shall remain from such damages or other sums recovered, [CONFIDENTIAL TREATMENT REQUESTED] /*/. 

 

 13 

 LICENSE AGREEMENT 

 

 6.4 Third Party IP Claims. In the event of (i) a holding in any action or
proceeding enjoining Aegerion or any of its Affiliates or Sublicensees from manufacturing, using, selling, offering for sale, importing, developing or commercializing any Licensed Compounds or Licensed Products, or holding Aegerion or any such other
entities liable for damages for any such activities, in each case such holding unappealable or unappealed within the time allowed for appeal, or (ii) a settlement of any action or proceeding requiring payment of damages by Aegerion or any such
party, Bayer shall refund to Aegerion royalties paid with respect to all Licensed Products affected by such action or proceeding, from the time such action or proceeding is first brought, sufficient to reimburse Aegerion and all such entities for
[CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%) of all damages and costs and expenses paid or incurred by any of them with respect to such action or proceeding attributable to infringement or
misappropriation of any Third Party’s patent or other intellectual property rights, provided that in no event shall Bayer be required to refund more than [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED]
/*/%) of any such royalties paid by Aegerion, and provided further, in the event that such refund is not sufficient to compensate for such [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%) of all such
damages and expenses, Aegerion shall be entitled to reduce royalties payable to Bayer by up to [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%) hereunder in each subsequent calendar quarter until such
time as Aegerion recovers in full such [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%) of all such damages and expenses. 

6.5 Patent Extensions; Orange Book Listings; Patent Certifications. 

(a) Patent Term Extension. If elections with respect to obtaining patent term extension or supplemental protection
certificates or their equivalents in any country with respect to Bayer Patent Rights or other patent rights covering Licensed Products or their manufacture or use are available, Aegerion shall have the sole right to make any such elections.

 (b) Data Exclusivity and Orange Book Listings. With respect to data exclusivity periods (such as those
periods listed in the FDA’s Orange Book (including any available pediatric extensions) or periods under national implementations of Article 10.1(a)(iii) of Directive 2001/EC/83, and all equivalents in any country), Aegerion shall have the sole
right to seek and maintain all such data exclusivity periods available for the Licensed Products. 
 (c)
Notification of Patent Certification. Bayer shall notify and provide Aegerion with copies of any allegations of alleged patent invalidity, unenforceability or non-infringement of a Bayer Patent Right pursuant to a Paragraph IV Patent
Certification by a Third Party filing an Abbreviated New Drug Application, an application under §505(b)(2) of the United States Federal Food, Drug, and Cosmetic Act, as amended, or any other similar patent certification by a Third Party, and
any foreign equivalent thereof. Such notification and copies shall be provided to Aegerion within two (2) days after Bayer receives such certification, and shall be sent to the address set forth in Section 10.5. 

Section 7. Confidential Information and Publicity. 

7.1 Confidentiality. 

(a) Confidential Information. Except as expressly provided herein, each of the Parties agrees that, for itself and
its Affiliates, and for as long as this Agreement is in effect and for a period of 
  

 14 

 LICENSE AGREEMENT 

 

 
ten (10) years thereafter, a Party and its Affiliates (the “Receiving Party”) receiving Confidential Information of the other Party or its Affiliates
(the “Disclosing Party”) shall (i) not disclose such Confidential Information to any Third Party without the prior written consent of the Disclosing Party, except for disclosures expressly permitted below, and (ii) not use
such Confidential Information for any purpose except those licensed or otherwise authorized or permitted by this Agreement. For clarity, all Confidential Information of Aegerion received by or disclosed to Bayer hereunder shall be used by Bayer only
for ensuring that Aegerion complies with its obligations hereunder and for no other purposes. 
 (b)
Exceptions. The obligations in Section 7.1(a) shall not apply with respect to any portion of the Confidential Information that the Receiving Party can show by competent proof: 

(i) is publicly disclosed by the Disclosing Party, either before or after it is disclosed to the Receiving Party
hereunder; 
 (ii) was known to the Receiving Party or any of its Affiliates, without any obligation to keep it
confidential or any restriction on its use, prior to disclosure by the Disclosing Party; 
 (iii) is subsequently
disclosed to the Receiving Party or any of its Affiliates by a Third Party lawfully in possession thereof and without any obligation to keep it confidential or any restriction on its use; 

(iv) is published by a Third Party or otherwise becomes publicly available or enters the public domain, either before or
after it is disclosed to the Receiving Party; or 
 (v) has been independently developed by employees or
contractors of the Receiving Party or any of its Affiliates without the aid, application or use of Confidential Information of the Disclosing Party. 

(c) Authorized Disclosures. The Receiving Party may disclose Confidential Information belonging to the Disclosing
Party to the extent (and only to the extent) such disclosure is reasonably necessary in the following instances: 

(i) subject to Section 7.2, by either Party in order to comply with applicable non-patent law (including any
securities law or regulation or the rules of a securities exchange) and with judicial process, if in the reasonable opinion of the Receiving Party’s counsel, such disclosure is necessary for such compliance; 

(ii) by either Party, in connection with prosecuting or defending litigation, making regulatory filings, and filing,
prosecuting and enforcing patent applications and patents (including Bayer Patent Rights in accordance with Section 6); 

(iii) by Aegerion, to its Affiliates, potential and future collaborators (including Sublicensees), permitted acquirers or
assignees under Section 10.1, research collaborators, subcontractors, investment bankers, investors, lenders, and their and each of Aegerion and its Affiliates’ respective directors, employees, contractors and agents; and 

(iv) by Bayer to its Affiliates, permitted acquirers or assignees under Section 10.1, investment bankers, investors,
lenders, and their and Bayer and its Affiliates’ respective directors, employees, contractors and agents, 
 provided that (1) with
respect to Section 7.1(c)(i) or 7.1(c)(ii), where reasonably possible, the Receiving Party shall notify the Disclosing Party of the Receiving Party’s intent to make any disclosure pursuant thereto sufficiently prior to making such
disclosure so as to allow the Disclosing Party adequate time to take whatever action it may deem appropriate to protect the confidentiality of the information to be disclosed, and (2) with respect to Sections 7.1(c)(iii)
and 7.1(c)(iv), each of those named people and entities must be bound prior to disclosure by confidentiality and non-use restrictions at least as restrictive 

 

 15 

 LICENSE AGREEMENT 

 

 
as those contained in this Section 7 (other than investment bankers, investors and lenders, who must be bound prior to disclosure by commercially reasonable obligations of confidentiality).
In addition to the foregoing, Aegerion and its Affiliates and Sublicensees may make such disclosures of Bayer Know-How specifically concerning the Licensed Compound and its use as any of them may deem reasonably necessary for their business.

 7.2 Terms of this Agreement; Publicity. 

(a) The Parties agree that the terms of this Agreement shall be treated as Confidential Information of both Parties, and
thus may be disclosed only as permitted by Section 7.1(c). Each Party agrees not to issue any press release or public statement disclosing information relating to this Agreement or the transactions contemplated hereby or the terms hereof
without the prior written consent of the other Party (or as such consent may be obtained in accordance with Section 7.2(b)), which consent shall not be unreasonably withheld, or as permitted by Section 7.1(c). 

(b) In the event either Party (the “Issuing Party”) desires to issue a press release or other public
statement disclosing information relating to this Agreement or the transactions contemplated hereby or the terms hereof, the Issuing Party shall provide the other Party (the “Reviewing Party”) with a copy of the proposed press
release or public statement (the “Release”). The Reviewing Party shall have three (3) business days to provide any comments on such Release, and if the Receiving Party fails to provide any comments during such three-day
period, the Reviewing Party shall be deemed to have consented to the issuance of such Release. If the Receiving Party provides any comments, the Parties shall consult on the such Release and work in good faith to prepare a mutually acceptable
Release. Either Party may subsequently publicly disclose any information previously contained in any Release so consented to. 

7.3 Relationship to the Confidentiality Agreement. This Agreement supersedes the Confidentiality Agreement, provided that
all “Confidential Information” disclosed or received by the Parties thereunder shall be deemed “Confidential Information” hereunder and shall be subject to the terms and conditions of this Agreement. 

Section 8. Warranties; Limitations of Liability; Indemnification 

8.1 Bayer Representations and Warranties. Bayer covenants, represents and warrants to Aegerion that as of the Effective Date:

 (a) Bayer is a corporation duly organized, validly existing and in good standing under the laws of state or
jurisdiction in which it is incorporated, and it has full right and authority to enter into this Agreement and to grant the licenses and other rights to Aegerion as herein described. 

(b) This Agreement has been duly authorized by all requisite corporate action, and when executed and delivered will become
a valid and binding contract of Bayer enforceable against Bayer in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium and other law affecting creditors’ rights generally from time to time if
effect, and to general principles of equity. 
 (c) The execution, delivery and performance of this Agreement
does not conflict with any other agreement, contract, instrument or understanding, oral or written, to which Bayer is a party, or by which it is bound, nor will it violate any law applicable to Bayer. 

(d) All necessary consents, approvals and authorizations of all regulatory and governmental authorities and other persons
or entities required to be obtained by Bayer in connection with the execution and delivery of this Agreement and the performance of its obligations hereunder have been obtained. 

(e) Exhibit A contains a list of all Bayer Know-How in Bayer’s possession as of the Effective Date that Bayer
has reasonably concluded Aegerion will find reasonably necessary or useful for 
  

 16 

 LICENSE AGREEMENT 

 

 
the manufacture, use, sale, offer for sale, importation, research, development or commercialization or other exploitation of any Licensed Compounds or Licensed Products or Improvements. Attached
hereto as Exhibit B is a complete and accurate list of all patents and patent applications owned (in whole or in part) or otherwise Controlled by Bayer or any of its Affiliates that the manufacture, use, sale, offer for sale or
importation of any Licensed Compounds (alone or as part of any Combination Product) would infringe. To the knowledge of Bayer, the issued claims included in the Bayer Patent Rights are valid and enforceable, and no written claim has been made
(except by a patent examiner during prosecution of the patent application(s) that resulted in any such issued patent claims), and no action or proceeding has been commenced or threatened, alleging to the contrary. Bayer is the sole and exclusive
owner of all right, title and interest in and to the Bayer Patent Rights. None of the Bayer Patent Rights or Bayer Know-How is subject to any lien, security interest or other encumbrance. To Bayer’s knowledge, the conception and reduction to
practice of the Bayer Patent Rights have not constituted or involved the misappropriation of trade secrets or other rights or property of any Third Party. There are no claims, judgments or settlements against or amounts with respect thereto owed by
Bayer or any of its Affiliates relating to the Bayer Patent Rights. To Bayer’s knowledge, there has been no infringement by any Third Party of any Bayer Patent Rights. The use or practice of the license grant contained in Section 2.1 shall
not trigger any payment obligation by Bayer or any of its Affiliates or Former Licensees (as defined below) to any Third Party. 

(f) There is no pending action or proceeding alleging, or, to Bayer’s knowledge, any written communication alleging,
that the manufacture, use, sale, offer for sale or importation of any Licensed Compounds (alone or as part of any Combination Product), the activities of Bayer or any of its Affiliates or any of their licensees with respect to any such Licensed
Compounds, or the practice or use of the Bayer Patent Rights or Bayer Know-How, has or will infringe or misappropriate any patent or other intellectual property rights of any Third Party. Bayer has notified Aegerion of all such rights of any Third
Party of which Bayer is aware that are related to the foregoing activities, including those patents set forth on Exhibit E-1. 

(g) Except as set forth in Exhibit E-2: 

(i) Pharmaceutical Product Development, Inc. (together with its affiliates, including Medical Research Laboratories
International, LLC, collectively “PPD”) and Evan Stein, MD, PhD (“Dr. Stein”) constitute all Former Licensees known to Bayer, wherein “Former Licensees” means Bayer’s former licensees under any Bayer Patent Rights
or Bayer Know-How with respect to any Licensed Compounds and their sublicensees, subcontractors, clinical partners and other collaborators. 

(ii) Since Bayer has not done an in-depth analysis of IP since 2002 when implitapide was originally out-licensed, Bayer
can only represent that to its knowledge in light of the gap identified, it has sufficient rights (by ownership or license) in and to all Former Licensees IP (as defined below) for all Former Licensee IP to be treated as Bayer Patent Rights and
Bayer Know-How hereunder (including being subject to the exclusive license grant contained in Section 2.1), wherein “Former Licensee IP” means all Technology and patent and other intellectual property rights created or owned or
otherwise Controlled by any Former Licensee or any of its Affiliates, in each case related to the manufacture, use, sale, offer for sale, importation, development or commercialization of any Licensed Compounds. Without limiting the generality of the
foregoing, and to Bayer’s knowledge, PPD does not retain any right, title or interest in or to any Former Licensee IP, and no Former Licensee has filed or obtained any patent rights concerning any of those activities. 

(iii) To the knowledge of Bayer, no Former Licensee has any supply of Licensed Compounds. 

(h) To the extent that Bayer has the benefit of any contractual rights from any Former Licensees concerning the
development or commercialization of any Licensed Compounds, Bayer shall 
  

 17 

 LICENSE AGREEMENT 

 

 
use commercially reasonable efforts to exercise the same on behalf of Aegerion or any of its Affiliates or Sublicensees upon request (or if not so commercially reasonable, shall transfer the
right to exercise the same to Aegerion or any of its Affiliates or Sublicensees as Aegerion may designate and as may be permitted by the applicable terms). 

(i) As of the Effective Date, except as set forth in Exhibit E-3, Bayer does not have any knowledge of any
scientific or clinical facts or circumstances that would materially and adversely affect the safety, efficacy or market performance of any Licensed Compounds (alone or as part of any Combination Product) that have not been communicated to Aegerion.

 8.2 Aegerion Representations and Warranties. Aegerion covenants, represents and warrants to Bayer that as of the
Effective Date: 
 (a) Aegerion is a corporation duly organized, validly existing and in good standing under the
laws of state in which it is incorporated, and it has full right and authority to enter into this Agreement and to accept the rights and licenses granted as herein described. 

(b) This Agreement has been duly authorized by all requisite corporate action, and when executed and delivered will become
a valid and binding contract of Aegerion enforceable against Aegerion in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium and other laws affecting creditors’ rights generally from time to time
if effect, and to general principles of equity. 
 (c) The execution, delivery and performance of this Agreement
does not conflict with any other agreement, contract, instrument or understanding, oral or written, to which Aegerion is a party, or by which it is bound, nor will it violate any law applicable to Aegerion. 

(d) All necessary consents, approvals and authorizations of all regulatory and governmental authorities and other persons
or entities required to be obtained by Aegerion in connection with the execution and delivery of this Agreement and the performance of its obligations hereunder have been obtained. 

8.3 Disclaimer. EXCEPT AS EXPRESSLY SET FORTH HEREIN, NEITHER BAYER NOR AEGERION MAKES ANY REPRESENTATION OR WARRANTY, EXPRESS OR
IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 
 8.4 Limitation of Liability.
NOTWITHSTANDING ANYTHING IN THIS AGREEMENT OR OTHERWISE, NEITHER PARTY SHALL BE LIABLE TO THE OTHER OR ANY THIRD PARTY WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT FOR ANY INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES; PROVIDED, HOWEVER, THAT
THIS SECTION 8.4 SHALL NOT APPLY TO THE PARTIES’ INDEMNIFICATION RIGHTS AND OBLIGATIONS UNDER SECTIONS 8.6(a) AND 8.6(b). 

8.5 Performance by Affiliates. The Parties recognize that each Party may perform some or all of its obligations under this
Agreement through Affiliates and Third Party contractors provided, however, that each Party shall remain responsible and liable for the performance by its Affiliates and Third Party contractors and shall cause its Affiliates and Third Party
contractors to comply with the provisions of this Agreement in connection therewith. 
 8.6 Indemnification. 

(a) Aegerion Indemnity. Aegerion hereby agrees to indemnify and hold Bayer and its Affiliates, and their respective
employees, directors, agents and contractors, and their respective successors, heirs and assigns and representatives (“Bayer Indemnitees”) harmless from and against all claims, liability, threatened claims, damages, expenses (including
reasonable attorneys’ fees), suits, proceedings, losses or judgments, whether for money or equitable relief, of any kind, including death, 

 

 18 

 LICENSE AGREEMENT 

 

 
personal injury, illness, product liability or property damage or the failure to comply with applicable law (but not infringement or misappropriation of patents or other intellectual property
rights) (collectively, “Losses”), arising from any Third Party claim due to the use, manufacture, sale, development or commercialization of any Licensed Compounds or Licensed Products by or for Aegerion or any of its Affiliates,
Sublicensees, agents and contractors, except to the extent that such Losses arise from (a) the negligence, recklessness or willful misconduct of any Bayer Indemnitees or (b) any breach of this Agreement by Bayer. 

(b) Bayer Indemnity. Bayer hereby agrees to indemnify and hold Aegerion, its Affiliates and Sublicensees, and their
respective employees, directors, agents and contractors, and their respective successors, heirs and assigns and representatives (“Aegerion Indemnitees”) harmless from and against all Losses arising from any Third Party claim due to the
use, manufacture, sale, development or commercialization of any Licensed Compounds or Licensed Products by or for Bayer or any of its Affiliates, licensees (other than Aegerion and its Affiliates and Sublicensees), agents and contractors, except to
the extent that such Losses arise from (a) the negligence, recklessness or willful misconduct of any Aegerion Indemnitees or (b) any breach of this Agreement by Aegerion. 

(c) Indemnification Procedure. A claim to which indemnification applies under Section 8.6(a) or
Section 8.6(b) shall be referred to herein as a “Claim”. If any person or entity (each, an “Indemnitee”) intends to claim indemnification under this Section 8.6, the Indemnitee shall notify the other Party
(the “Indemnitor”) in writing promptly upon becoming aware of any claim that may be a Claim (it being understood and agreed, however, that the failure by an Indemnitee to give such notice shall not relieve the Indemnitor of its
indemnification obligation under this Agreement except and only to the extent that the Indemnitor is actually prejudiced as a result of such failure to give notice). The Indemnitor shall have the right to assume and control the defense of such Claim
at its own expense with counsel selected by the Indemnitor and reasonably acceptable to the Indemnitee; provided, however, that an Indemnitee shall have the right to retain its own counsel, with the fees and expenses to be paid by the Indemnitee, if
representation of such Indemnitee by the counsel retained by the Indemnitor would be inappropriate due to actual or potential differing interests between such Indemnitee and any other party represented by such counsel in such proceedings. If the
Indemnitor does not assume the defense of such Claim as aforesaid, the Indemnitee may defend such Claim but shall have no obligation to do so. The Indemnitee shall not settle or compromise any Claim without the prior written consent of the
Indemnitor, and the Indemnitor shall not settle or compromise any Claim in any manner which would have an adverse effect on the Indemnitee’s interests, without the prior written consent of the Indemnitee, which consent, in each case, shall not
be unreasonably withheld. The Indemnitee shall reasonably cooperate with the Indemnitor at the Indemnitor’s expense and shall make available to the Indemnitor all pertinent information under the control of the Indemnitee, which information
shall be subject to Section 7.1. 
 8.7 Insurance. Aegerion shall procure and maintain insurance policies for the
following coverages with respect to personal injury, bodily injury and property damage arising out of Aegerion’s performance under this Agreement: (a) during the term of this Agreement, comprehensive general liability, including broad form
and contractual liability, in a minimum amount of $3,000,000 combined single limit per occurrence and in the aggregate; (b) prior to the commencement of clinical trials involving any Licensed Products, clinical trials coverage in a minimum
amount of $5,000,000 combined single limit per occurrence and in the aggregate; and (c) prior to the First Commercial Sale of the first Licensed Product, product liability coverage, in a minimum amount of $2,000,000 combined single limit per
occurrence and in the aggregate, with the coverage provided for in clauses (b) and (c) to remain in force during the term of this Agreement and for at least five (5) years thereafter. The policies of insurance required by this
Section 8.7 shall be issued by an insurance carrier with an A.M. Best rating of “A” or better. Aegerion shall provide Bayer with insurance certificates evidencing the required coverage within thirty (30) days after the Effective
Date and the commencement of each policy period and any renewal periods. 
  

 19 

 LICENSE AGREEMENT 

 

 Section 9. Term, Termination and Survival. 

9.1 Term. This Agreement shall commence as of the Effective Date and, unless sooner terminated in accordance with the terms hereof
or by mutual written consent, shall continue on a country-by-country and product-by-product basis until the end of the period during which royalties are due hereunder on Net Sales of such Licensed Product in such country. Upon the end of such period
for such Licensed Product in such country, the license grant contained in Section 2.1 shall become perpetual, irrevocable and fully paid up with respect to such Licensed Product in such country. 

9.2 Termination for Material Default. Either Party shall have the right to terminate this Agreement upon delivery of written
notice to the other Party in the event of any default in the performance by such other Party of any of such other Party’s material obligations under this Agreement, provided that such default has not been cured within ninety (90) days, or, in
the event such default results in a failure to make payment when due hereunder, thirty (30) days, after written notice thereof is given by the non-defaulting Party to the defaulting Party specifying the nature of the alleged default, provided the
Parties shall take all reasonable steps to resolve the matter pursuant to the process set forth in Section 10.6(a) during the applicable cure period and before any such termination becomes effective. Termination of this Agreement by Bayer under
this Section 9.2 shall be on a country-by-country and product-by-product basis (and not for the Agreement as a whole) if the default giving rise to termination is reasonably specific to one or more countries or one or more products
(e.g., a royalty dispute for one product in one or more countries). 
 9.3 Termination for Convenience by
Aegerion. Aegerion may terminate this Agreement in full for any reason effective upon sixty (60) days prior written notice to Bayer. 

9.4 Termination for Insolvency. To the extent permitted by law, upon the filing or institution of bankruptcy, reorganization,
liquidation or receivership proceedings, or upon an assignment of a substantial portion of the assets for the benefit of creditors (a “Bankruptcy Event”) by either Party, Bayer, in the case of a Bankruptcy Event by Aegerion, or
Aegerion, in the case of a Bankruptcy Event by Bayer, may terminate this Agreement; provided, however, that, in the case of any involuntary bankruptcy proceeding, such right to terminate shall only become effective if the subject Party consents to
the involuntary bankruptcy or such proceeding is not dismissed within ninety (90) days after the filing thereof. Each Party shall retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code and foreign
equivalents, including that upon commencement of a bankruptcy proceeding by or against such Party undergoing a bankruptcy proceeding (the “Affected Party”) under the U.S. Bankruptcy Code or foreign equivalents, the non-Affected Party
shall be entitled to complete duplicates of or complete access to, as such non-Affected Party deems appropriate, any Technology and patent and other intellectual property rights and all embodiments hereof licensed or to be transferred to such
non-Affected Party hereunder by the Affected Party. Such Technology, rights and embodiments shall be promptly delivered to the non-Affected Party (i) upon any such commencement of a bankruptcy proceeding and upon written request thereof by the
non-Affected Party, unless the Affected Party elects to continue to perform all of its obligations under this Agreement, or (ii) if not delivered under the foregoing clause (i), upon the rejection of this Agreement by or on
behalf of the Affected Party upon written request therefore by the non-Affected Party. This Section 9.4 is without prejudice to any rights the non-Affected Party may have arising under the U.S. Bankruptcy Code, foreign equivalents or other law.

  

 20 

 LICENSE AGREEMENT 

 

 9.5 Effect of Certain Terminations. Upon termination of this Agreement by Bayer
pursuant to Section 9.2 or 9.4 or by Aegerion pursuant to Section 9.3, or with respect to each applicable product and country as to which termination occurs pursuant to Section 9.2 (the rights and obligations of the Parties as to the
remaining products and countries in which termination under Section 9.2 has not occurred, being unaffected by such termination), all rights and licenses granted to Aegerion in Section 2 shall terminate with respect to each such terminated
product and country, with all rights of Aegerion under Bayer Patent Rights for each such terminated product and country reverting to Bayer, and Section 2.2(b) shall apply to all Sublicensees in each such terminated country for each such
terminated product. Further, upon any such termination and at Bayer’s reasonable request, on a country-by-country and product-by-product basis, Aegerion shall grant to Bayer a license to use, and shall provide to Bayer a copy of, all regulatory
approvals, data, filings and correspondence (including DMFs) then in Aegerion’s Control relating to such product and applicable to such country, but only for the continued development and commercialization of such product in such country, and
provided that (i) all such information shall be treated as Confidential Information of Aegerion hereunder, (ii) such license and use shall be subject to any rights of any Sublicensees that survive any such termination as contemplated by
Section 2.2(b) and this Section 9 (including, if such Sublicensee is an exclusive sublicensee for such product in such country, then there shall not be any such license nor any provision of such information by Aegerion but such Sublicensee
shall agree to be bound to Bayer in place of Aegerion for purposes of this sentence), and (iii) if such termination occurs after Aegerion or any of its Affiliates or Sublicensees has filed for an NDA or its foreign equivalent or has obtained
regulatory approval or has made a First Commercial Sale for such product in such country, then Bayer shall pay to Aegerion commercially reasonable royalties in an amount to be agreed to by the Parties on sales of such product in such country to
reflect the investment in and value contributed by Aegerion and its Affiliates and Sublicensees to the development and commercialization of such product. 

9.6 Right to Sell-Off Inventory. Upon termination of this Agreement for any reason, should Aegerion or any of its Affiliates or
Sublicensees have any inventory of any Licensed Product, each of them shall have six (6) months thereafter in which to dispose of such inventory (subject to the payment to Bayer of any royalties due hereunder thereon). 

9.7 Survival. In addition to the termination consequences set forth in Section 9.5, the following provisions shall
survive expiration or termination of this Agreement for any reason, as well as any other provision which by its terms or by the context thereof, is intended to survive such termination: Sections 2.2(b), 2.5, 5.5(d), 5.7,
6.3 (but only with respect to any action or proceeding initiated before such expiration or termination), 6.4, 8.3, 8.4, 8.5 and 8.6, and Section 1, Section 7, Section 9 and Section 10.
Expiration or termination of this Agreement for any reason shall not relieve the Parties of any liability or obligation which accrued hereunder prior to the effective date of such termination or expiration, nor preclude either Party from pursuing
all rights and remedies it may have hereunder or at law or in equity, subject to Section 10.6, with respect to any breach of this Agreement nor prejudice either Party’s right to obtain performance of any obligation. 

Section 10. General Provisions. 

10.1 Assignment. Except as expressly provided by Section 2.1, 2.2 or 8.5, neither Party may assign this Agreement, delegate
its obligations or otherwise transfer licenses or other rights created by this Agreement, without the prior written consent of the other Party, which consent shall not be unreasonably withheld; provided that each Party may assign this Agreement as a
whole without such consent to an Affiliate or in connection with the acquisition (whether by merger, consolidation, sale or otherwise) of such Party or of that part of such Party’s business to which this Agreement relates, provided that such
Party provides written notice to the other Party of such assignment and the assignee thereof agrees in writing to be bound as such Party hereunder. Any assignment or transfer in violation of this Section 10.1 shall be void. This Agreement shall
inure to the benefit of, and be binding upon, the legal representatives, successors and permitted assigns of the Parties. 
  

 21 

 LICENSE AGREEMENT 

 

 10.2 Force Majeure. Neither Party shall be held liable or responsible to the
other Party nor be deemed to have defaulted under or breached this Agreement for failure or delay in fulfilling or performing any term of this Agreement if, but only to the extent that, such failure or delay results from causes beyond the reasonable
control of the affected Party, potentially including fire, floods, embargoes, terrorism, war, acts of war (whether war be declared or not), insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, acts of God or acts,
omissions or delays in acting by any governmental authority or any other Party; provided that the Party affected shall promptly notify the other of the force majeure condition and shall exert reasonable efforts to eliminate, cure or overcome any
such causes and to resume performance of its obligations as soon as possible. 
 10.3 Severability. If any one or more of
the provisions contained in this Agreement is held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless
the absence of the invalidated provision(s) adversely affects the substantive rights of the Parties. The Parties shall in such an instance use their reasonable best efforts to replace the invalid, illegal or unenforceable provision(s) with valid,
legal and enforceable provision(s) which, insofar as practical, implement the purposes of this Agreement. 
 10.4 Amendment;
Waiver. This Agreement may not be modified, amended or rescinded, in whole or part, except by a written instrument signed by the Parties; provided that any unilateral undertaking or waiver made by one Party in favor of the other shall be
enforceable if undertaken in a writing signed by the Party to be charged with the undertaking or waiver. No delay or omission by either Party hereto in exercising any right or power occurring upon any noncompliance or default by the other Party with
respect to any of the terms of this Agreement shall impair any such right or power or be construed to be a waiver thereof. A waiver by either of the Parties of any of the covenants, conditions or agreements to be performed by the other shall not be
construed to be a waiver of any succeeding breach thereof or of any other covenant, condition or agreement herein contained. 
  

 22 

 LICENSE AGREEMENT 

 

 10.5 Notices. Except as otherwise provided herein, all notices under this
Agreement shall be sent by certified mail or by overnight courier service, postage prepaid, to the following addresses of the respective Parties: 
  

					
	If to Aegerion, to:	 	Aegerion Pharmaceuticals, Inc.
		 	c/o Scheer & Company, Inc.
		 	250 West Main Street
		 	Branford, Connecticut 06405
		 	Attention:	  	President
		
	With a required copy to:	 	Goodwin Procter LLP
		 	53 State Street
		 	Boston, MA 02109
		 	Attention:	  	Kingsley L. Taft, Esq.
		
	If to Bayer, to:	 	Bayer HealthCare AG
		 	Aprather, WEG18A
		 	42096 Wuppertal, Germany
		 	Attention:	  	Dr. Gunnar Riemann, Member of the Board of Management and President of the Pharmaceuticals Division
		
	With a required copy to:	 	Bayer HealthCare
		 	400 Morgan Lane
		 	West haven, CT 06516
		 	Attention:	  	Paul Berry, Senior Vice President, General Counsel and Secretary

or to such address as each Party may hereafter designate by notice to the other Party. A notice shall be deemed to have been given on the date it is
received by all required recipients for the noticed Party. 
 10.6 Dispute Resolution. Disputes arising under or in
connection with this Agreement shall be resolved pursuant to this Section 10.6; provided, however, that in the event a dispute cannot be resolved without an adjudication of the rights or obligations of a Third Party (other than a Bayer
Indemnitee or Aegerion Indemnitee identified in Sections 8.6(a) or 8.6(b), as applicable), the dispute procedures set forth in this Section 10.6 shall be inapplicable as to such dispute. 

(a) In the event of a dispute between the Parties, the Parties shall first attempt in good faith to resolve such dispute
by negotiation and consultation between themselves. In the event that such dispute is not resolved on an informal basis within forty-five (45) days, any Party may, by written notice to the other, have such dispute referred to each of the
Parties’ respective CEOs or his or her designee (who shall be a senior executive), who shall attempt in good faith to resolve such dispute by negotiation and consultation for a thirty (30) day period following receipt of such written
notice. 
 (b) In the event the Parties’ CEOs (or designees) are not able to resolve such dispute, either
Party may at any time after such 30-day period submit such dispute to be finally settled by arbitration administered in accordance with the Commercial Arbitration Rules of the American Arbitration Association (“AAA”) in effect at the time
of submission. The arbitration shall be heard and determined by three (3) arbitrators. Aegerion and Bayer shall each appoint one arbitrator and the third arbitrator shall be selected by the two Party-appointed arbitrators, or, failing agreement
within sixty e(60) days following the date of receipt by the respondent of the claim, by the AAA. Such arbitration shall take place in New York, NY. The arbitration award so given shall be a final and binding determination of the dispute, shall be
fully enforceable in any court of competent jurisdiction, and shall not include any damages expressly prohibited by Section 8.4. 
  

 23 

 LICENSE AGREEMENT 

 

 (c) Costs of arbitration are to be divided by the Parties in the
following manner: Aegerion shall pay for the arbitrator it chooses, Bayer shall pay for the arbitrator it chooses, and the costs of the third arbitrator shall be divided equally between the Parties. Except in a proceeding to enforce the results of
the arbitration or as otherwise required by law, neither Party nor any arbitrator may disclose the existence, content or results of any arbitration hereunder without the prior written consent of both Parties. 

10.7 Applicable Law. This Agreement shall be governed by and construed in accordance with the laws of the state of New Jersey,
without regard to its conflicts of law provisions. 
 10.8 Further Assurances. Each Party agrees to do and perform all
such further acts and things and shall execute and deliver such other agreements, certificates, instruments and documents necessary or that the other Party may deem advisable in order to carry out the intent and accomplish the purposes of this
Agreement and to evidence, perfect or otherwise confirm its rights hereunder. 
 10.9 Relationship of the Parties. Each
Party is an independent contractor under this Agreement. Nothing contained herein is intended or is to be construed so as to constitute Bayer and Aegerion as partners, agents or joint venturers. Neither Party shall have any express or implied right
or authority to assume or create any obligations on behalf of or in the name of the other Party or to bind the other Party to any contract, agreement or undertaking with any Third Party. There are no express or implied third party beneficiaries
hereunder (except for Aegerion Indemnitees other than Aegerion and Bayer Indemnitees other than Bayer for purposes of Section 8.6). 

10.10 Entire Agreement. This Agreement (along with the Exhibits) contains the entire understanding of the Parties with respect to
the subject matter hereof and supersedes and replaces any and all previous arrangements and understandings, including the Confidentiality Agreement, whether oral or written, between the Parties with respect to the subject matter hereof. 

10.11 Headings. The captions to the several Sections hereof are not a part of this Agreement, but are merely guides or labels to
assist in locating and reading the several Sections hereof. 
 10.12 Waiver of Rule of Construction. Each Party has had
the opportunity to consult with counsel in connection with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting party shall not
apply. 
 10.13 Interpretation. Whenever any provision of this Agreement uses the term “including” (or
“includes”), such term shall be deemed to mean “including without limitation” (or “includes without limitations”). “Herein,” “hereby,” “hereunder,” “hereof” and other
equivalent words refer to this Agreement as an entirety and not solely to the particular portion of this Agreement in which any such word is used. All definitions set forth herein shall be deemed applicable whether the words defined are used herein
in the singular or the plural. Unless otherwise provided, all references to Sections and Exhibits in this Agreement are to Sections and Exhibits of this Agreement. References to any Sections include Sections and subsections that are part of the
related Section (e.g., a section numbered “Section 2.2” would be part of “Section 2”, and references to “Section 2.2” would also refer to material contained in the subsection described as
“Section 2.2(a)”) 
 10.14 Counterparts; Facsimiles. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same instrument. Facsimile execution and delivery of this Agreement by either Party shall constitute a legal, valid and binding execution
and delivery of this Agreement by such Party. 
 [Remainder of this Page Intentionally Left Blank] 

 

 24 

 LICENSE AGREEMENT 

 

 IN WITNESS WHEREOF, the Parties have caused this License Agreement to be executed by
their respective duly authorized officers as of the Effective Date. 
  

			
	BAYER HEALTHCARE AG
		
	By:	 	/s/ Gunnar Riemann
		 	(Signature)
	Name:	 	Dr. Gunnar Riemann
	Title:	 	Member of the Board of Management and President of the Pharmaceuticals Division
		
	Date:	 	June 5, 2006

  

			
	BAYER HEALTHCARE AG
		
	By:	 	/s/ Alexander Bey
		 	(Signature)
	Name:	 	Alexander Bey
	Title:	 	CAO, Head of Law and Patents
		
	Date:	 	May 31, 2006

  

			
	AEGERION PHARMACEUTICALS, INC.
		
	By:	 	/s/ Gerald Wisler
		 	(Signature)
	Name:	 	Gerald Wisler
	Title:	 	President & CEO
		
	Date:	 	May 24, 2006

 LICENSE AGREEMENT 

 

 EXHIBIT A 

BAYER KNOW-HOW TO BE TRANSFERRED TO AEGERION 

 

	 	•	 	 Most recent version of the investigators brochure for implitapide (BAY 13-9952) 

 

	 	•	 	 Complete contents of the implitapide (BAY 13-9952) Investigational New Drug Application filed with the FDA including: 

 

	 	•	 	 In vitro, preclinical and clinical study and trial protocols 

 

	 	•	 	 In vivo, preclinical and clinical study and trial data sets and study reports 

 

	 	•	 	 Chemistry, Manufacturing and Control information 

  

	 	•	 	 Correspondence with FDA 

  

	 	•	 	 Other research and development items not included within those Investigational New Drug Application files including: 

 

	 	•	 	 Publications (meeting abstracts and journal articles) 

 

	 	•	 	 Methods relating to manufacture of implitapide (BAY 13-9952) and drug product formulation 

 

	 	•	 	 Protocols, data sets and study reports relating to preclinical and clinical studies 

 

	 	•	 	 Correspondence and submissions with any other regulatory authorities 

Bayer shall not be required to transfer to Aegerion any Bayer Know-How for which Bayer does not have the right to transfer to Aegerion (including data
owned by PPD). 

 LICENSE AGREEMENT 

EXHIBIT B-1 

BAYER PATENT RIGHTS 

BAYER PATENT RIGHTS UNDER SECTION 1.3(a) 

 

															
	 Le A 30 699

								
	 Land
	  	Anmeldenr.	  	Anmeldedat.	  	Erteilungsnr.	  	Erteilungsdat.	  	Ablaufdat.	  	Veröff.-nr.	  	Offenl.-dat.
	 AR
	  	333677	  	28.09.1995	  		  		  	28.09.2015	  		  	
	 AR 01
	  	104863	  	15.09.2000	  		  		  	28.09.2015	  		  	
	 AU
	  	32920-95	  	27.09.1995	  	700609	  	20.11.1998	  	27.09.2015	  		  	
	 BY
	  	950624	  	03.10.1995	  	5422	  	24.04.2003	  	03.10.2015	  		  	
	 CA
	  	2159546	  	29.09.1995	  		  		  	29.09.2015	  		  	
	 CL
	  	1513-95	  	02.10.1995	  	40031	  	19.07.1999	  	19.07.2014	  		  	
	 CN
	  	95117117	  	04.10.1995	  	52189	  	10.12.1999	  	04.10.2015	  		  	
	 CN 01
	  	98126085	  	30.12.1998	  		  		  	04.10.2015	  		  	
	 CZ
	  	2567-95	  	03.10.1995	  	291348	  	11.12.2002	  	03.10.2015	  		  	
	 DO
	  		  	27.09.1995	  	5232	  	11.04.1996	  	27.09.2010	  		  	
	 DZ
	  	116-95	  	02.10.1995	  		  		  	02.10.2015	  		  	
	 EE
	  	9500071	  	03.10.1995	  	3527	  	15.10.2001	  	03.10.2015	  		  	
	 FI
	  	954681	  	02.10.1995	  	113048	  	27.02.2004	  	02.10.2015	  		  	
	 FI 01
	  	20002693	  	08.12.2000	  	108791	  	28.03.2002	  	02.10.2015	  		  	
	 HK
	  	98104346	  	19.05.1998	  		  		  	20.09.2015	  		  	
	 HN
	  	9160-95	  	29.09.1995	  	3769-181-VII	  	15.06.2000	  	29.09.2015	  		  	
	 HU
	  	9502891	  	03.10.1995	  		  		  	03.10.2015	  		  	
	 ID
	  	952018	  	04.10.1995	  	9015	  	21.10.2002	  	04.10.2015	  		  	
	 IL
	  	115493	  	02.10.1995	  	115493	  	30.01.2000	  	02.10.2015	  		  	
	 IL 01
	  	129641	  	28.04.1999	  	129641	  	03.12.2000	  	02.10.2015	  		  	
	 JP
	  	279664-95	  	04.10.1995	  		  		  	04.10.2015	  		  	
	 KR
	  	33651-95	  	02.10.1995	  	355986	  	26.09.2002	  	02.10.2015	  		  	
	 M1
	  	1323	  	02.10.1995	  		  		  	02.10.2015	  		  	
	 MA
	  	24026	  	02.10.1995	  	23682	  		  	02.10.2015	  		  	
	 MX
	  	954196	  	03.10.1995	  	193845	  	27.10.1999	  	03.10.2015	  		  	
	 MX 01
	  	997137	  	02.08.1999	  		  		  	03.10.2015	  		  	
	 MY
	  	95002964	  	04.10.1995	  		  		  	04.10.2015	  		  	
	 NO
	  	953930	  	03.10.1995	  	305365	  	18.05.1999	  	03.10.2015	  		  	
	 NZ
	  	280130	  	29.09.1995	  	280130	  		  	29.09.2015	  		  	
	 PH
	  	51415	  	03.10.1995	  	31400	  	29.10.1998	  	29.10.2015	  		  	
	 PH 01
	  	1-1998-02241	  	28.08.1998	  		  		  	28.08.2018	  		  	

															
	 Le A 30 699

								
	 Land
	  	Anmeldenr.	  	Anmeldedat.	  	Erteilungsnr.	  	Erteilungsdat.	  	Ablaufdat.	  	Veröff.-nr.	  	Offenl.-dat.
	 PL
	  	310756	  	03.10.1995	  	183154	  	09.10.2001	  	03.10.2015	  		  	
	 RU
	  	95117070	  	03.10.1995	  	2157803	  	20.10.2000	  	03.10.2015	  		  	
	 SG
	  	9501478	  	03.10.1995	  	63528	  	30.03.1999	  	03.10.2015	  		  	
	 SK
	  	1239-95	  	03.10.1995	  		  		  	03.10.2015	  		  	
	 TH
	  	28216	  	02.10.1995	  	13768	  	01.11.2002	  	02.10.2015	  		  	
	 TN
	  	95098	  	02.10.1995	  		  		  	02.10.2015	  		  	
	 TW
	  	84-110247	  	02.10.1995	  	140388	  	04.01.2002	  	01.10.2015	  		  	
	 UA
	  	95104372	  	03.10.1995	  	44700	  	15.03.2002	  	03.10.2015	  		  	
	 US
	  	535698	  	28.09.1995	  	5684014	  	04.11.1997	  	28.09.2015	  		  	
	 US 01
	  	887781	  	03.07.1997	  	6245775	  	12.06.2001	  	28.09.2015	  		  	
	 US 02
	  	313035	  	17.05.1999	  	6265431	  	24.07.2001	  	28.09.2015	  		  	
	 US 03
	  	734955	  	11.12.2000	  		  		  	11.12.2020	  		  	
	 US 04
	  	814263	  	21.03.2001	  	6479503	  	12.11.2002	  	28.09.2015	  		  	
	 US 05
	  	198315	  	18.07.2002	  		  		  		  		  	
	 ZA
	  	95-8297	  	03.10.1995	  	95-8297	  		  	03.10.2015	  		  	
	
	 Le A 30 699

								
	 Land
	  	Anmeldenr.	  	Anmeldedat.	  	Erteilungsnr.	  	Erteilungsdat.	  	Ablaufdat.	  	Veröff.-nr.	  	Offenl.-dat.
	 E BE
	  	95114877.4	  	21.09.1995	  	EBE 0705831	  	03.12.2003	  	21.09.2015	  		  	
	 E DE
	  	95114877.4	  	21.09.1995	  	59510839.3	  	03.12.2003	  	21.09.2015	  		  	
	 E DK
	  	95114877.4	  	21.09.1995	  	EDK 0705831	  	03.12.2003	  	21.09.2015	  		  	
	 E EP
	  	95114877.4	  	21.09.1995	  	95114877.4	  	03.12.2003	  	21.09.2015	  	705831	  	10.04.1996
	 E ES
	  	95114877.4	  	21.09.1995	  	EES 0705831	  	03.12.2003	  	21.09.2015	  		  	
	 E FR
	  	95114877.4	  	21.09.1995	  	EFR 0705831	  	03.12.2003	  	21.09.2015	  		  	
	 E GB
	  	95114877.4	  	21.09.1995	  	EGB 0705831	  	03.12.2003	  	21.09.2015	  		  	
	 E GR
	  	95114877.4	  	21.09.1995	  	EGR 0705831	  	03.12.2003	  	21.09.2015	  		  	
	 E IE
	  	95114877.4	  	21.09.1995	  	EIE 0705831	  	03.12.2003	  	21.09.2015	  		  	
	 E IT
	  	95114877.4	  	21.09.1995	  	EIT 0705831	  	03.12.2003	  	21.09.2015	  		  	
	 E LT
	  	95114877.4	  	21.09.1995	  	ELT 0705831	  	03.12.2003	  	21.09.2015	  		  	
	 E LU
	  	95114877.4	  	21.09.1995	  	ELU 0705831	  	03.12.2003	  	21.09.2015	  		  	
	 E LV
	  	95114877.4	  	21.09.1995	  	ELV 0705831	  	03.12.2003	  	21.09.2015	  		  	
	 E NL
	  	95114877.4	  	21.09.1995	  	ENL 0705831	  	03.12.2003	  	21.09.2015	  		  	
	 E PT
	  	95114877.4	  	21.09.1995	  	EPT 0705831	  	03.12.2003	  	21.09.2015	  		  	
	 E SE
	  	95114877.4	  	21.09.1995	  	95114877.4	  	03.12.2003	  	21.09.2015	  		  	

															
	 Le A 34 644

								
	 Land
	  	Anmeldenr.	  	Anmeldedat.	  	Erteilungsnr.	  	Erteilungsdat.	  	Ablaufdat.	  	Veröff.-nr.	  	Offenl.-dat.
	 CA
	  	2413277	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 JP
	  	503264-2002	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 US
	  	311761	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E AT
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E BE
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E CH
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E CY
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E DE
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E DK
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E EP
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  	1296681	  	02.04.2003
	 E ES
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E FI
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E FR
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E GB
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E GR
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E IE
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E IT
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E LU
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E MC
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E NL
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E PT
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E SE
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 E TR
	  	01951571.7	  	08.06.2001	  		  		  	08.06.2021	  		  	
	 P WO
	  	PCT/01/06526	  	08.06.2001	  		  		  	08.06.2021	  	01/97787	  	27.12.2001

															
	 Le A 31 659

								
	 Land
	  	Anmeldenr.	  	Anmeldedat.	  	Erteilungsnr.	  	Erteilungsdat.	  	Ablaufdat.	  	Veröff.-nr.	  	Offenl.-dat.
	 CA
	  	2201435	  	01.04.1997	  		  		  	01.04.2017	  		  	
	 JP
	  	96351-97	  	01.04.1997	  		  		  	01.04.2017	  		  	
	 US
	  	829566	  	31.03.1997	  	5952498	  	14.09.1999	  	31.03.2017	  		  	
	 US 01
	  	307980	  	10.05.1999	  		  		  		  		  	
	 E DE
	  	97104941.6	  	24.03.1997	  	59710487.5	  	30.07.2003	  	24.03.2017	  		  	
	 E EP
	  	97104941.6	  	24.03.1997	  	97104941.6	  	30.07.2003	  	24.03.2017	  	799829	  	08.10.1997
	 E ES
	  	97104941.6	  	24.03.1997	  	EES 0799829	  	30.07.2003	  	24.03.2017	  		  	
	 E FR
	  	97104941.6	  	24.03.1997	  	EFR 0799829	  	30.07.2003	  	24.03.2017	  		  	
	 E GB
	  	97104941.6	  	24.03.1997	  	EGB 0799829	  	30.07.2003	  	24.03.2017	  		  	
	 E IT
	  	97104941.6	  	24.03.1997	  	EIT 0799829	  	30.07.2003	  	24.03.2017	  		  	
	 E SE
	  	97104941.6	  	24.03.1997	  	97104941.6	  	30.07.2003	  	24.03.2017	  		  	
	
	 Le A 33 739

								
	 Land
	  	Anmeldenr.	  	Anmeldedat.	  	Erteilungsnr.	  	Erteilungsdat.	  	Ablaufdat.	  	Veröff.-nr.	  	Offenl.-dat.
	 CA
	  	2378379	  	12.07.2000	  		  		  	12.07.2020	  		  	
	 JP
	  	511902-2001	  	12.07.2000	  		  		  		  		  	
	 US
	  	31129	  	12.07.2000	  	6569455	  	27.05.2003	  	12.07.2020	  		  	
	 E DE
	  	00949311.5	  	12.07.2000	  		  		  	12.07.2020	  		  	
	 E EP
	  	00949311.5	  	12.07.2000	  		  		  	12.07.2020	  	1202715	  	08.05.2002
	 E ES
	  	00949311.5	  	12.07.2000	  		  		  	12.07.2020	  		  	
	 E FR
	  	00949311.5	  	12.07.2000	  		  		  	12.07.2020	  		  	
	 E GB
	  	00949311.5	  	12.07.2000	  		  		  	12.07.2020	  		  	
	 E IT
	  	00949311.5	  	12.07.2000	  		  		  	12.07.2020	  		  	
	 P WO
	  	PCT/00/06584	  	12.07.2000	  		  		  	12.07.2020	  	01/07015	  	01.02.2001

 The following patent applications shall also be treated as “Bayer Patent Rights” under this
Agreement, provided that any of the following patent applications may have lapsed, may have been cancelled, or are otherwise no longer still pending as of the Effective Date: 

 

															
	 Le A 30 699

								
	 Land
	  	Anmeldenr.	  	Anmeldedat.	  	Erteilungsnr.	  	Erteilungsdat.	  	Ablaufdat.	  	Veröff.-nr.	  	Offenl.-dat.
	 CU
	  	88-95	  	04.10.1995	  	22885	  	13.03.2003	  	04.10.2010	  		  	
	 HR
	  	950505	  	27.09.1995	  	950505	  	03.04.2002	  	27.09.2015	  		  	
	 MX 01
	  	997137	  	02.08.1999	  		  		  	03.10.2015	  		  	
	 SA
	  	96160624	  	28.02.1996	  		  		  	28.02.2016	  		  	
	 SV
	  	62-95	  	04.10.1995	  	154-1-309	  	11.09.2000	  	04.10.2010	  		  	
	
	 Le A 30 699

								
	 Land
	  	Anmeldenr.	  	Anmeldedat.	  	Erteilungsnr.	  	Erteilungsdat.	  	Ablaufdat.	  	Veröff.-nr.	  	Offenl.-dat.
	 E AT
	  	95114877.4	  	21.09.1995	  	EAT 0705831	  	03.12.2003	  	21.09.2015	  		  	
	 E CH
	  	95114877.4	  	21.09.1995	  	ECH 0705831	  	03.12.2003	  	21.09.2015	  		  	
	 E MC
	  	95114877.4	  	21.09.1995	  	EMC 0705831	  	03.12.2003	  	21.09.2015	  		  	
	 E SI
	  	95114877.4	  	21.09.1995	  	ESI 0705831	  	03.12.2003	  	21.09.2015	  		  	
	
	 Le A 33 846

								
	 Land
	  	Anmeldenr.	  	Anmeldedat.	  	Erteilungsnr.	  	Erteilungsdat.	  	Ablaufdat.	  	Veröff.-nr.	  	Offenl.-dat.
	 AR
	  	103129	  	22.06.2000	  		  		  	22.06.2020	  		  	
	 BS
	  	1242	  	08.06.2000	  	1242	  	29.01.2002	  	08.06.2016	  		  	
	 CA
	  	2376881	  	13.06.2000	  		  		  	13.06.2020	  		  	
	 CL
	  	1671-2000	  	23.06.2000	  		  		  	23.06.2020	  		  	
	 CO
	  	48079	  	27.06.2000	  		  		  	27.06.2020	  		  	
	 DO
	  	04/19/06/00	  	19.06.2000	  		  		  	19.06.2020	  		  	
	 EC
	  	2000-3541	  	23.06.2000	  		  		  	23.06.2020	  		  	
	 GT
	  	2000-0099	  	21.06.2000	  		  		  	21.06.2020	  		  	
	 HN
	  	2000-100	  	15.06.2000	  	4029-431-VII	  	18.10.2001	  	15.06.2020	  		  	
	 JM
	  	18.01.4021	  	16.06.2000	  		  		  	16.06.2014	  		  	
	 JP
	  	505893-2001	  	13.06.2000	  		  		  		  		  	
	 MY
	  	20002807	  	22.06.2000	  		  		  	22.06.2020	  		  	
	 PE
	  	625-2000	  	23.06.2000	  		  		  	23.06.2020	  		  	
	 PH
	  	1-2000-01652	  	23.06.2000	  		  		  	23.06.2020	  		  	
	 PK P
	  	593-2000	  	24.06.2000	  		  		  	24.06.2020	  		  	
	 SV
	  	109-2000	  	23.06.2000	  		  		  	23.06.2020	  		  	

															
	 Le A 30 699

								
	 Land
	  	Anmeldenr.	  	Anmeldedat.	  	Erteilungsnr.	  	Erteilungsdat.	  	Ablaufdat.	  	Veröff.-nr.	  	Offenl.-dat.
	 TH
	  	58386	  	16.06.2000	  		  		  	16.06.2020	  		  	
	 TW
	  	89-112042	  	20.06.2000	  		  		  	20.06.2020	  		  	
	 US
	  	19007	  	13.06.2000	  		  		  		  		  	
	 UY
	  	26218	  	23.06.2000	  		  		  	23.06.2020	  		  	
	 VE
	  	2000-001372	  	22.06.2000	  		  		  	22.06.2020	  		  	
	 E DE
	  	00942056.3	  	13.06.2000	  		  		  	13.06.2020	  		  	
	 E EP
	  	00942056.3	  	13.06.2000	  		  		  	13.06.2020	  	1196194	  	17.04.2002
	 E ES
	  	00942056.3	  	13.06.2000	  		  		  	13.06.2020	  		  	
	 E FR
	  	00942056.3	  	13.06.2000	  		  		  	13.06.2020	  		  	
	 E GB
	  	00942056.3	  	13.06.2000	  		  		  	13.06.2020	  		  	
	 E IT
	  	00942056.3	  	13.06.2000	  		  		  	13.06.2020	  		  	
	 P WO
	  	PCT0/00/05410	  	13.06.2000	  		  		  	13.06.2020	  	01/00183	  	04.01.2001

 LICENSE AGREEMENT 

 

 EXHIBIT B-2 

BAYER PATENT RIGHTS 

BAYER IMPROVEMENT PATENTS UNDER SECTION 1.3(b)

To be updated by the parties as contemplated by Section 6.1 

 LICENSE AGREEMENT 

 

 EXHIBIT C 

SUMMARY OF BATCHES IN BAYER’S INVENTORY OF LICENSED COMPOUND 

[CONFIDENTIAL TREATMENT REQUESTED] /*/ 

 LICENSE AGREEMENT 

 

 EXHIBIT D 

PROPOSED IMPLITAPIDE CLINICAL DEVELOPMENT PROGRAM 

Phase II Trials* 
  

	 	•	 	 Dose-ranging trials to determine the efficacy, safety and tolerability of implitapide monotherapy in patients with primary hypercholesterolemia or
mixed dyslipidemia 

  

	 	•	 	 Dose-ranging trials to determine the efficacy, safety and tolerability of implitapide used in combination with other commonly used lipid-lowering
therapies in patients with primary hypercholesterolemia or mixed dyslipidemia 

  

	*	Note that the number and design of trials conducted in this phase of research will be determined by the scope, completeness and availability of the data related to the
phase II trials conducted by Pharmaceutical Product Development, Inc. 

 Phase III Trials** 

Larger-scale phase 3 trials will be conducted to pursue some combination of the following indications: 

 

	 	•	 	 Implitapide monotherapy for the reduction of plasma lipids in patients with primary hypercholesterolemia and mixed dyslipidemia.

  

	 	•	 	 The combination of implitapide and other lipid-lowering agents for the reduction of plasma lipids in patients with primary hypercholesterolemia and
mixed dyslipidemia. 

  

	 	•	 	 Implitapide as monotherapy or as part of combination therapy with other lipid-lowering agents for the reduction of plasma lipids in patients with
severe and/or hereditary forms of dyslipidemia (e.g. heterozygous familial hypercholesterolemia or Frederickson Type IV hypertriglyceridemia). 

  

	**	Note that the exact number and design of the phase 3 clinical program will be determined based upon the findings within the phase II program and consultation with
regulatory authorities. 

 The contents of this Exhibit C by themselves shall not add to Aegerion’s obligations
under this Agreement. 

 LICENSE AGREEMENT 

 

 EXHIBIT E-1 

PATENTS UNDER SECTION 8.1(f) 

United States Patent No. 6,492,365 
 European
Patent No. EP-B-584446 

 LICENSE AGREEMENT 

 

 EXHIBIT E-2 

BAYER’S EXCEPTIONS UNDER SECTION 8.1(g) 

[CONFIDENTIAL TREATMENT REQUESTED] /*/ 

 LICENSE AGREEMENT 

 

 EXHIBIT E-3 

BAYER’S EXCEPTIONS UNDER SECTION 8.1(i) 

Bayer has communicated to Aegerion that Bayer’s development of the Licensed Compounds was discontinued by Bayer on the basis of a negative
risk-benefit assessment of the Licensed Compounds conducted by Bayer under their clinical development program. Aegerion acknowledges Bayer made the judgment not to continue development of the Compounds due to what it perceived under its clinical
development program as unacceptable adverse events for daily dosages of 80 mg and 160 mg per day form compared with the observed cholesterol lowering efficacy. 

 Amendment 

to the License Agreement concluded between Bayer HealthCare AG (“Bayer”) and Aegerion Pharmaceuticals, Inc. (“Aegerion”) on
May 31, 2006 (the “Agreement”) 
  

	 	1.	The following patent rights are herewith added to Exhibit B-1 of the Agreement and shall be regarded as Bayer Patent Rights under Section 1.3(a);

 BHC 061035 

EP 06010232.4, filed on 2006-05-18 
  

	 	2.	All other terms and conditions of the Agreement remain unchanged. 

Date: February 15, 2007 
  

					
	 Bayer HealthCare AG
	  		 	
			
	 /s/ Dr. Dieter Linkenheil
	  		 	 /s/ Dr. Markus Albers

	Dr. Dieter Linkenheil	  		 	Dr. Markus Albers
			
	Date: February 15, 2007	  		 	
			
	 /s/ William H. Lewis
	  		 	
	 William H. Lewis

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}]]